Document:

Exhibit
10.2

 

FI No: 87906/87907

Serapis: 2016-0719

 

Biofrontera (EGFF)

 

Finance Contract

 

between the

 

European Investment Bank

 

and

 

Biofrontera AG

 

Luxembourg, 19 May 2017

 

     

     

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	ARTICLE 1	Credit and Disbursements	16
	 	 	 
	ARTICLE 2	The Loan	22
	 	 	 
	ARTICLE 3	Interest	22
	 	 	 
	ARTICLE 4	Repayment	25
	 	 	 
	ARTICLE 5	Payments	30
	 	 	 
	ARTICLE 6	Borrower undertakings and representations	31
	 	 	 
	ARTICLE 7	Security	42
	 	 	 
	ARTICLE 8	Information and Visits	45
	 	 	 
	ARTICLE 9	Charges and expenses	51
	 	 	 
	ARTICLE 10	Events of Default	52
	 	 	 
	ARTICLE 11	Law and jurisdiction, miscellaneous	56
	 	 	 
	ARTICLE 12	Final clauses	58
	 	 	 
	Schedule A	60
	 	 
	Project Specification and Reporting	60
	 	 
	Schedule B	63
	 	 
	Definitions of EURIBOR	63
	 	 
	Schedule C	65
	 	 
	Form of Disbursement Offer/Acceptance (Articles 1.02B and 1.02C)	65
	 	 
	Schedule D	67
	 	 
	Form of Certificate from Borrower (Article 1.04(B))	67
	 	 
	Schedule E	68
	 	 
	Form of Compliance Certificate	68
	 	 
	Schedule F	69
	 	 
	Performance Participation Interest Examples	69
	 	 
	Schedule G	70

 

    	i

     

    

 

	THIS CONTRACT IS MADE BETWEEN:	 
	 	 
	The European Investment Bank having its seat at 100 boulevard Konrad Adenauer, L-2950 Luxembourg, represented by Adrian Kamenitzer Director and Stefan Becker, Senior Counsel	(the “Bank”),
	 	 
	of the first part, and	 
	 	 
	Biofrontera AG, a public listed company incorporated under the laws of Germany, registered with the commercial register of the local court (Amtsgericht) of Leverkusen under the registration number 49717, and having its registered address at Hemmelrather Weg 201.D-51377 Leverkusen, represented by Prof. Dr. Hermann Lübbert, CEO (Vorstandsvorsitzender), and Thomas Schaffer, CFO (Vorstand)	(the “Borrower”).
	 	 
	of the second part.	 

 

    	1

     

    

 

WHEREAS

 

		(1)	The Borrower has stated that it is undertaking various research and development programmes as more
particularly described in the technical description (the “Technical Description”) set out in Part Al of Schedule
A (the “Project”).

 

		(2)	The total cost of the Project, as estimated by the Bank, is EUR 40,500,000 (forty million five
hundred thousand euros) and the Borrower has stated that it intends to finance the Project as follows:

 

	Source	 	Amount (EUR)	 
	 	 	 	 
	Own funds	 	 	20,500,000	 
	 	 	 	 	 
	Credit from the Bank	 	 	20,000,000	 
	 	 	 	 	 
	TOTAL	 	 	40,500,000	 

 

		(3)	In order to fulfil the financing plan set out in Recital (2), the Borrower has requested from the
Bank a credit up to EUR 20,000,000 (twenty million euros).

 

		(4)	The Bank considering that the financing of the Project falls within the scope of its functions,
and having regard to the statements and facts cited in these Recitals, has decided to give effect to the Borrower’s request
providing to it a credit in an amount up to EUR 20,000,000 (twenty million euros) under this Finance Contract (the “Contract”);
provided that the amount of the Bank loan shall not, in any case, exceed 50% (fifty per cent) of the total cost of the Project
set out in Recital (2).

 

		(5)	The board of directors of the Borrower has authorised the borrowing of the sum of EUR 20,000,000
(twenty million euros) represented by this credit on the terms and conditions set out in this Contract.

 

		(6)	The financial obligations of the Borrower under this Contract are to be guaranteed by the Material
Subsidiaries which as at the date of this Contract are Biofrontera Bioscience AG, Biofrontera Pharma GmbH and Biofrontera Inc.
(the “Guarantors”) under a guarantee and indemnity (the “Guarantee”) by execution of a guarantee
and indemnity agreement in form and substance satisfactory to the Bank (the “Guarantee Agreement”).

 

		(7)	This operation benefits from a guarantee from the European Union under the European Fund for Strategic
Investments (“EFSI”).

 

		(8)	The statute of the Bank provides that the Bank shall ensure that its funds are used as rationally
as possible in the interests of the European Union and, accordingly, the terms and conditions of the Bank’s loan operations
must be consistent with relevant policies of the European Union.

 

    	2

     

    

 

		(9)	The Bank considers that access to information plays an essential role in the reduction of environmental
and social risks, including human rights violations, linked to the projects it finances and has therefore established its Transparency
policy, the purpose of which is to enhance the accountability of the EIB Group towards its stakeholders and the citizens of the
European Union in general.

 

		(10)	The processing of personal data shall be carried out by the Bank in accordance with applicable
European Union legislation on the protection of individuals with regard to the processing of personal data by the European Union
institutions and bodies and on the free movement of such data.

 

    	3

     

    

 

NOW THEREFORE it is hereby agreed as
follows:

 

INTERPRETATION AND DEFINITIONS

 

		(a)	Interpretation

 

In this Contract:

 

		(i)	References to Articles, Recitals and Schedules are, save if explicitly stipulated otherwise, references
respectively to articles, recitals and schedules to this Contract.

 

		(ii)	References to a provision of law are references to that provision as amended or re-enacted.

 

		(iii)	References to any other agreement or instrument are references to that other agreement or instrument
as amended, novated, supplemented, extended or restated.

 

		(iv)	This Contract is drafted in the English language. For the avoidance of doubt, the English language
version of this Contract shall prevail over any translation of this Contract. However, where a German translation of a word or
phrase appears in the text of this Contract, the German translation of such word or phrase shall prevail with respect to any Obligor
incorporated in Germany.

 

		(a)	Definitions

 

In this Contract:

 

“Acceptance Deadline” for
a notice means:

 

		(a)	16h00 Luxembourg time on the day of delivery, if the notice is delivered by 14h00 Luxembourg time
on a Business Day; or

 

		(b)	11h00 Luxembourg time on the next following day which is a Business Day, if the notice is delivered
after 14h00 Luxembourg time on any such day or is delivered on a day which is not a Business Day;

 

“Accepted Tranche” means
a Tranche in respect of a Disbursement Offer which has been duly accepted by the Borrower in accordance with its terms on or before
the Disbursement Acceptance Deadline:

 

“Accounting Reference Date”
has the meaning given to it in Article 6.21(s);

 

“Affiliates” means in relation
to a person, a Subsidiary of that person, or a Holding Company of that person or any other Subsidiary of that Holding Company;

 

“Application Form” means
the Borrowers application form for financing dated 18 July 2016:

 

“Authorisation” means an
authorisation, permit, consent, approval, resolution, licence, exemption, filing, notarisation or registration;

 

    	4

     

    

 

“Bankruptcy Code” means
Title 11 of the United States Code entitled “Bankruptcy,” as now or hereafter in effect, or any successor statute;

 

“Business Day” means a day
(other than a Saturday or Sunday) on which the Bank and commercial banks are open for general business in Luxembourg;

 

“Cash Pay Margin” means
400 bps;

 

“Change-of-Control Event”
has the meaning given to it in Article 4.03A(3);

 

“Change-of-Law Event” has
the meaning given to it in Article 4.03A(4);

 

“Compliance Certificate”
means a certificate substantially in the form of Schedule E;

 

“Contract” has the meaning
given to it in Recital (4);

 

“Credit” has the meaning
given to it in Article 1.01:

 

“Default” means an Event
of Default or any event or circumstance specified in Article 10.01A which would (with the expiry of a grace period, the giving
of notice, the making of any determination under this Contract or any combination of the foregoing) be an Event of Default;

 

“Deferred interest” has
the meaning given to it in Article 3.02;

 

“Deferred Interest Rate”
has the meaning given to it in Article 3.02;

 

“Disbursement Acceptance”
means a copy of the Disbursement Offer duly countersigned by the Borrower;

 

“Disbursement Acceptance Deadline”
means the date and time of expiry of a Disbursement Offer as specified therein;

 

“Disbursement Date” means
the date on which actual disbursement of a Tranche is made by the Bank;

 

“Disbursement Date Market Capitalisation”
has the meaning given to it under Article 3.03;

 

“Disbursement Date Notional Equity
Proportion” has the meaning given to it under Article 3.03;

 

“Disbursement Offer” means
a letter substantially in the form set out in Schedule C;

 

“Disruption Event” means
either or both of

 

		(a)	a material disruption to those payment or communications systems or to those financial markets
which are, in each case, required to operate in order for payments to be made in connection with this Contract; or

 

    	5

     

    

 

		(b)	the occurrence of any other event which results in a disruption (of a technical or systems-related
nature) to the treasury or payments operations of either the Bank or the Borrower, preventing that party:

 

		(i)	from performing its payment obligations under this Contract; or

 

		(ii)	from communicating with other parties in accordance with the terms of this Contract,

 

and which disruption (in either such case as
per (a) or (b) above) is not caused by, and is beyond the control of, the party whose operations are disrupted;

 

“EBITDA” means, in respect
of any Relevant Period, the consolidated operating profit of the Group before taxation (excluding the results from discontinued
operations):

 

		(a)	before deducting any interest, commission, fees, discounts, prepayment fees, premiums or charges
and other finance payments whether paid, payable or capitalised by any member of the Group (calculated on a consolidated basis)
in respect of that Relevant Period;

 

		(b)	not including any accrued interest owing to any member of the Group;

 

		(c)	after adding back any amount attributable to the amortisation or depreciation of assets of members
of the Group;

 

		(d)	before taking into account any Exceptional Items;

 

		(e)	after deducting the amount of any profit (or adding back the amount of any loss) of any member
of the Group which is attributable to minority interests;

 

		(f)	plus or minus the Group’s share of the profits or tosses (after finance costs and tax) of
Non-Group Entities:

 

		(g)	before taking into account any unrealised gains or losses on any financial instrument (other than
any derivative instrument which is accounted for on a hedge accounting basis); and

 

		(h)	before taking into account any gain arising from an upward revaluation of any other asset,

 

in each case, to the extent added, deducted
or taken into account, as the case may be, for the purposes of determining operating profits of the Group before taxation;

 

“EFSI” has the meaning given
in Recital (7);

 

“EFSI Regulation” means
the Regulation 2015/1017 of the European Parliament and of the Council of 25 June 2015 on the European Fund for Strategic Investments,

 

    	6

     

    

 

“Environment” means the
following, in so far as they affect human health and social well-being:

 

		(a)	fauna and flora;

 

		(b)	soil, water, air, climate and the landscape; and

 

		(c)	cultural heritage and the built environment,

 

and includes, without limitation, occupational
and community health and safety;

 

“Environmental Approval”
means any Authorisation required by Environmental Law;

 

“Environmental Claim” means
any claim, proceeding, formal notice or investigation by any person in respect of any Environmental Law;

 

“Environmental Law” means:

 

		(a)	European Union law, including principles and standards;

 

		(b)	German laws and regulations; and

 

		(c)	applicable international treaties,

 

of which a principal objective is the preservation,
protection or improvement of the Environment;

 

“EURIBOR” has the meaning
given to it in Schedule B;

 

“EUR” or “euro”
means the lawful currency of the Member States of the European Union which adopt or have adopted it as their currency in accordance
with the relevant provisions of the Treaty on European Union and the Treaty on the Functioning of the European Union or their succeeding
treaties;

 

“Event of Default” means
any of the circumstances, events or occurrences specified in Article 10.01;

 

“Exceptional Items” means
any material items of an unusual or non-recurring nature which represent gains or losses including those arising on:

 

		(a)	the restructuring of the activities of an entity and reversals of any provisions for the cost of
restructuring;

 

		(b)	disposals, revaluations, write downs or impairment of non-current assets or any reversal of any
write down or impairment;

 

		(c)	disposals of assets associated with discontinued operations; and

 

    	7

     

    

 

		(d)	any other examples of “exceptional items” (as such term has the meaning attributed
to it in IFRS);

 

“Final Availability Date”
means the date falling 2 (two) years from and (including) the date of this Contract;

 

“Financial Quarter” means
the period commencing on the day after one Quarter Date and ending on the next Quarter Date;

 

“Financial Year” means the
annual accounting period of the Group ending on the Accounting Reference Date;

 

“Floating Rate” means a
fixed-spread floating interest rate, that is to say an annual interest rate determined by the Bank for each successive Floating
Rate Reference Period equal to EURIBOR plus the Cash Pay Margin;

 

“Floating Rate Reference Period”
means each period from one Payment Date to the next relevant Payment Date; the first Floating Rate Reference Period shall commence
on the date of disbursement of the Tranche;

 

“GAAP” means generally accepted
accounting principles in Germany (Grundsätze ordnungsgemäßer Buchführong) under the German Commercial
Code (Handelsgesetzbuch) including, where permitted by the German Commercial Code (Handelsgesetzbuch) or other applicable
law (and with respect to any US Guarantor means the generally accepted accounting principles and rules used in the US), including
IFRS;

 

“Good Industry Practice”
means the exercise of that degree of skill, diligence, prudence and foresight which would reasonably and ordinarily be expected
from a skilled and experienced person acting in good faith and carrying out the same type of activity under the same or equivalent
circumstances and conditions and acting generally in accordance with applicable law;

 

“Group” means the Borrower
and its Affiliates from time to time;

 

“Guarantee” means a guarantee
and indemnity to the Bank guaranteeing the performance by the Borrower of all of its obligations under this Contract;

 

“Guarantee Agreement” means
each guarantee and indemnity agreement executed by a Guarantor, in form and substance satisfactory to the Bank;

 

“Guarantor” means:

 

		(a)	as at the date of this Contract, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH and Biofrontera
Inc.; and

 

		(b)	and any other company which becomes a Guarantor in accordance with Article 7.01.

 

“Holding Company” means,
in relation to a person, any other person in respect of which it is a Subsidiary;

 

    	8

     

    

 

“IFRS” means international
accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the relevant financial statements;

 

“Illegal Activities” means
any of the following illegal activities or activities carried out for illegal purposes: tax evasion, tax fraud, fraud, corruption,
coercion, collusion, obstruction, money laundering, financing of terrorism, organised crime or any illegal activity that may affect
the financial interests of the EU according to applicable law:

 

“Indebtedness” means any:

 

		(a)	obligations for borrowed money;

 

		(b)	indebtedness under any acceptance credit;

 

		(c)	indebtedness under any bond, debenture, note or similar instrument;

 

		(d)	instrument under any bill of exchange:

 

		(e)	indebtedness in respect of any interest rate or currency swap or forward currency sale or purchase
or other form of interest or currency hedging transaction (including without limit caps, collars and floors);

 

		(f)	indebtedness under any finance lease;

 

		(g)	indebtedness (actual or contingent) under any guarantee, bond security, indemnity or other agreement;

 

		(h)	indebtedness (actual or contingent) under any instrument entered into for the purpose of raising
finance;

 

		(i)	indebtedness in respect of a liability to reimburse a purchaser of any receivables sold or discounted
in the event that any amount of those receivables is not paid:

 

		(j)	indebtedness arising under a securitisation: or

 

		(k)	other transaction which has the commercial effect of borrowing;

 

“Indemnifiable Prepayment Event”
means a Prepayment Event other than those specified in Article 4.03A(2) or Article 4.03A(5);

 

“Intellectual Property Rights”
means, including without limitation, intellectual property of every designation (including patents, utility patents, copyrights,
design rights, trademarks, service marks and know how) whether capable of registration or not;

 

“Joint Venture” means any
joint venture entity, whether a company, unincorporated firm undertaking, association, joint venture or partnership or any other
entity;

 

    	9

     

    

 

“Lead Organisation” means
the European Union, the United Nations, the International Monetary Fund, the Financial Stability Board, the Financial Action Task
Force and the Organisation for Economic Cooperation and Development;

 

“Loan” means the aggregate
amount of Tranches disbursed from time to time by the Bank under this Contract;

 

“Margin Stock” has the meaning
assigned to that term in Regulation U issued by the Board of Governors of the Federal Reserve System as in effect from time to
time;

 

“Market Abuse Regulation”
means Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse
regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC,
2003/125/EC and 2004/72/EC;

 

“Material Adverse Change”
means, any event or change of condition, which, in the opinion of the Bank has a material adverse effect on:

 

		(a)	the ability of the Borrower or any Guarantor to perform its obligations under this Contract or
any Guarantee (as applicable);

 

		(b)	the business, operations, property, condition (financial or otherwise) or prospects of the Borrower,
any Guarantor or the Group as a whole; or

 

		(c)	the validity or enforceability of, or the rights or remedies of the Bank under this Contract or
any Guarantee;

 

“Material Subsidiary” means
any Subsidiary of the Borrower from time to time, whose gross revenues, total assets or EBITDA represents not less than 5% (five
per cent) of (i) the consolidated gross revenues of the Group taken as a whole and attributable to the shareholders of the Borrower
or, (ii) the consolidated total assets of the Borrower and its Subsidiaries taken as a whole or, (iii) as the case may be,
the consolidated EBITDA of the Group, as calculated based on the then latest consolidated audited accounts of the Group;

 

“Maturity Date” means the
sole repayment date of a Tranche specified pursuant to Article 4.01;

 

“Non-Group Entity” means
any investment or entity (which is not itself a member of the Group (including associates and Joint Ventures)) in which any member
of the Group has an ownership interest;

 

“Obligor” means a Borrower
or a Guarantor;

 

“Payment Date” means the
quarterly dates specified in the Disbursement Offer until the Maturity Date, save that, in case any such date is not a Relevant
Business Day, it means, the next day, if any, of that calendar month that is a Relevant Business Day or, failing that, the nearest
preceding day that is a Relevant Business Day, in all cases with corresponding adjustment to the interest due under Article 3.01;

 

    	10

     

    

 

“Permitted Acquisition”
means an acquisition:

 

		(a)	by a member of the Group of an asset sold, leased, transferred or otherwise disposed of by another
member of the Group in circumstances permitted by Article 6.06;

 

		(b)	by the Borrower or any other member of the Group of shares or other ownership interests by way
of acquisition of a wholly owned shelf company, provided that such company is incorporated in a country that is a member of either
or both of the European Union or the Organisation of Economic Co-Operation and Development;

 

		(c)	of shares or other ownership interests in a Target Entity, which do not exceed an aggregate amount
of EUR 2,000,000 (two million euros) during the term of the Credit.

 

but, in relation to paragraphs (b),
and (c) above, only if:

 

		(ii)	no Event of Default is continuing on the date the relevant acquisition agreement is entered into
or would occur as a result of the acquisition;

 

		(ii)	the acquired Target Entity, business or undertaking is engaged in a business similar or complementary
to the business carded on by the Group as at the date of this Contract,

 

		(iii)	the acquired Target Entity, business or undertaking is not incorporated or located in a jurisdiction
that is blacklisted by any Lead Organisation in connection with activities such as money laundering, financing of terrorism, tax
fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time;

 

		(iv)	legal and financial due diligence reports (including customary reliance letters) and a business
plan (in the form of the most recent budget supplemented to account for the effects of the acquisition) in respect of the 3 (three)
next following financial years and any other due diligence reports received in connection with the acquisition (if any) are provided
to the Bank; and

 

		(v)	the Borrower demonstrates that the acquisition has been approved by the Borrower’s board
of directors;

 

“Permitted Disposal” means
any act effecting a sale, transfer, lease or other disposal:

 

		(a)	related to the sale of finished products and/or services made on arm’s length terms in the
ordinary course of business of the Borrower or other member of the Group;

 

		(b)	by one Obligor to another Obligor;

 

		(c)	for cash in an amount reflecting or exceeding the fair market value of such assets, which is reinvested
in assets of comparable or superior type, value and quality;

 

    	11

     

    

 

		(d)	(other than shares, businesses or Intellectual Property Rights) made in exchange for other assets
comparable or superior as to type, value and quality;

 

		(e)	constituted by a licence of Intellectual Property Rights in the ordinary course of business;

 

		(f)	made in relation to non-material assets which have depreciated to less than 25% (twenty five per
cent) of their initial value or which are obsolete: or

 

		(g)	excluding any disposal permitted under (a) to (f) above, disposals where the higher of the market
value or consideration receivable for such disposals does not exceed EUR 1,000,000 (one million euros) during the term of the Credit,

 

“Permitted Guarantees” means
guarantees issued in the ordinary course of trade by any member of the Group:

 

		(a)	under or in connection with any Guarantee Agreement;

 

		(b)	under or in connection with any negotiable instruments;

 

		(c)	under or in connection with any performance bond;

 

		(d)	in connection with any Permitted Indebtedness;

 

		(e)	to another member of the Group; or

 

		(f)	in the ordinary course of business,

 

provided that at any point in time the guarantees
issued pursuant to (a) to (f) above do not guarantee an aggregate amount of EUR 1,000,000 (one million euros) or greater;

 

“Permitted Indebtedness”
means Indebtedness of the Borrower and/or members of the Group incurred under

 

		(a)	this Contract,

 

		(b)	existing Indebtedness as at the date of this Contract listed in Schedule G (Existing Indebtedness);

 

		(c)	any deferred purchase arrangements for assets or services acquired in the ordinary course of its
business which is:

 

		(i)	on terms that require the indebtedness to be repaid within 60 days of delivery of the goods or
performance of the services, as the case may be, and

 

		(ii)	not more than 30 days overdue;

 

		(d)	leasing costs, incurred in the ordinary course of its business, for non-specific company assets,
provided that the capital value of the assets does not exceed EUR 2,500,000 in aggregate at any one time;

 

    	12

     

    

 

		(e)	any finance or capital leases of equipment if the aggregate liability in respect of the equipment
leased does not at any time exceed EUR 250,000 (two hundred and fifty thousand euros) (or its equivalent in another currency or
currencies);

 

		(f)	the leasing agreement of the Borrower’s business premises;

 

		(g)	a Permitted Guarantee;

 

		(h)	any intercompany loan made by one Obligor to another Obligor, provided such intercompany loan is
on arms’ length terms;

 

		(i)	excluding Indebtedness permitted under (a) to (f) above, Indebtedness which does not exceed EUR
1,000,000 (one million euros); or

 

		(j)	any other Indebtedness incurred with the prior written consent of the Bank;

 

“Permitted Merger” means
any amalgamation, demerger, merger or corporate reconstruction which, in the reasonable opinion of the Bank, does not result in
a Material Adverse Change and which is on a solvent basis, and where:

 

		(a)	only members of the Group are involved;

 

		(b)	the resulting entity will not be incorporated or located in a country which is in a jurisdiction
that is blacklisted by any Lead Organisation in connection with activities such as money laundering, financing of terrorism, tax
fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time; and

 

		(c)	where the Borrower is involved, (i) the rights and obligations of the Borrower under this Contract
will remain with the Borrower, (ii) the surviving entity will be the Borrower and the statutory seat of the Borrower would not
as a result of such merger be transferred to a different jurisdiction, (iii) the merger will not have an effect on the validity,
legality or enforceability of the Borrowers obligations under this Contract; and (iv) all of the business and assets of the Borrower
are retained by it,

 

“Permitted Payments” means:

 

		(a)	shares purchased from former employees, managers or directors, provided that such shares were awarded
under a share programme of the Borrower;

 

		(b)	any payments required to be made under any intercompany loan or intercompany service agreement
made by one Obligor to another Obligor, provided such intercompany loan or intercompany service agreement is on arms’ length
terms; and

 

		(c)	any other payments made with the prior written consent of the Bank, in each case without double
counting:

 

“Permitted Security” means
any security permitted under Article 7.02(b);

 

    	13

     

    

 

“Prepayment Amount” means
the amount of a Tranche to be prepaid by the Borrower in accordance with Article 4.02A;

 

“Prepayment Date” means
the date, which shall be a Payment Date, on which the Borrower proposes to effect prepayment of a Prepayment Amount;

 

“Prepayment Event” means
any of the events described in Article 4.03A;

 

“Prepayment Fee” means the
prepayment fee payable in accordance with Article 4.02B;

 

“Prepayment Notice” means
a written notice from the Bank to the Borrower in accordance with Article 4.02C;

 

“Prepayment Request” means
a written request from the Borrower to the Bank to prepay all or part of the Loan, in accordance with Article 4.02A;

 

“Project” has the meaning
given to it in Recital (1);

 

“Quarter Date” means each
of 31 March, 30 June, 30 September and 31 December from the date of this Contract until the Maturity Date;

 

“Regulations T, U, X” means,
respectively, Regulations T, U and X of the Board of Governors of the Federal Reserve System of the United States (or any successor);

 

“Relevant Business Day”
means a day on which the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which utilises a single
shared platform and which was launched on 19 November 2007 (TARGET2) is open for the settlement of payments in EUR;

 

“Relevant Period” means
each period of twelve months ending on or about the last day of the Financial Year and each period of twelve months ending on or
about the last day of the second Financial Quarter of a Financial Year;

 

“Restricted Party” means
a person that is:

 

		(a)	listed on, or owned or controlled by a person listed on, a Sanctions List, or a person acting on
behalf of such a person;

 

		(b)	located in or organised under the laws of a country or territory that is the subject of country-
or territory-wide Sanctions, or a person who is owned or controlled by, or acting on behalf of such a person; or

 

		(c)	otherwise a subject of Sanctions;

 

“Sanctions” means any trade,
economic or financial sanctions laws, regulations, embargoes or restrictive measures administered, enacted or enforced by a Sanctions
Authority;

 

“Sanctions Authority” means;

 

    	14

     

    

 

		(a)	the Security Council of the United Nations;

 

		(b)	the US;

 

		(c)	the European Union:

 

		(d)	the UK; and

 

		(e)	the governments and official institutions or agencies of any of paragraphs (a) to (d) above, including
OFAC, the US Department of State and Her Majesty’s Treasury:

 

“Sanctions List” means the
Specially Designated Nationals and Blocked Persons list maintained by OFAC, the Consolidated List of Financial Sanctions Targets
and the Investment Ban List maintained by Her Majesty’s Treasury, or any similar list maintained by, or public announcement
of a Sanctions designation made by, a Sanctions Authority, each as amended, supplemented or substituted from time to time;

 

“Scheduled Disbursement Date”
means the dale on which a Tranche is scheduled to be disbursed in accordance with Article 1.02B;

 

“Security” means any mortgage,
pledge, lien, charge, assignment, hypothecation, or other security interest securing any obligation of any person or any other
agreement or arrangement having a similar effect;

 

“Subsidiary” means:

 

		(a)	a subsidiary (Tochterunternehmen) within the meaning of section 17 German Stock Corporation
Act (Aktiengesetz) or section 290 German Commercial Code (Handelsgesetzbuch) in relation to the Borrower; and

 

		(b)	any other entity of which the Borrower has direct or indirect control or owns beneficially directly
or indirectly more than 50% of the voting capital or similar right of ownership and “control” for this purpose means
the power to control the composition of or direct the management (Geschäftsleitung) and the policies (Geschäftspolitik)
of the entity, whether through the ownership of voting capital, by contract or otherwise;

 

“Target Entity” means any
limited liability company, corporation, limited liability partnership or any equivalent;

 

“Tax” means any tax, levy,
impost, duty or other charge or withholding of a similar nature (including any penalty or interest payable in connection with any
failure to pay or any delay in paying any of the same);

 

“Technical Description”
has the meaning given to it in Recital (1);

 

“Total Assets” means the
total consolidated assets of the Group, as shown in the Borrowers latest consolidated financial statements;

 

    	15

     

    

 

“Tranche” means each disbursement
made or to be made under this Contract. In case no Disbursement Acceptance has been received, Tranche shall mean a Tranche as offered
under Article 1.02B;

 

“US” means the United States
of America; and

 

“US Guarantor” means any
Guarantor organised under the laws of the US, any state thereof or the District of Columbia.

 

ARTICLE
1

 

Credit and Disbursements

 

		1.01	Amount of Credit

 

By this Contract the Bank establishes
in favour of the Borrower, and the Borrower accepts, a credit in an amount of up to EUR 20,000,000 (twenty million euros) for the
financing of the Project (the “Credit”).

 

		1.02	Disbursement procedure

 

		1.02A	Tranches

 

The Bank shall disburse the Credit
in up to four Tranches. The amount of each Tranche, if not being the undrawn balance of the Credit, shall be in a minimum amount
of EUR 5,000,000 (five million euros).

 

		1.02B	Disbursement Offer

 

Subject to Article 1.04 and upon
request by the Borrower the Bank shall send to the Borrower a Disbursement Offer for the disbursement of a Tranche. The latest
time for receipt by the Borrower of a Disbursement Offer is 10 (ten) days before the Final Availability Date. The Disbursement
Offer shall specify:

 

		(a)	the amount and currency of the Tranche;

 

		(b)	the Scheduled Disbursement Date, which shall be a Relevant Business Day falling at least 10 (ten)
days after the date of the Disbursement Offer and on or before the Final Availability Date;

 

		(c)	the Cash Pay Margin applicable until the Maturity Date;

 

		(d)	the Disbursement Date Market Capitalisation;

 

		(e)	the Disbursement Date Notional Equity Proportion;

 

		(f)	the Deferred Interest Rate;

 

    	16

     

    

 

		(g)	the payment dates and interest payment periodicity for the Tranche, in accordance with the provisions
of Article 3.01;

 

		(h)	the first Payment Date for the Tranche;

 

		(i)	the Maturity Date; and

 

		(j)	the Disbursement Acceptance Deadline.

 

		1.02C	Disbursement Acceptance

 

The Borrower may accept a Disbursement
Offer by delivering a Disbursement Acceptance to the Bank no later than the Disbursement Acceptance Deadline. The Disbursement
Acceptance shall be accompanied:

 

		(a)	by the IBAN code (or appropriate format in line with local banking practice) and SWIFT BIC of the
bank account to which disbursement of the Tranche should be made in accordance with Article 1.02D; and

 

		(b)	by evidence of the authority of the person or persons authorised to sign the Disbursement Acceptance
and the specimen signature of such person or persons or a declaration by the Borrower that no change has occurred in relation to
the authority of the person or persons authorised to sign Disbursement Acceptances under this Contract.

 

If a Disbursement Offer is duly accepted
by the Borrower in accordance with its terms on or before the Disbursement Acceptance Deadline, and provided that the conditions
under Article 1.04 are met, the Bank shall make the Accepted Tranche available to the Borrower in accordance with the relevant
Disbursement Offer and subject to the terms and conditions of this Contract.

 

The Borrower shall be deemed to have
refused any Disbursement Offer which has not been duly accepted in accordance with its terms on or before the Disbursement Acceptance
Deadline.

 

		1.02D	Disbursement Account

 

Disbursement shall be made to such
account of the Borrower as the Borrower shall notify in writing to the Bank in the Disbursement Acceptance.

 

Only one account may be specified
for each Tranche.

 

		1.03	Currency of disbursement

 

The Bank shall disburse each Tranche
in EUR.

 

		1.04	Conditions of disbursement

 

    	17

     

    

 

		1.04A	First Tranche

 

The disbursement of the first Tranche
under Article 1.02 is conditional upon receipt by the Bank, in form and substance satisfactory to it, before the date falling 5
Business Days before the Disbursement Offer, of the following documents or evidence:

 

		(a)	a certified copy of the resolution of the competent body (management board (Vorstand)) of
the Borrower duly authorising the execution of this Contract and duly authorising the person or persons signing this Contract on
behalf of the Borrower together with the specimen signature of each such person or persons;

 

		(b)	a certified copy of the resolution of the competent body (management board (Geschäftsführung)
and CEO, respectively and with respect to a Guarantor that is a US Guarantor, its board of directors or other management body))
of each Guarantor duly authorising the execution of the Guarantee Agreement and duly authorising the person or persons signing
the Guarantee Agreement on behalf of each Guarantor together with the specimen signature of each such person or persons;

 

		(c)	evidence that the Borrower has obtained all necessary Authorisations required in connection with
this Contract and the Project:

 

		(d)	evidence that this Contract has been executed by the Borrower,

 

		(e)	the duly executed Guarantee Agreement in a form and substance satisfactory to the Bank;

 

		(f)	a legal opinion of Ashurst LLP, addressed to the Bank, in form and substance satisfactory to the
Bank, on the legality, validity and enforceability of this Contract and distributed to the Bank prior to the signing of this Contract;

 

		(g)	a legal opinion of LLR Legerlotz Laschet und Partner Rechtsanwälte Partnerschaft mbB, Mevissenstraße
15, 50668 Cologne, Germany, legal adviser to the Borrower, addressed to the Bank in form and substance satisfactory to the Bank,
on the valid existence of the Borrower, the authority and capacity of the Borrower to enter into this Contract and on the due execution
and choice of law of this Contract;

 

		(h)	a legal opinion of LLR Legerlotz Laschet und Partner Rechtsanwälte Partnerschaft mbB, Mevissenstraße
15, 50668 Cologne, Germany, legal adviser to each Guarantor, addressed to the Bank in form and substance satisfactory to the Bank,
on the valid existence of each Guarantor incorporated in Germany, the authority and capacity of each Guarantor incorporated in
Germany to enter into the Guarantee Agreement and on the due execution and choice of law of the Guarantee Agreement;

 

    	18

     

    

 

		(i)	legal opinion of Foley Hoag LLP, legal adviser to the US Guarantor, addressed to the Bank in form
and substance satisfactory to the Bank, on the valid existence of the US Guarantor, the authority and capacity of the US Guarantor
to enter into the Guarantee Agreement and on the due execution and choice of law of the Guarantee Agreement;

 

		(j)	evidence of the latest audited financial statements of the Borrower and each Guarantor;

 

		(k)	an up-to date pdf copy from the German commercial register (Handelsregister) with regard
to the Borrower and each Guarantor incorporated in Germany;

 

		(l)	a pdf copy of the list of shareholders (Geselischafterliste) of each Guarantor, if applicable;

 

		(m)	a pdf copy of the articles of association (Setzung) of the Borrower and each Guarantor (and
with respect to a US Guarantor. its certificate of incorporation or other organizational document) and the rules of procedure of
the management board (Geschäftsordnung), supervisory board (Aufsichtsrat) and/or advisory board (Beirat),
and with respect to a US Guarantor, its by-laws or other operating document, if any;

 

		(n)	the Group structure chart showing the Group as of the date of this Contract;

 

		(o)	a certificate of an authorised signatory of the Borrower and each Guarantor certifying that each
copy document relating to it specified in this Article 1.04A is correct, complete and in full force and effect as at a date no
earlier than the date of this Contract,

 

		(p)	evidence that insurances in accordance with the requirements of Article 6.05(c) are in place;

 

		(q)	evidence of appointment of the Borrowers and each Guarantors’ agent of service;

 

		(r)	evidence of payment of all the fees and expenses as required under this Contract and the Guarantee
Agreement;

 

		(s)	in the case of each Guarantor that is a US Guarantor, a certificate as to the existence and good
standing of such Guarantor from the appropriate governmental authorities in such Guarantor’s jurisdiction of organisation;

 

		(t)	a solvency certificate signed by the chief financial officer, chief accounting officer or other
similar officer of each Guarantor that is a US Guarantor in form and substance reasonably satisfactory to the Bank; and

 

		(u)	a copy of any other document, authorisation, opinion or assurance which the Bank considers to be
necessary (if it has notified the Borrower and each Guarantor accordingly) in connection with the entry into and performance of
this Contract.

 

    	19

     

    

 

		1.04B	Further Conditions Precedent for all Trenches

 

The disbursement of each Tranche
under Article 1.02, including the first, is subject to the following conditions:

 

		(a)	that the Bank has received, in form and substance satisfactory to it, before the date falling 5
Business Days before the Disbursement Offer for the proposed Tranche, the following documents or evidence:

 

(i)         a
certificate from the Borrower in the form of Schedule D, signed by an authorised representative of the Borrower and dated no earlier
than the date falling 10 (ten) days before the Scheduled Disbursement Date;

 

(ii)        evidence
of each Guarantors consent to the Borrower’s acceptance of the Disbursement Offer;

 

(iii)       evidence
of the authority of the person or persons authorised to sign each Guarantor’s consent under paragraph (ii) above and the
specimen signature of such person or persons; and

 

(iv)       a
copy of any other authorisation or other document, opinion or assurance which the Bank has notified the Borrower is necessary in
connection with the entry into and performance of, and the transactions contemplated by, this Contract or the validity and enforceability
of the same;

 

		(b)	that on the Disbursement Date for the proposed Tranche:

 

(i)         the
representations and warranties which are repeated pursuant to Article 6.21 are correct in all respects;

 

(ii)        no
Default has occurred and is continuing or would result from the disbursement of the proposed Tranche; and

 

(iii)       no
event or circumstance has occurred and is continuing which constitutes or would with the expiry of a grace period and/or the giving
of notice under this Contract constitute a Prepayment Event (other than pursuant to Article 4.03A(1) (Project Cost Reduction) or
Article 4.03A(2) (Pari Passu to Non-EIB Financing)), or would result from the disbursement of the proposed Tranche;

 

		(c)	if the amount of the proposed Tranche, when aggregated with the Loans outstanding under all Tranches
is more than EUR 10,000,000, the Bank has received before the Disbursement Offer for the proposed Tranche, (in form and substance
satisfactory to it) evidence of Group consolidated revenues of over EUR 15 million on a 12-month rolling basis: and

 

    	20

     

    

 

		(d)	if the amount of the proposed Tranche, when aggregated with the Loans outstanding under all Tranches
is more than EUR 15,000,000, the Bank has received before the Disbursement Offer for the proposed Tranche, the following documents
or evidence (in form and substance satisfactory to it):

 

(i)         evidence
of Group consolidated revenues of over EUR 35 million on a 12-month rolling basis, and

 

(ii)        evidence
of an equity raise of at least EUR 5 million.

 

		1.05	Cancellation

 

		1.05A	Borrower’s right to cancel

 

The Borrower may at any time by notice
in writing to the Bank cancel, in whole or in part and with immediate effect, the undisbursed portion of the Credit. However, the
notice shall have no effect in respect of an Accepted Tranche which has a Scheduled Disbursement Date falling within 5 (five) Business
Days of the date of the notice.

 

		1.05B	Bank’s right to cancel

 

The Bank may, by notice in writing
to the Borrower, cancel the undisbursed portion of the Credit in whole or in part at any time and with immediate effect:

 

		(a)	upon the occurrence of a Prepayment Event other than pursuant to Articles 4.03A(1) or 4.03A(2),
a Default or an event or circumstance which would with the passage of time or giving of notice under this Contract constitute a
Prepayment Event other than pursuant to Articles 4.03A(1) or 4.03A(2); or

 

		(b)	by an amount equal to the amount by which it is entitled to cancel the Credit pursuant to Articles
4.03A(1) or 4.03A(2).

 

		1.05C	Indemnity for cancellation of a Tranche

 

If an Accepted Tranche is not disbursed
on the Scheduled Disbursement Date because the conditions precedent set out in Article 1.04 are not satisfied on such date, such
Tranche shall be cancelled and, the Borrower shall indemnify the Bank under Article 4.02B.

 

If pursuant to Article 1.05A, the
Borrower cancels any part of the Credit it shall indemnify the Bank under Article 4.02B.

 

if the Bank cancels:

 

		(a)	an Accepted Tranche upon an Indemnifiable Prepayment Event, the Borrower shall indemnify the Bank
as per Article 4.02B; or

 

		(b)	an Accepted Tranche upon an Event of Default, the Borrower shall indemnify the Bank under Article
10.03.

 

Save in these cases, no indemnity
is payable upon cancellation of a Tranche by the Bank.

 

    	21

     

    

 

		1.06	Cancellation after expiry of the Credit

 

On the day following the Final Availability
Date, and unless otherwise specifically agreed to in writing by the Bank, the part of the Credit in respect of which no Disbursement
Acceptance has been made in accordance with Article 1.02C shall be automatically cancelled, without any notice being served by
the Bank to the Borrower and without liability arising on the part of either party.

 

		1.07	Sums due under Article 1

 

Sums due under Article 1 shall be
payable in EUR. They shall be payable within 15 (fifteen) days of the Borrower’s receipt of the Bank’s demand or within
any longer period specified in the Bank’s demand.

 

ARTICLE
2

 

The Loan

 

		2.01	Amount of Loan

 

The Loan shall comprise the aggregate
amount of Tranches disbursed by the Bank under the Credit.

 

		2.02	Currency of repayment, interest and other charges

 

Interest, repayments and other charges
payable in respect of each Tranche shall be made by the Borrower in the currency in which the Tranche is disbursed.

 

Any other payment shall be made in
the currency specified by the Bank having regard to the currency of the expenditure to be reimbursed by means of that payment.

 

ARTICLE
3

 

Interest

 

		3.01	Payment of cash interest

 

		(a)	Subject to Article 3.02 and Article 3.03, the Borrower shall pay interest on the outstanding balance
of each Tranche at the Floating Rate quarterly in arrears on the relevant Payment Dates, as specified in the Disbursement Offer
commencing on the first such Payment Date following the Disbursement Date of the Tranche. If the period from the Disbursement Date
to the first Payment Date is 15 days or less then the payment of interest accrued during such period shall be postponed to the
following Payment Date.

 

		(b)	The Bank shall notify the Floating Rate to the Borrower within 10 (ten) days following the commencement
of each Floating Rate Reference Period

 

    	22

     

    

 

		(c)	Interest shall be calculated in respect of each Floating Rate Reference Period on the basis of
Article 5.01. If the Floating Rate for any Floating Rate Reference Period is below zero, it will be set at zero.

 

		3.02	Payment of deferred interest

 

In addition to the interest referred
to in Article 3.01 and 3.03, the Borrower shall pay, on the Maturity Date of the relevant Tranche (and as specified in the relevant
Disbursement Offer) interest at the Deferred Interest Rate which accrues on a daily basis on the outstanding amount of each Tranche
during the period starting on the Disbursement Date of such Tranche and ending on the Maturity Date of the relevant Tranche (or
on any date earlier than that Maturity Date in the event of a prepayment or an acceleration of all or part of that Tranche) (the
“Deferred Interest”).

 

For the purposes of this Contract
“Deferred Interest Rate” means a fixed interest rate of 6% per annum.

 

		3.03	Payment of performance participation interest

 

		(a)	In addition to the interest referred to in Article 3.01 and Article 3.02, the Borrower shall pay,
on the Maturity Date of the relevant Tranche (or on any date earlier than that Maturity Date in the event of a prepayment or an
acceleration of all or part of that Tranche) an amount equal to the Performance Participation Interest in respect of that Tranche.

 

		(b)	The Borrower and the Bank hereby agree that the calculations illustrated as examples of the Performance
Participation Interest under Schedule F, fairly represent the intention of the Parties.

 

For the purposes of this Contract:

 

“Auditor” means
any firm of accountants with sufficient skill and expertise and appropriate geographical reach or any other firm approved in advance
by the Bank (such approval not to be unreasonably withheld or delayed);

 

“Disbursement Date Notional
Equity Proportion” means the Bank’s notional equity share in the Borrower’s issued share capital calculated
as at the Disbursement Offer of a relevant Tranche as follows:

 

Disbursement Date Notional Equity
Proportion = the amount expressed as a per centage of (Amount of the Tranche) x (Participation Interest Notional Rate) x (Term
of the Tranche) / (Disbursement Date Market Capitalisation);

 

“Disbursement Date Market
Capitalisation” means the Market Capitalisation of the Borrower’s entire issued share capital as notified by the
Bank in the Disbursement Offer;

 

    	23

     

    

 

“Market Capitalisation”
means:

 

		(a)	for so long as the Borrower is listed for trading on the Frankfurt Stock Exchange, the market value
of the issued share capital of the Borrower shall be calculated on the basis of a non-weighted average closing price of the shares
in the Xetra trading system over a period equal to 90 Trading Days prior to the Disbursement Date or the Maturity Date of the relevant
Tranche (as applicable); and

 

		(b)	if at any time the Borrower is de-listed from trading on the Frankfurt Stock Exchange, the market
value of the issued share capital of the Borrower on the Disbursement Date or the Maturity Date (or on any date earlier than that
Maturity Date in the event of a prepayment or an acceleration of all or part of that Tranche) shall be determined by an Auditor
(at the cost of the Borrower) and such Auditor shall attribute a value to the appropriated financial collateral in a commercially
reasonable manner;

 

“Maturity Date Market Capitalisation”
means the Market Capitalisation of the Borrower’s entire issued share capital in relation to the Maturity Date (or on any
date earlier than that Maturity Date in the event of a prepayment or an acceleration of all or part of that Tranche);

 

“Participation Interest
Notional Rate” means a fixed interest rate of 2% per annum;

 

“Performance Participation
Interest” means the amount expressed in Euros notified by the Bank to the Borrower representing the value of the Bank’s
notional equity return in the Borrower’s issued share capital based on (i) the Bank’s Disbursement Date Notional Equity
Proportion and (ii) the Maturity Date Market Capitalisation, calculated as follows:

 

Performance Participation Interest
= (Disbursement Date Notional Equity Proportion) x (Maturity Date Market Capitalisation).

 

provided that, other than in the
case of a voluntary prepayment, the maximum Performance Participation Interest payable in respect of a Tranche shall not exceed
an amount equal to 4% per annum; and

 

“Trading Day”
means a day (other than a Saturday or Sunday) on which the Frankfurt Stock Exchange is open for trading.

 

		3.04	Interest on overdue sums

 

Without prejudice to Article 10 and
by way of exception to Article 3.01, if the Borrower fails to pay any amount payable by it under this Contract on its due date,
interest shall accrue (subject to mandatory provisions of the applicable laws) on any overdue amount payable under the terms of
this Contract from the due date to the date of actual payment at an annual rate equal to:

 

		(a)	for overdue sums related to Trenches, the applicable Floating Rate plus 2% (200 basis points);
or

 

    	24

     

    

 

		(b)	for overdue sums other than under (i) above, EURIBOR plus 2% (200 basis points),

 

and shall be payable in accordance
with the demand of the Bank. For the purpose of determining the EURIBOR in relation to this Article 3.04, the relevant periods
within the meaning of Schedule B shall be successive periods of one month commencing on the due date.

 

If the overdue sum is in a currency
other than the currency of the Loan, the following rate per annum shall apply, namely the relevant interbank rate that is generally
retained by the Bank far transactions in that currency plus 2% (200 basis points), calculated in accordance with the market practice
for such rate.

 

ARTICLE
4

 

Repayment

 

		4.01	Repayment

 

The Borrower shall repay each Tranche,
together with all other outstanding amounts under this Contract in relation to the Tranche, in a single instalment on the Maturity
Date specified in the Disbursement Offer relating to that Tranche being a Payment Date falling 5 years from the Scheduled Disbursement
Date of that Tranche.

 

		4.02	Voluntary prepayment

 

		4.02A	Prepayment option

 

Subject to Articles 4.02B, 4.02C
and 4.04, the Borrower may at any time after the first anniversary of the relevant Disbursement Date prepay all or part of any
Tranche, together with accrued interest (including Deferred Interest and Performance Participation Interest) and indemnities if
any, upon giving a Prepayment Request with at least 1 (one) month’s prior notice specifying (i) the Prepayment Amount, (ii)
the Prepayment Date, (iii) if applicable, the choice of application method of the Prepayment amount in line with Article 5.05(c)(i);
and (iv) the contract number (“Fl nr”) mentioned on the cover page of this Contract.

 

Subject to Article 4.02C the Prepayment
Request shall be binding and irrevocable.

 

		4.02B	Prepayment Fee

 

Upon prepayment of all or part of
any Tranche under Article 4.02 or cancellation under Article 1.05C, the Borrower shall pay a fee, for each Tranche, as follows:

 

		(a)	a fee of 6% of the Prepayment Amount if the Prepayment Date is on or after the first anniversary
of the relevant Disbursement Date but before the second anniversary of such Disbursement Date; or

 

    	25

     

    

 

		(b)	a fee of 3% of the Prepayment Amount if the Prepayment Date is on or after the second anniversary
of the relevant Disbursement Date but before the third anniversary of such Disbursement Date; or

 

		(c)	a fee of 1.5% of the Prepayment Amount if the Prepayment Date is on or after the third anniversary
of the relevant Disbursement Date but before the fourth anniversary of such Disbursement Date,

 

with each fee being payable on the
applicable Prepayment Date.

 

For the avoidance of doubt, no such
fee shall be payable if the Prepayment Date is on or after the fourth anniversary of the relevant Disbursement Date.

 

		4.02C	Prepayment mechanics

 

Upon presentation by the Borrower
to the Bank of a Prepayment Request, the Bank shall issue a Prepayment Notice to the Borrower, not later than 15 (fifteen) days
prior to the Prepayment Date. The Prepayment Notice shalt specify the Prepayment Amount, the accrued interest due thereon (including
any Deferred Interest and Performance Participation Interest), the Prepayment Fee payable under Article 4.02B or, as the case may
be, that no fee is due, the method of application of the Prepayment Amount and the Acceptance Deadline.

 

If the Borrower accepts the Prepayment
Notice no later than by the Acceptance Deadline, it shall effect the prepayment. In any other case, the Borrower may not effect
the prepayment.

 

The Borrower shall accompany the
prepayment by the payment of accrued interest (including Deferred Interest and Performance Participation Interest) and fee, if
any, due on the Prepayment Amount, as specified in the Prepayment Notice.

 

		4.03	Compulsory prepayment

 

		4.03A	Prepayment Events

 

4.03A(1) PROJECT COST REDUCTION

 

If the total cost of the Project
falls below the figure stated in Recital (2) so that the amount of the Credit exceeds 50% (fifty per cent) of such total cost,
the Bank may forthwith, by notice to the Borrower, cancel the undisbursed portion of the Credit and/or demand prepayment of the
Loan up to the amount by which the Credit exceeds 50% (fifty per cent) of the total cost of the Project. The Borrower shall effect
payment of the amount demanded on the date specified by the Bank, such date being a date falling not less than 30 (thirty) days
from the date of the demand.

 

    	26

     

    

 

4.03A(2) PARI PASSU TO NON-EIB FINANCING

 

If the Borrower (or any other member
of the Group) or a Guarantor voluntarily prepays (for the avoidance of doubt, prepayment shall include a repurchase, redemption
or cancellation where applicable) a part or the whole of any Non-EIB Financing and:

 

		(a)	such prepayment is not made within a revolving credit facility (save for the cancellation of the
revolving credit facility); or

 

		(b)	such prepayment is not made out of the proceeds of a loan or other indebtedness having a term at
least equal to the unexpired term of the Non-EIB Financing prepaid;

 

the Bank may, by notice to the Borrower,
cancel the undisbursed portion of the Credit and demand prepayment of the Loan. The proportion of the Loan that the Bank may require
to be prepaid shall be the same as the proportion that the prepaid amount of the Non-EIB Financing bears to the aggregate outstanding
amount of all Non-EIB Financing.

 

The Borrower shall effect payment
of the amount demanded on the date specified by the Bank, such date being a date falling not less than 30 (thirty) days from the
date of the demand.

 

This Article 4.03(A)(2) shall not
apply to a voluntary prepayment by the Borrower of the following:

 

		(a)	a prepayment of an outstanding option bond due 1 January 2018 (as set out under Schedule G (Existing
Indebtedness));

 

		(b)	a prepayment of a convertible bond due 1 January 2021 (as set out under Schedule G (Existing Indebtedness))
in accordance with the terms of the “Early Redemption for reasons of minimal outstanding Principal Amount” provision
listed under the relevant part of the column entitled “De-minimis repayment provisions” of Schedule G (Existing Indebtedness));
and

 

		(c)	a prepayment of a convertible bond due 1 January 2022 (as set out under Schedule G (Existing Indebtedness))
in accordance with the terms of the “Early Redemption for reasons of minimal outstanding Principal Amount” provision
listed under the relevant part of the column entitled “De-minimis repayment provisions” of Schedule G (Existing Indebtedness)).

 

For the purposes of this Article,
“Non-EIB Financing” includes any loan (save for the Loan and any other direct loans from the Bank to the Borrower
(or any other member of the Group)) or a Guarantor, credit bond or other form of financial indebtedness or any obligation for the
payment or repayment of money originally granted to the Borrower (or any other member of the Group) or a Guarantor for a term of
more than 3 (three) years.

 

    	27

     

    

 

4.03A(3) CHANGE OF CONTROL

 

The Borrower shall promptly inform
the Bank if a Change-of-Control Event has occurred or is likely to occur in respect of itself or any Guarantor. At any time after
the occurrence of a Change-of-Control Event, the Bank may, try notice to the Borrower, cancel the undisbursed portion of the Credit
and demand prepayment of the Loan, together with accrued interest and all other amounts accrued or outstanding under this Contract.

 

In addition, if the Borrower has
informed the Bank that a Change-of-Control Event is about to occur, or if the Bank has reasonable cause to believe that a Change-of-Control
Event is about to occur, the Bank may request that the Borrower consult with it. Such consultation shall take place within 30 (thirty)
days from the date of the Bank’s request. After the earlier of (a) the lapse of 30 (thirty) days from the date of such request
for consultation, or (b) at any time thereafter, upon the occurrence of the anticipated Change-of-Control Event the Bank may, by
notice to the Borrower, cancel the undisbursed portion of the Credit and demand prepayment of the Loan, together with accrued interest
and all other amounts accrued or outstanding under this Contract.

 

The Borrower shall effect payment
of the amount demanded on the date specified by the Bank, such date being a date failing not less than 30 (thirty) days from the
date of the demand.

 

For the purposes of this Article

 

		(a)	a “Change-of-Control Event” occurs if any person or group of persons acting
in concert gains control of the Borrower or of the entity directly or ultimately controlling the Borrower;

 

		(b)	“acting in concert” means acting together pursuant to an agreement or understanding
(whether formal or informal): and

 

		(c)	“control” means the power to direct the management and policies of an entity,
whether through the ownership of voting capital, by contract or otherwise.

 

4.03A(4) CHANGE OF LAW

 

The Borrower shall promptly inform
the Bank if a Change-of-Law Event has occurred or is likely to occur. In such case, or if the Bank has reasonable cause to believe
that a Change-of-Law Event has occurred or is about to occur, the Bank may request that the Borrower consult with it. Such consultation
shall take place within 30 (thirty) days from the date of the Bank’s request. If, after the lapse of 30 (thirty) days from
the date of such request for consultation the Bank is of the opinion that the effects of the Change-of-Law Event cannot be mitigated
to its satisfaction, the Bank may by notice to the Borrower, cancel the undisbursed portion of the Credit and demand prepayment
of the Loan, together with accrued interest and all other amounts accrued or outstanding under this Contract.

 

    	28

     

    

 

The Borrower shall effect payment
of the amount demanded on the date specified by the Bank, such date being a date falling not less than 30 (thirty) days from the
date of the demand.

 

For the purposes of this Article
“Change-of-Law Event” means the enactment, promulgation, execution or ratification of or any change in or amendment
to any law, rule or regulation (or in the application or official interpretation of any law, rule or regulation) that occurs after
the date of this Contract and which, in the opinion of the Bank, would materially impair the Borrower’s or Guarantor’s
ability to perform its obligations under this Contract or any guarantee provided in respect of this Contract.

 

4.03A(5) ILLEGALITY

 

If it becomes unlawful in any applicable
jurisdiction for the Bank to perform any of its obligations as contemplated in this Contract or to fund or maintain the Loan, the
Bank shall promptly notify the Borrower and may immediately (i) suspend or cancel the undisbursed portion of the Credit and/or
(ii) demand prepayment of the Loan, together with accrued interest and all other amounts accrued or outstanding under this Contract
on the date indicated by the Bank in its notice to the Borrower.

 

		4.03B	Prepayment mechanics

 

Any sum demanded by the Bank pursuant
to Article 4.03A together with any interest or other amounts accrued or outstanding under this Contract including, without limitation,
any fee or indemnity due under Article 4.03C and Article 4.04, shall be paid on the date indicated by the Bank in its notice of
demand.

 

		4.03C	Prepayment fee

 

In the case of an indemnifiable Prepayment
Event, the fee, if any, shall be determined in accordance with Article 4.02B.

 

		4.04	General

 

A repaid or prepaid amount may not
be reborrowed. This Article 4 shall not prejudice Article 10.

 

If the Borrower prepays a Tranche
on a date other than a relevant Payment Date, the Borrower shall indemnify the Bank in such amount as the Bank shall certify is
required to compensate it for receipt of funds otherwise than on a relevant Payment Date.

 

    	29

     

    

 

ARTICLE
5

 

Payments

 

		5.01	Day count convention

 

Any amount due by way of interest,
indemnity or fee from the Borrower under this Contract, and calculated in respect of a fraction of a year, shall be determined
on the following respective conventions in respect of interest and indemnities due under a Tranche, a year of 360 (three hundred
and sixty) days and the number of days elapsed.

 

		5.02	Time and place of payment

 

Unless otherwise specified in this
Contract or in the Bank’s demand, all sums other than sums of interest, indemnity and principal are payable within 15 (fifteen)
days of the Borrower’s receipt of the Bank’s demand.

 

Each sum payable by the Borrower
under this Contract shall be paid to the relevant account notified by the Bank to the Borrower. The Bank shall notify the account
not less than 15 (fifteen) days before the due date for the first payment by the Borrower and shall notify any change of account
not less than 15 (fifteen) days before the date of the first payment to which the change applies. This period of notice does not
apply in the case of payment under Article 10.

 

The Borrower shall indicate in each
payment made hereunder the contract number (“Fl nr”) found on the cover page of this Contract.

 

A sum due from the Borrower shall
be deemed paid when the Bank receives it.

 

Any disbursements by and payments
to the Bank under this Contract shall be made using account(s) acceptable to the Bank. For the avoidance of doubt, any account
in the name of the Borrower held with a duly authorised financial institution in the jurisdiction where the Borrower is incorporated
or where the Project is undertaken is deemed acceptable to the Bank.

 

		5.03	No set-off by the Borrower

 

All payments to be made by the Borrower
under this Contract shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim.

 

		5.04	Disruption to Payment Systems

 

If either the Bank determines (in
its discretion) that a Disruption Event has occurred or the Bank is notified by the Borrower that a Disruption Event has occurred:

 

		(a)	the Bank may, and shall if requested to do so by the Borrower, consult with the Borrower with a
view to agreeing with the Borrower such changes to the operation or administration of this Contract as the Bank may deem necessary
in the circumstances;

 

		(b)	the Bank shall not be obliged to consult with the Borrower in relation to any changes mentioned
in paragraph (a) if, in its opinion, it is not practicable to do so in the circumstances and, in any event, shall have no obligation
to agree to such changes; and

 

    	30

     

    

 

		(c)	the Bank shall not be liable for any damages, costs or losses whatsoever arising as a result of
a Disruption Event or for taking or not taking any action pursuant to or in connection with this Article 5.04.

 

		5.05	Application of sums received

 

		(a)	General

 

Sums received from the Borrower shall
only discharge its payment obligations if received in accordance with the terms of this Contract.

 

		(b)	Partial payments

 

If the Bank receives a payment that
is insufficient to discharge all the amounts then due and payable by the Borrower under this Contract, the Bank shall apply that
payment in or towards payment of

 

(i)         first,
any unpaid fees, costs, indemnities and expenses due under this Contract;

 

(ii)        secondly,
any accrued interest due but unpaid under this Contract,

 

(iii)       thirdly,
any principal due but unpaid under this Contract; and

 

(iv)       fourthly,
any other sum due but unpaid under this Contract.

 

		(c)	Allocation of sums related to Tranches

 

(i)         The
Bank may apply sums received between Tranches at its discretion

 

(ii)        In
case of receipt of sums which cannot be identified as applicable to a specific Tranche, and on which there is no agreement between
the Bank and the Borrower on their application, the Bank may apply these between Tranches at its discretion.

 

ARTICLE
6

Borrower undertakings and representations

 

The undertakings in this Article
6 remain in force from the date of this Contract for so long as any amount is outstanding under this Contract or the Credit is
in force.

 

		A.	Project undertakings

 

		6.01	Use of Loan and availability of other funds

 

The Borrower shall use all amounts
borrowed by it under the Loan for the execution of the Project.

 

    	31

     

    

 

The Borrower shall ensure that it
has available to it the other funds listed in Recital (2) and that such funds are expended, to the extent required, on the financing
of the Project.

 

		6.02	Completion of Project

 

The Borrower shall or shall procure
that the Project is carried out in accordance with the Technical Description as may be modified from time to time with the approval
of the Bank, and complete it by the final date specified therein.

 

		6.03	Increased cost of Project

 

If the total cost of the Project
exceeds the estimated figure set out in Recital (2), the Borrower shall obtain the finance to fund the excess cost without recourse
to the Bank, so as to enable the Project to be completed in accordance with the Technical Description. The plans for funding the
excess cost shall be communicated to the Bank without delay.

 

		6.04	Procurement procedure

 

The Borrower shall purchase equipment,
secure services and order works for the Project (a) in so far as they apply to it or to the Project, in accordance with European
Union law in general and in particular with the relevant European Union Directives and (b) in so far as European Union Directives
do not apply, by procurement procedures which, to the satisfaction of the Bank, respect the criteria of economy and efficiency
and, in case of public contracts, the principles of transparency, equal treatment and non-discrimination on the basis of nationality.

 

		6.05	Continuing Project undertakings

 

The Borrower shall:

 

		(a)	Maintenance: maintain, repair, overhaul and renew all project assets as required to keep
such assets in good working order;

 

		(b)	Project assets: unless the Bank shall have given its prior consent in writing retain title
to and possession of all or substantially all the project assets or, as appropriate, replace and renew such assets and maintain
the Project in substantially continuous operation in accordance with its original purpose; provided that the Bank may withhold
its consent only where the proposed action would prejudice the Bank’s interests as lender to the Borrower or would render
the Project ineligible for financing by the Bank under its statute or under Article 309 of the Treaty on the Functioning of the
European Union;

 

		(c)	Insurance: insure all works and property forming part of the Project with first class insurance
companies in accordance with Good Industry Practice;

 

		(d)	Rights and Permits: maintain in force all rights of way or use and all Authorisations necessary
for the execution and operation of the Project; and

 

    	32

     

    

 

		(e)	Environment:

 

(i)         implement
and operate the Project in compliance with Environmental Law;

 

(ii)        obtain
and maintain requisite Environmental Approvals for the Project; and

 

(iii)       comply
with any such Environmental Approvals;

 

On becoming aware of any breach of
this Article 6.05(e).

 

		A.	the Borrower shall promptly notify the Bank;

 

		B.	the Borrower and the Bank will consult for 15 Business Days from the date of notification (the
consultation period) with a view to agreeing the manner in which the breach should be rectified; and

 

		C.	the Borrower will use its best endeavours to comply with the provisions set out in paragraphs (i)
to (iii) (inclusive) above and shall in any event remedy the breach within 30 Business Days of the end of the consultation period.

 

		(f)	Integrity: take, within a reasonable timeframe, appropriate measures in respect of any member
of its management bodies who has been convicted by a final and irrevocable court ruling of an Illegal Activity perpetrated in the
course of the exercise of his/her professional duties, in order to ensure that such member is excluded from any Borrowers activity
in relation to the Loan or the Project;

 

		(g)	Integrity Audit Rights: ensure that all contracts under the Project to be procured after
the date of signature of this Contract in accordance with European Union Directives on procurement provide for;

 

(i)         the
requirement that the relevant contractor promptly informs the Bank of a genuine allegation, complaint or information with regard
to Illegal Activities related to the Project;

 

(ii)        the
requirement that the relevant contractor keeps books and records of all financial transactions and expenditures in connection with
the Project; and

 

(iii)       the
Bank’s right, in relation to an alleged Illegal Activity, to review the books and records of the relevant contractor in relation
to the Project and to take copies of documents to the extent permitted by law.

 

B.       General
undertakings

 

    	33

     

    

 

		6.06	Disposal of assets

 

The Borrower shall not, and shall
procure that no other member of the Group will, either in a single transaction or in a series of transactions whether related or
not and whether voluntarily or involuntarily dispose of all or any part of the Borrowers or ether Group member’s business,
undertaking or assets, including any Intellectual Property Rights or any shares or securities of any entity or business undertaking,
unless such disposal is a Permitted Disposal.

 

For the purposes of this Article,
“dispose” and “disposal” includes any act effecting sale, transfer, lease or other disposal.

 

		6.07	Compliance with laws, Hedging, US regulations, Sanctions and Anti-Money Laundering

 

		6.07A	Compliance with laws

 

The Borrower shall, and shall procure
that each other member of the Group (including the Guarantors) shall, comply in all respects with all laws and regulations to which
it or the Project is subject.

 

		6.07B	Hedging

 

The Borrower shall not, and shalt
procure that each other member of the Group shall not enter into any derivative transaction other than non-speculative currency
hedging transactions on market standard terms in connection with Group’s business in the US.

 

		6.07C	US Governmental Regulation

 

		(a)	The Borrower shall not, and shall procure that each member of the Group and any of their respective
Subsidiaries shall not, be subject at any time to regulation under the US Federal Power Act or the US Interstate Commerce Act or
under any other US federal or state statute or regulation which may limit its ability to incur or guarantee indebtedness or which
may otherwise render all or any portion of their respective obligations under the Contract or any Guarantee Agreement unenforceable.

 

		(b)	The Borrower shall not at any time, and shall procure that each member of the Group and any of
their respective Subsidiaries shall not any time, be an “investment company” or a company “controlled”
by an “investment company’ as defined in, or subject to regulation under, the US Investment Company Act of 1940, as
amended.

 

		6.07D	US Securities Activities and Margin Regulations

 

		(a)	The Borrower shall not at any time, and shall procure that each member of the Group and any of
their respective Subsidiaries shall not at any time, engage principally, or as one of its important activities, in the business
of purchasing or carrying Margin Stock or extending credit for the purpose of purchasing or carrying any Margin Stock.

 

    	34

     

    

 

		(b)	No part of the proceeds of any of the Loans will be used for any purpose which violates the provisions
of Regulations T, U or X issued by the Board of Governors of the Federal Reserve System.

 

		6.07E	Sanctions

 

The Borrower shall not, and shall
procure that each member of the Group and any of their respective Subsidiaries shall not, nor any of their respective Subsidiaries,
any directors, officers, employees, agents, Affiliates of each of the foregoing:

 

		(a)	be a Restricted Party or engage in or be engaged in any transaction or conduct that could result
in it becoming a Restricted Party;

 

		(b)	be subject to any claim, proceeding, formal notice or investigation with respect to Sanctions;

 

		(c)	engage in or be engaged in any transaction that evades or avoids, or has the purpose of evading
or avoiding, or breaches or attempts to breach, directly or indirectly, any Sanctions applicable to it or

 

		(d)	engage or be engaged, directly or indirectly, in any trade, business or other activities with or
for the benefit of any Restricted Party.

 

		6.07F	Anti-Money Laundering

 

The Borrower shall at all times,
and shall procure that each member of the Group and any of their respective Subsidiaries shall at all times be in compliance with
the (a) Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury
Department (31 CFR, Subtitle B, Chapter V, as amended) and any other enabling legislation or executive order relating thereto,
and (b) the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of
2001 (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), as amended. No part of the proceeds of any Loan will be
used, directly or indirectly, for any payments to any governmental official or employee, political party, official of a political
party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business
or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.

 

		6.08	Change in business

 

The Borrower shall procure that no
substantial change is made to the general nature business of the Borrower or the Group as a whole from that carried on at the date
of this Contract.

 

    	35

     

    

 

		6.09	Merger

 

The Borrower shall not, and shall
ensure that no other member of the Group shall, enter into any amalgamation, demerger, merger or corporate reconstruction unless:

 

		(a)	with the prior written consent of the Bank; or

 

		(b)	such amalgamation, demerger, merger or corporate reconstruction is a Permitted Merger.

 

		6.10	Ownership

 

		(a)	The Borrower shall maintain not less than 51% (fifty one per cent) of the share capital, directly
or indirectly, of each of its Material Subsidiaries, unless a prior written consent of the Bank is received by the Borrower.

 

		(b)	The Borrower shall in aggregate maintain not less than 100% (one hundred per cent) of the share
capital, directly or indirectly, of each Guarantor, unless prior written consent of the Bank is received by the Borrower.

 

		(c)	The Borrower shall immediately notify the Bank in the event of a new entity becoming a majority
owned subsidiary (meaning ownership of 50.1% (fifty point one per cent) or more) through any means, including but not limited to
acquisition, creation and spin-off.

 

		(d)	The undertakings in paragraphs (a) and (h) above shall be calculated in accordance with GARP as
applied by the Borrower on the date of this Contract and as GAAP is amended from time to time and tested annually.

 

		6.11	Books and records

 

The Borrower shalt ensure that it
has kept and will continue to keep proper books and records of account, in which full and correct entries shall be made of all
financial transactions and the assets and business of the Borrower, including expenditures in connection with the Project, in accordance
with GAAP as in effect from time to time.

 

		6.12	Visibility

 

The Borrower agrees to cooperate
with the Bank to ensure that any press releases or publications made by the Borrower regarding the financing and the Project include
an appropriate acknowledgment of the financial support provided by the Bank with the backing of the European Union through EFSI.

 

		6.13	Acquisitions

 

The Borrower shall not, and shall
ensure that no other member of the Group shall invest in or acquire any entity or a business going concern or an undertaking (whether
whole or substantially the whole of the assets or business), or any division or operating unit thereof, or any shares or securities
of any entity or a business or undertaking (or in each case, any interest in any of them) (or agree to any of the foregoing), unless:

 

    	36

     

    

 

		(a)	with the prior written consent of the Bank; or

 

		(b)	such acquisition is a Permitted Acquisition.

 

		6.14	Indebtedness

 

The Borrower shall not, and shalt
ensure that no other member of the Group shall incur any Indebtedness, unless:

 

		(a)	with the prior written consent of the Bank; or

 

		(b)	such Indebtedness is Permitted Indebtedness.

 

		6.15	Guarantees

 

The Borrower shall not, and shall
procure that no other member of the Group will issue or allow to remain outstanding any guarantees in respect of any liability
or obligation of any person unless:

 

		(a)	with the prior written consent of the Bank; or

 

		(b)	such guarantees are Permitted Guarantees.

 

		6.16	Permitted Payments

 

The Borrower shall not, and shall
procure that no other member of the Group shall declare or distribute dividends, or make any payment in respect of any intercompany
loan, or return or purchase shares unless:

 

		(a)	with the prior written consent of the Bank;

 

		(b)	such payments are Permitted Payments;

 

		(c)	such distribution of dividends is made from one Obligor to another Obligor; or

 

		(d)	it relates to the solvent liquidation or reorganisation of any member of the Group which is not
an Obligor so long as any payments or assets distributed as a result of such liquidation or reorganisation are distributed to other
members of the Group.

 

		6.17	Intellectual Property Rights

 

The Borrower shall, and shall procure
that each other member of the Group shall, (i) safeguard and maintain its rights with respect to the Intellectual Property
Rights required for the implementation of the Project in accordance with this Contract, including complying with all material contractual
provisions and that the implementation of the Project in accordance with this Contract will not result in the infringement of the
rights of any person with regard to the Intellectual Property Rights and (ii) ensure that any Intellectual Property Rights required
for the implementation of the Project will be owned by or licensed to the Borrower, and where such Intellectual Property Rights
which are owned by a member of the Group are capable of registration, are registered to that Obligor.

 

    	37

     

    

 

		6.18	Maintenance of Status

 

The Borrower shall, and shall procure
that each other member of the Group shall, remain duly incorporated and/or organised and validly existing as a corporate or other
legal entity (as applicable) with limited liability under the jurisdiction in which it is incorporated or organised (and with respect
to any US Guarantor, is in good standing under its jurisdiction of incorporation or organisation or formation) that it will have
no centre of main interests, permanent establishment or place of business outside the jurisdiction in which it is incorporated,
and that it will continue to have the power to carry on its business as it is now being conducted and continue to own its property
and other assets.

 

		6.19	Eligibility Prerequisites

 

The Borrower shall, and shall procure
that each other member of the Group shall, satisfy the eligibility prerequisites, as amended from time to time, that are required
to be satisfied in order to obtain finance under the joint initiative between the Bank and the European Commission as set out in
Recital (8).

 

		6.20	Illicit origin

 

The Borrower shall, and shall procure
that each other member of the Group shall, promptly inform the Bank if at any time it becomes aware of any funds that are invested
in the Project by the Borrower or by any other member of the Group that are of illicit origin, including products of money laundering
or linked to the financing of terrorism.

 

		6.21	General Representations and Warranties

 

The Borrower represents and warrants
to the Bank that:

 

		(a)	it is duly incorporated and validly existing as a public listed company under the laws of Germany
and it has power to carry on its business as it is now being conducted and to own its property and other assets;

 

		(b)	it has the power to execute, deliver and perform its obligations under this Contract and all necessary
corporate, shareholder and other action has been taken to authorise the execution, delivery and performance of the same by it;

 

		(c)	this Contract constitutes its legally valid, binding and enforceable obligations;

 

		(d)	the execution and delivery of, the performance of its obligations under and compliance with the
provisions of this Contract do not and will not

 

(i)         contravene
or conflict with any applicable law, statute, rule or regulation, or any judgement, decree or permit to which it is subject;

 

    	38

     

    

 

(ii)        contravene
or conflict with any agreement or other instrument binding upon it which might reasonably be expected to have a material adverse
effect on its ability to perform its obligations under this Contract; and

 

(iii)       contravene
or conflict with any provision of its articles of association (Satzung) or the rules of procedure of the management board
(Geschäftsordnung), supervisory board (Aufsichtsrat) and/or advisory board (Beirat), if any;

 

		(e)	the latest available consolidated audited accounts of the Borrower and if applicable each Guarantor
have been prepared on a basis consistent with previous years and have been approved by its auditors as representing a true and
fair view of the results of its operations for that year and accurately disclose or reserve against all the liabilities (actual
or contingent) of the Borrower;

 

		(f)	there has been no Material Adverse Change since 9 November 2016;

 

		(g)	no event or circumstance which constitutes an Event of Default has occurred and is continuing unremedied
or unwaived;

 

		(h)	no litigation, arbitration, administrative proceedings or investigation is current or to its knowledge
is threatened or pending before any court, arbitral body or agency which has resulted, or if adversely determined is reasonably
likely to result in, a Material Adverse Change, nor is there subsisting against it or any of its subsidiaries any unsatisfied judgement
or award;

 

		(i)	it has obtained all necessary Authorisations in connection with this Contract and in order to lawfully
comply with its obligations hereunder, and the Project and all such Authorisations are in full force and effect and admissible
in evidence;

 

		(j)	its payment obligations under this Contract rank not less than pari passu in right of payment with
all other present and future unsecured and unsubordinated obligations under any of its debt instruments except for obligations
mandatorily preferred by law applying to companies generally;

 

		(k)	it is in compliance with Article 6.05(e) and to the best of its knowledge and belief (having made
due and careful enquiry) no Environmental Claim has been commenced or is threatened against it;

 

		(l)	no financial covenants have been concluded with any other creditor of the Borrower other than the
covenants disclosed to the Bank under Schedule G (Existing Indebtedness);

 

		(m)	the Group structure chart delivered in accordance with Article 1 .04A(m) is true, complete and
accurate in all material respects and represents the complete corporate structure of the Group as at the date of this Contract;

 

    	39

     

    

 

		(n)	it is not required to make any deduction for or on account of any Tax from any payment it may make
under this Contract;

 

		(o)	to the best of its knowledge, no funds invested in the Project by the Borrower or by its controlling
entities or by another member of the Group are of illicit origin, including products of money laundering or linked to the financing
of terrorism. The Borrower shall promptly inform the Bank if at any time it becomes aware of the illicit origin of any such funds;

 

		(p)	all Tax returns required to have been filed by it or on its behalf under any applicable law have
been filed when due and contain the information required by applicable law to be contained in them;

 

		(q)	it has paid when due all Taxes payable by it under applicable law except to the extent that it
is contesting payment in good faith and by appropriate means;

 

		(r)	with respect to Taxes which have not fallen due or which it is contesting, it is maintaining reserves
adequate for their payment and in accordance, where applicable, with GAAP;

 

		(s)	the accounting reference date of the Borrower is 31 December (the “Accounting Reference Date);

 

		(t)	under the laws of Germany it is not necessary that this Contract be filed, recorded or enrolled
with any court or other authority in Germany or that any stamp, registration or similar tax be paid on or in relation to this Contract,
or the transactions contemplated by this Contract;

 

		(u)	any factual information provided by the Borrower and any member of the Group for the purposes of
entering into this Contract and any related documentation was true and accurate in all material respects as at the date it was
provided or as at the date (if any) at which it is stated;

 

		(v)	the Borrower has no Indebtedness outstanding other than the Permitted Indebtedness;

 

		(w)	neither it, nor any of its assets, is entitled to immunity from suit, execution, attachment or
other legal process;

 

		(x)	it has done, or will have done by the appropriate time for the Project to be implemented in accordance
with this Contract, all that is reasonably required to obtain, safeguard and maintain its rights with respect to the Intellectual
Property Rights required for the implementation of the Project in accordance with this Contract including complying with all contractual
provisions;

 

    	40

     

    

 

		(y)	to the best of its knowledge and belief, having made reasonable enquiry the implementation of the
Project in accordance with this Contract, will not result in the infringement of the rights of any person with regard to the Intellectual
Property Rights;

 

		(z)	the pension schemes for the time being operated by the Borrower (if any) are funded in accordance
with their rules and to the extent required by law or otherwise comply with the requirements of any law applicable in the jurisdiction
in which the relevant pension scheme is maintained;

 

		(aa)	it is in compliance with all applicable European Union and German legislation, including any applicable
anti-corruption legislation;

 

		(bb)	other than as set out in the Group structure chart, the Borrower owns no other equity and/or shares
in any other business entity;

 

		(cc)	it has acquainted itself with this Contract and determined that it is in its best commercial interest
and consistent with its purpose of operations to enter into this Contract;

 

		(dd)	no member of the Group is dormant (other than Biofrontera Neuroscience GmbH and Biofrontera Development
GmbH);

 

		(ee)	as on the date of this Contract, (i) information provided by the Borrower under the Application
Form is complete, accurate and true in all respects; and (ii) the Borrower (and the Group as a whole where relevant) complies with
the eligibility and exclusion criteria to be the beneficiary of the Credit as such criteria are listed in the Application Form;

 

		(ff)	it is in compliance with all undertakings under this Contract;

 

		(gg)	it is not engaged in any Illegal Activities and to the best of its knowledge no Illegal Activities
have occurred in connection with the Project;

 

		(hh)	the choice of the laws of England and Wales as the governing law of this Contract will be recognised
and enforced in its jurisdiction of incorporation and any judgement obtained in England and Wales in relation to this Contract
will be recognised and enforced in its jurisdiction of incorporation;

 

		(ii)	it has not disclosed any information (whether confidential or otherwise) to the Bank, prior to
the date of this Contract and at any time from the date of this Contract, which constitutes inside information within the meaning
of Article 7 of the Market Abuse Regulation;

 

		(jj)	it, the Guarantors and any other member of the Group have not issued or do not have in issue “financial
instruments” which fall within the scope of Article 2 of the Market Abuse Regulations (Regulation 596/2014) save for the
following:

 

		(A)	its shares under ISINs DE0006046113 and DE000A2E41E4; and

 

    	41

     

    

 

		(B)	the bonds referred to under Schedule G (Existing Indebtedness); and

 

		(kk)	it is not, nor to its knowledge any other member of the Group or any of their respective Subsidiaries
and any of directors, officers, employees, agents of any of the foregoing is not:

 

		(A)	a Restricted Party or engaging in or engaged in any transaction or conduct that could result in
it becoming a Restricted Party;

 

		(B)	or never has been subject to any claim, proceeding, formal notice or investigation with respect
to Sanctions;

 

		(C)	engaging or engaged in any transaction that evades or avoids, or has the purpose of evading or
avoiding, or breaches or attempts to breach, directly or indirectly, any Sanctions applicable to it, or

 

		(D)	engaged or engaging, directly or indirectly, in any trade, business or other activities with or
for the benefit of any Restricted Party.

 

The representations and warranties
set out above shall survive the execution of this Contract and are, with the exception of the representations set out in paragraph
(f), (m), (n), (t), (ee), (gg) and (kk) above, deemed repeated on each Disbursement Acceptance, Disbursement Date and on each Payment
Date by reference to the facts and circumstances then existing.

 

ARTICLE
7

 

Security

 

The undertakings in this Article 7 remain in
force from the date of this Contract for so long as any amount is outstanding under this Contract or the Credit is in force.

 

		7.01	Guarantee

 

		(a)	The obligations of the Bank under this Contract are conditional upon the prior execution and delivery
to the Bank of the Guarantee Agreement in form and substance satisfactory to it. The Borrower hereby acknowledges and consents
to the terms of the Guarantee Agreement.

 

		(b)	The Borrower shall procure that as soon as any other member of the Group becomes a Material Subsidiary
(other than in the case of a Material Subsidiary incorporated in France), the Borrower shall promptly inform the Bank and procure
that such member of the Group shalt (to the extent this is permitted under applicable mandatory corporate law, assuming that all
relevant corporate approvals have been obtained) shall:

 

(i)       enter
into a Guarantee Agreement duly executed by it;

 

    	42

     

    

 

(ii)        provide
the Bank with a certified copy of its resolution of the competent body (board of directors or general meeting of shareholders or
other management body) duly authorising the execution of the Guarantee Agreement and duly authorising the person or persons signing
the Guarantee Agreement on its behalf, together with the specimen signature of each such person or persons.

 

(iii)       provide
the Bank with evidence that the Material Subsidiary has obtained all necessary Authorisations required in connection with the Guarantee
Agreement;

 

(iv)       provide
the Bank with a legal opinion of a reputable law firm in the jurisdiction of incorporation of such Material Subsidiary, addressed
to the Bank in form and substance satisfactory to the Bank, on the valid existence of the Guarantor, the authority and capacity
of the Guarantor to enter into the Guarantee Agreement and on the due execution and choice of law of the Guarantee Agreement;

 

(v)        evidence
of the constitutional documents of the Guarantor;

 

(vi)       a
certificate of an authorised signatory of the Guarantor certifying that each copy document relating to it specified in this Article
7.01 is correct, complete and in full force and effect as at a date no earlier than the date of the Guarantee Agreement;

 

(vii)      evidence
of appointment of the Guarantor’s agent of service;

 

(viii)     in
the case of a Guarantor that is a US Guarantor, a certificate as to the existence and good standing of such Guarantor from the
appropriate governmental authorities in such Guarantors jurisdiction of organisation; and

 

(ix)       a
solvency certificate signed by the chief financial officer, chief accounting officer or other similar officer of a Guarantor that
is a US Guarantor, each in form and substance satisfactory to the Bank.

 

		7.02	Negative pledqe

 

		(a)	The Borrower shall not (and the Borrower shall ensure that no other member of the Group will) create
or permit to subsist any Security over any of its assets.

 

For the purposes of this Article 7.02,
the term Security shall also include any arrangement or transaction on assets or receivables or money (such as the sale, transfer
or other disposal of assets on terms whereby they are or may be leased to or re-acquired by the Borrower or any other member of
the Group, the sale, transfer or otherwise dispose of any receivables on recourse terms or any arrangement under which money or
the benefit of a bank account or other account may be applied or set off or any preferential arrangement having a similar effect)
in circumstances where the arrangement or transaction is entered into primarily as a method of raising credit or of financing the
acquisition of an asset.

 

    	43

     

    

 

		(b)	Paragraph (a) above does not apply to any Security, listed below:

 

(i)          any
netting or set-off arrangement entered into by any member of the Group in the ordinary course of its banking arrangements for the
purpose of netting debit and credit balances;

 

(ii)         any
lien arising by operation of law and in the ordinary course of trading;

 

(iii)        any
Security over or affecting any asset acquired by a member of the Group after the date of this Contract if:

 

		A.	the Security was not created in contemplation of the acquisition of that asset by a member of the
Group;

 

		B.	the principal amount secured has not been increased in contemplation of or since the acquisition
of that asset by a member of the Group; and

 

		C.	the Security is removed or discharged within 3 (three) months of the date of acquisition of such
asset;

 

(iv)        any
Security over or affecting any asset of any company which becomes a member of the Group after the date of this Contract, where
the Security is created prior to the date on which that company becomes a member of the Group, if:

 

		A.	the Security was not created in contemplation of the acquisition of that company;

 

		B.	the principal amount secured has not increased in contemplation of or since the acquisition of
that company; and

 

		C.	the Security is removed or discharged within 3 (three) months of that company becoming a member
of the Group;

 

(v)          any
Security arising under any retention of title, hire purchase or conditional sale arrangement or arrangements having similar effect
in respect of goods supplied to a member of the Group in the ordinary course of trading and on the suppliers standard or usual
terms and not arising as a result of any default or omission by any member of the Group; or

 

(vi)         any
Security securing indebtedness the principal amount of which (when aggregated with the principal amount of any other indebtedness
which has the benefit of Security given by any member of the Group other than any permitted under paragraphs (i) to (v) above)
does not exceed EUR 500,000 (five hundred thousand euros) (or its equivalent in another currency or currencies).

 

    	44

     

    

 

		7.03	Pari passu ranking

 

The Borrower shall ensure that its
payment obligations under this Contract rank, and will rank not less than pari passu in right of payment with ail other present
and future unsecured and unsubordinated obligations under any of its debt instruments except for obligations mandatorily preferred
by law applying to companies generally.

 

		7.04	Clauses by inclusion

 

If the Borrower or any other member
of the Group concludes with any other financial creditor a financing agreement that includes a loss-of-rating clause or a covenant
or other provision regarding its financial ratios, if applicable, that is not provided for in this Contract or is more favourable
to the relevant financial creditor than any equivalent provision of this Contract is to the Bank, the Borrower shall promptly inform
the Bank and shall provide a copy of the more favourable provision to the Bank. The Bank may request that the Borrower promptly
executes an agreement to amend this Contract so as to provide for an equivalent provision in favour of the Bank.

 

		7.05	Bond de-minimis repayment provisions

 

The Borrower may only voluntarily
prepay the convertible bond due 1 January 2021 (as set out under Schedule G (Permitted Indebtedness)) and the convertible bond
due 1 January 2022 (as set out under Schedule G (Permitted Indebtedness)) in accordance with the terms of the “Early Redemption
for reasons of minimal outstanding Principal Amount” provision listed under the relevant part of the column entitled “De-minimis
repayment provisions” of Schedule G (Existing Indebtedness)). The Borrower may not amend the “Early Redemption for
reasons of minimal outstanding Principal Amount” provision of such bonds (or any other provisions of such bonds which may
affect the de-minimis repayment terms of such bonds), without the prior written consent of the Bank.

 

ARTICLE
8

 

Information and Visits

 

		8.01	Information concerning the Project

 

The Borrower shall:

 

		(a)	deliver to the Bank:

 

(i)       the
information in content and in form, and at the times, specified in Part A2 of Schedule A or otherwise as agreed from time to time
by the parties to this Contract;

 

(ii)       any
such information or further document concerning the Project as the Bank may reasonably require to comply with its obligations under
the EFSI Regulation, and

 

    	45

     

    

 

(iii)       any
such information or further document concerning the financing, procurement, implementation, operation and environmental matters
of or for the Project as the Bank may reasonably require within a reasonable time,

 

provided always that if such information
or document is not delivered to the Bank on time, and the Borrower does not rectify the omission within a reasonable time set by
the Bank in writing, the Bank may remedy the deficiency, to the extent feasible, by employing its own staff or a consultant or
any other third party, at the Borrowers expense and the Borrower shall provide such persons with all assistance necessary for the
purpose;

 

		(b)	submit for the approval of the Bank without delay any material change to the Project, also taking
into account the disclosures made to the Bank in connection with the Project prior to the signing of this Contract, in respect
of, inter alia, the price, design, plans, timetable or to the expenditure programme or financing plan for the Project;

 

		(c)	promptly inform the Bank of:

 

(i)       any
action or protest initiated or any objection raised by any third party or any genuine complaint received by the Borrower or any
material Environmental Claim that is to its knowledge commenced, pending or threatened against it with regard to environmental
or other matters affecting the Project: and

 

(ii)       any
fact or event known to the Borrower, which may substantially prejudice or affect the conditions of execution or operation of the
Project;

 

(iii)       a
genuine allegation, complaint or information with regard to Illegal Activities related to the Loan and/or the Project:

 

(iv)       any
non-compliance by it with any applicable Environmental Law and

 

(v)       any
suspension, revocation or modification of any Environmental Approval,

 

and set out the action to be taken
with respect to such matters; and

 

		(d)	provide to the Bank, if so requested a certificate of its insurers showing fulfilment of the requirements
of Article 6.05(c);

 

		8.02	Information concerning the Borrower

 

The Borrower shall:

 

		(a)	deliver to the Bank:

 

    	46

     

    

 

(i)         as
soon as they become available, but in any event within 180 days after the end of each of its financial, its audited consolidated
and unconsolidated annual report, balance sheet, profit and loss account and auditors report for that financial year, provided
that if Article 8.05 (Confidential Information) applies, such information shall be provided to the Bank as soon as it becomes publicly
available;

 

(ii)         as
soon as they become available, but in any event within 120 days after the end of each of the relevant accounting periods for its
interim consolidated and unconsolidated semi-annual report, balance sheet and profit and loss account for the first half-year of
each of its financial years, provided that if Article 8.05 (Confidential Information) applies, such information shall be provided
to the Bank as soon as it becomes publicly available;

 

(iii)         on
the earlier of

 

		(A)	the date on which its financial, its audited consolidated and unconsolidated annual report, balance
sheet, profit and loss account and auditors report for that financial year are delivered to the Bank under paragraph (i) above;
and

 

		(B)	the date which is within 180 days after the end of each of its financial years,

 

a Compliance Certificate as set out
in Schedule E signed by two directors of the Borrower (provided that if at the relevant time the Borrower only has one appointed
director, the Compliance Certificate shall be signed by such director);

 

(iv)         on
the earlier of:

 

		(A)	the date on which its interim consolidated and unconsolidated semi-annual report, balance sheet
and profit and loss account for the first half-year of each of its financial years are delivered to the Bank under paragraph (ii)
above; and

 

		(B)	the date which is within 120 days after the end of each of the accounting periods for its interim
consolidated and unconsolidated semi-annual report,

 

a Compliance Certificate as set out
in Schedule E signed by two directors of the Borrower (provided that if at the relevant time the Borrower only has one appointed
director, the Compliance Certificate shall be signed by such director);

 

(v)         subject
to the provisions of Article 8.05 (Confidential information), as soon as they become available but in any event within 30 days
after the end of each of its financial half years:

 

    	47

     

    

 

		A.	the budgets which were delivered to and approved by the board of directors;

 

		B.	an update on the financial performance of the Borrower against the agreed budgets;

 

		C.	a succinct notification on the significant clinical and regulatory development milestones or achievements
of the Borrower’s product portfolio; and

 

		D.	a succinct notification on the significant changes in the development, licensing and distribution
contracts portfolio related to the Borrower’s product portfolio;

 

(vi)         from
time to time, such further information on its general financial situation as the Bank may reasonably require or such certificates
of compliance with the undertakings of Article 6 as the Bank may deem necessary;

 

(vii)        any
such information or further document concerning customer due diligence matters of or for the Borrower as the Bank may reasonably
require within a reasonable time; and

 

(viii)       notify
the Bank at least 5 Business Days prior to any prepayment of any bond listed under Schedule G (Permitted Indebtedness) and where
the prepayment relates to a convertible bond such notification shalt be accompanied with a confirmation from the Borrower that
the prepayment is in accordance with the terms of the “Early Redemption for reasons of minimal outstanding Principal Amount’
provision listed under the relevant part of the column entitled “De-minimis repayment provisions” of Schedule G (Existing
indebtedness));

 

and

 

		(b)	inform the Bank immediately in writing of:

 

(i)           any
material alteration to its articles of association or shareholding structure and of any change of ownership of 5% or more of its
shares after the date of this Contract;

 

(ii)          any
fact which obliges it to prepay any financial indebtedness or any European Union funding;

 

(iii)         any
event or decision that constitutes or may result in a Prepayment Event;

 

(iv)         any
intention on its part to grant any security over any of its assets in favour of a third party;

 

    	48

     

    

 

(v)       any
intention on its part to relinquish ownership of any material component of the Project;

 

(vi)       any
fact or event that is reasonably likely to prevent the substantial fulfilment of any obligation of the Borrower under this Contract;

 

(vii)      any
event listed in Article 10.01 having occurred or being threatened or anticipated;

 

(viii)     any
investigations concerning the integrity of the members of the Borrower’s Board of Directors, supervisory board or managers;

 

(ix)       to
the extent permitted by law, any material litigation, arbitration, administrative proceedings or investigation carried out by a
court, administration or similar public authority, which, to the best of its knowledge and belief, is current, imminent or pending
against the Borrower or its controlling entities or members of the Borrowers management bodies in connection with Illegal Activities
related to the Loan or the Project;

 

(x)        any
measure taken by the Borrower pursuant to Article 6.05 6.05(f) of this Contract; and

 

(xi)       any
litigation, arbitration or administrative proceedings or investigation which is current, threatened or pending and which might,
if adversely determined, reasonably likely result in a Material Adverse Change.

 

		8.03	Visits by the Bank

 

The Borrower shall allow the Bank
and, when either required by the relevant mandatory provisions of EU law or pursuant to the EFSI Regulation, the competent EU institutions
Including the European Court of Auditors, the Commission, the European Anti-Fraud Office, as well as person designated by the foregoing.

 

		(a)	to visit the sites, installations and works comprising the Project;

 

		(b)	to interview representatives of the Borrower, and not obstruct contacts with any other person involved
in or affected by the Project; and

 

		(c)	to conduct such on the spot audits and checks as they may wish and review the Borrower’s
books and records in relation to the execution of the Project and to be able to take copies of related documents to the extent
permitted by the law.

 

The Borrower shall provide the Bank,
or ensure that the Bank is provided, with all necessary assistance for the purposes described in this Article.

 

    	49

     

    

 

In the case of a genuine allegation,
complaint or information with regard to Illegal Activities related to the Loan and/or the Project, the Borrower shall consult with
the Bank in good faith regarding appropriate actions. In particular, if it is proven that a third party committed Illegal Activities
in connection with the Loan and/or the Prefect with the result that the Loan or the EFSI financing were misapplied, the Bank may,
without prejudice to the other provisions of this Contract, inform the Borrower if, in its view, the Borrower should take appropriate
recovery measures against such third party. In any such case, the Borrower shall in good faith consider the Bank’s views
and keep the Bank informed.

 

The Borrower acknowledges that the
Bank may be obliged to communicate information relating to the Borrower and the Project to any competent institution or body of
the European Union in accordance with the relevant mandatory provisions of European Union law.

 

		8.04	Disclosure and publication

 

The Borrower acknowledges and agrees
that:

 

		(a)	the Bank may be obliged to communicate information relating to the Borrower and the Project to
any competent institution or body of the European Union in accordance with the relevant mandatory provisions of European Union
law or pursuant to the EFSI Regulation; and

 

		(b)	the Bank may publish on its website or produce press releases containing information related to
the financing provided pursuant to this Contract, with support of the EFSI including the name, address of the Borrower, the purpose
of the financing and the type of financial support received under this Contract.

 

		(c)	The Borrower hereby releases the Bank from any bank secrecy. Accordingly, the Bank may disclose
all confidential information concerning this Contract, the Guarantee or any related document and the transactions envisaged thereunder
that has been provided to the Bank by the Borrower or, on their behalf, third parties (including, but without limitation, the fact
that the Bank and the Obligors entered into the business relationship established under this Contract, the Guarantee or any related
document, the amount and the conditions of the Loans, the interest rate, provided security interests, the presence of a Default,
any financial information on any of the Obligors) to such persons as permitted under this Article 8,04.

 

		(d)	To the extent legally permissible, the above release in respect of any bank secrecy is irrevocable.

 

		8.05	Confidential information

 

Where the Borrower provides information
to the Bank in connection with this Contract, it shall clearly indicate whether or not such information is already public, and
if it is confidential the Borrower shall ensure the public publication of such information at the same time, or immediately after,
it is shared with the Bank. The Borrower will not share any inside information with the Bank before it is published to the market

 

    	50

     

    

 

ARTICLE
9

 

Charges and expenses

 

		9.01	Taxes, uties and fees

 

The Borrower shall pay all Taxes,
duties, fees and other impositions of whatsoever nature, including stamp duty and registration fees, arising out of the execution
or implementation of this Contract or any related document and in the creation, perfection, registration or enforcement of any
security for the Loan to the extent applicable.

 

The Borrower shall pay all principal,
interest, indemnities and other amounts due under this Contract gross without deduction of any national or local impositions whatsoever;
provided that, if the Borrower is obliged to make any such deduction, it will gross up the payment to the Bank so that after deduction,
the net amount received by the Bank is equivalent to the sum due.

 

		9.02	Other charges

 

The Borrower shall bear all charges
and expenses, including professional, banking or exchange charges incurred in connection with the preparation, execution, implementation,
enforcement and termination of this Contract and/or any Guarantee or any related document, any amendment, supplement or waiver
in respect of this Contract and/or any Guarantee or any related document, and in the amendment, creation, management, enforcement
and realisation of any Guarantee.

 

		9.03	Increased costs, indemnity and set-off

 

		(a)	The Borrower shall pay to the Bank any sums or expenses incurred or suffered by the Bank as a consequence
of the introduction of or any change in (or in the interpretation, administration or application of) any law or regulation or compliance
with any law or regulation made after the date of signature of this Contract the Guarantee and/or any other related document, in
accordance with or as a result of which (i) the Bank is obliged to incur additional costs in order to fund or perform its obligations
under this Contract, the Guarantee and/or any other related document or (ii) any amount owed to the Bank under this Contract, the
Guarantee and/or any other related document or the financial income resulting from the granting of the Credit or the Loan by the
Bank to the Borrower is reduced or eliminated.

 

		(b)	Without prejudice to any other rights of the Bank under this Contract or under any applicable law,
the Borrower shall indemnify and hold the Bank harmless from and against any loss incurred as a result of any payment or partial
discharge that takes place in a manner other than as expressly set out in this Contract.

 

    	51

     

    

 

		(c)	The Bank may set off any matured obligation due from the Borrower under this Contract (to the extent
beneficially owned by the Bank) against any obligation (whether or not matured) owed by the Bank to the Borrower regardless of
the place of payment, backing branch or currency of either obligation. If the obligations are in different currencies, the Bank
may convert either obligation at a market rate of exchange in its usual course of business for the purpose of the set-off. If either
obligation is unliquidated or unascertained, the Bank may set off in an amount estimated by it in good faith to be the amount of
that obligation.

 

ARTICLE
10

 

Events of Default

 

		10.01	Right to demand repayment

 

Upon written demand being made by
the Bank in accordance with the following provisions the Borrower shall repay all or part of the Loan (as requested by the Bank)
forthwith, together with accrued interest and all other accrued or outstanding amounts under this Contract provided that, if an
Event of Default under Article 10.01A(m) below shall occur, then without notice, demand or any other act by the Bank or any other
person, the obligation of the Bank to make any Loan and the Credit shall automatically terminate, all of the Loans, together with
accrued interest, and all other amounts accrued or outstanding under this Contract or any Guarantee Agreement shall become immediately
due and payable without presentment, demand, protest or notice of any kind, all of which are expressly waived.

 

For the avoidance of doubt, the Bank’s
right to cancel the Credit pursuant to Article 1.05B shall not be restricted.

 

		10.01A	Immediate demand

 

The Bank may make such demand immediately:

 

		(a)	if the Borrower does not pay on the due date any amount payable pursuant to this Contract at the
place and in the currency in which it is expressed to be payable, unless (i) its failure to pay is caused by an administrative
or technical error or a Disruption Event and (ii) payment is made within 3 Business Days of its due date;

 

		(b)	if any information or document given to the Bank by or on behalf of the Borrower or any Guarantor
or any representation, warranty or statement made or deemed to be made by the Borrower or any Guarantor in or pursuant to this
Contract or any Guarantee (as applicable) is or proves to have been incorrect, incomplete or misleading in any material respect;

 

		(c)	if, following any default of the Borrower, any Guarantor or any other member of the Group in relation
to any loan, or any obligation arising out of any financial transaction other than the Loan:

 

(i)         the
Borrower, any Guarantor or any other member of the Group is required or is capable of being required or will, following expiry
of any applicable contractual grace period, be required or be capable of being required to prepay, discharge, close out or terminate
ahead of maturity such other loan or obligation; or

 

    	52

     

    

 

(ii)        any
financial commitment for such other loan or obligation is cancelled or suspended;

 

		(d)	if the Borrower, any Guarantor or any other member of the Group incorporated in Germany:

 

(i)         is
unable to pay its debts as they fall due (zahlungsunfähig) or is declared or is deemed to be unable to pay its debts
as they fall due (drohend zahlungsunfähig) within the meaning of sections 17 and 18 of the German Insolvency Code (Insolvenzordnung),
suspends making payments on all or a material part of its debts or announces an intention to do so;

 

(ii)        is
over-indebted within the meaning of section 19 of the German Insolvency Code (Insolvenzordnung) or, with respect to any
other member of the Group, the value of the assets of any member of the Group is less than its liabilities (taking into account
contingent and prospective liabilities);

 

(iii)       commences
negotiations with any one or more of its creditors with a view to the general readjustment or rescheduling of its indebtedness;

 

(iv)       files
for insolvency (Antrag auf Eröffnung eines Insolvenzverfahrens); or

 

(v)        preliminary
insolvency administrator has been appointed or any other action has been taken within the meaning of section 21 of the German Insolvency
Code (Insolvenzordnung) or the opening of insolvency proceedings is rejected due to insufficiency of funds (Abweisung
mangels Masse):

 

		(e)	if the Borrower, any Guarantor or any other member of the Group incorporated in any jurisdiction
other than Germany is unable to pay its debts as they fall due, or suspends its debts, or makes or seeks to make a composition
with its creditors including a moratorium, or commences negotiations with one or more of its creditors with a view to rescheduling
any of its financial indebtedness;

 

		(f)	if any corporate action, legal proceedings or other procedure or step is taken in relation to the
suspension of payments, a moratorium of any indebtedness, dissolution, administration or reorganisation (by way of voluntary arrangement,
scheme of arrangement or otherwise or an order is made or an effective resolution is passed for the winding up of the Borrower,
any Guarantor or any member of the Group, or if the Borrower, any Guarantor or any member of the Group takes steps towards a substantial
reduction in its capital, is declared insolvent or ceases or resolves to cease to carry on the whole or any substantial part of
its business or activities;

 

    	53

     

    

 

		(g)	if an encumbrancer takes possession of, or a receiver, liquidator, administrator, administrative
receiver or similar officer is appointed, whether by a court of competent jurisdiction or by any competent administrative authority
or by any person, of or over, any part of the business or assets of the Borrower, any Guarantor or any member of the Group or any
property forming part of the Project;

 

		(h)	if the Borrower, any Guarantor or any member of the Group defaults in the performance of any obligation
in respect of any other loan granted by the Bank or financial instrument entered into with the Bank,

 

		(i)	if the Borrower, any Guarantor or any member of the Group defaults in the performance of any obligation
in respect of any other loan made to it from the resources of the Bank or the European Union;

 

		(j)	if any distress, execution, sequestration or other process is levied or enforced upon the property
of the Borrower or any property forming part of the Project and is not discharged or stayed within 14 (fourteen) days;

 

		(k)	if a Material Adverse Change occurs, as compared with the Borrower’s or any Guarantor’s
condition at the date of this Contract;

 

		(l)	if it is or becomes unlawful for the Borrower or any Guarantor to perform any of its obligations
under this Contract or any Guarantee or this Contract or any Guarantee is not effective in accordance with its terms or is alleged
by the Borrower or any Guarantor to be ineffective in accordance with its terms; or

 

		(m)	without limiting any of the other clauses of this Article 10.01A:

 

(i)         a
court of the US or any state thereof (a “US Federal or State Court”) having jurisdiction in the premises shall enter
a decree or order for relief in respect of any other member of the Group or for all or any material part of its property in an
involuntary case under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law of the US or any
state thereof now or hereafter in effect, which decree or order is not stayed or dismissed within seven days of it being entered;
or any other similar relief shall be granted under any applicable US federal or state law;

 

(ii)        an
involuntary case shall be commenced against the Borrower, any Guarantor or any other member of the Group or for all or any material
part of its property under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law of the US or
any state thereof now or hereafter in effect; or a decree or order of a US Federal or State court having jurisdiction in the premises
for the appointment of a receiver, liquidator, sequestrator, trustee, custodian or other officer having similar powers over the
Borrower, any Guarantor or any other member of the Group, or over all or a material part of its property, shall have been entered;
and in any such event described in this paragraph (ii) shall continue for 60 days unless dismissed or discharged; or

 

    	54

     

    

 

(iii)       the
Borrower, any Guarantor or any other member of the Group shall have an order for relief entered with respect to it (or for all
or any material part of its property) in a voluntary case or commence a voluntary case under the Bankruptcy Code or under any other
applicable bankruptcy, insolvency or similar law of the US or any state thereof now or hereafter in effect, or shall consent to
the entry of an order for relieve in an involuntary case, or to the conversion of an involuntary case to a voluntary case, under
any such law.

 

10.01B Demand after notice to remedy

 

The Bank may also make such demand:

 

		(i)	if the Borrower fails to comply with any obligation under this Contract not being an obligation
mentioned in Article 10.01A or any Guarantor fails to comply with any obligation under any Guarantee or Guarantee Agreement: or

 

(ii)        if
any fact related to the Borrower or the Project stated in the Recitals materially alters and is not materially restored and if
the alteration either prejudices the interests of the Bank as lender to the Borrower or adversely affects the implementation or
operation of the Project, unless the non-compliance or circumstance giving rise to the non-compliance is capable of remedy and
is remedied within 20 Business Days from a notice served by the Bank on the Borrower or any Guarantor.

 

		10.02	Other rights at law

 

Article 10.01 shall not restrict
any other right of the Bank at law to require prepayment of the Loan.

 

		10.03	Indemnity

 

10.03(A) Trenches

 

In case of demand under Article 10.01
in respect of any Tranche, the Borrower shall pay to the Bank the amount demanded together with the Prepayment Fee on any amount
of principal due to be prepaid. Such Prepayment Fee payable as a result of cancellation and/or repayment of the Loan pursuant to
Article 10.01 in respect of any Tranche shall be calculated in accordance with Article 4.02E but on the basis that:

 

		(a)	the “Prepayment Date” shall be deemed to be the date specified in the written demand
from the Bank, and

 

		(b)	the “Prepayment Amount” shall be deemed to be the relevant amount demanded by the Bank
pursuant to this Article 10.01.

 

    	55

     

    

 

10.03(B) General

 

Amounts due by the Borrower pursuant
to this Article 10.03 shall be payable on the date of prepayment specified in the Bank’s demand.

 

		10.04	Non-Waiver

 

No failure or delay or single or
partial exercise by the Bank in exercising any of its rights or remedies under this Contract shall be construed as a waiver of
such right or remedy. The rights and remedies provided in this Contract are cumulative and not exclusive of any rights or remedies
provided by law.

 

ARTICLE
11

 

Law and jurisdiction,
miscellaneous

 

		11.01	Governing Law

 

This Contract and any non-contractual
obligations arising out of or in connection with it shall be governed by the laws of England and Wales.

 

		11.02	Jurisdiction

 

		(a)	The courts of England have exclusive jurisdiction to settle any dispute (a “Dispute”)
arising out of or in connection with this Contract (including a dispute regarding the existence, validity or termination of this
Contract or the consequences of its nullity) or any non-contractual obligation arising out of or in connection with this Contract.

 

		(b)	The parties agree that the courts of England are the most appropriate and convenient courts to
settle Disputes between them and, accordingly, that they will not argue to the contrary.

 

		(c)	This Article 11.02 is for the benefit of the Bank only. As a result and notwithstanding Article
11.02(a), it does not prevent the Bank from taking proceedings relating to a dispute (including a dispute relating to the existence,
validity or termination hereof or any non-contractual obligation arising out of or in connection with this Contract) in any other
courts with jurisdiction. To the extent allowed by law, the Bank may take concurrent proceedings in any number of jurisdictions.

 

		11.03	Agent of Service

 

Without prejudice to any other mode
of service allowed under any relevant law, the Borrower hereby irrevocably appoints Elemental Process Agent Limited (company number
01745936), 27 Old Gloucester Street, London WC1N 3AX as its agent of service for the purposes of accepting service on its behalf
of any writ, notice, order, judgement or other legal process. The Borrower agrees that failure by a process agent to notify it
of the process will not invalidate the proceedings concerned. The Borrower unconditionally releases the agent of service from the
restrictions of section 181 of the German Civil Code (Bürgeriiches Gesetzbuch), to the extent legally permissible.

 

    	56

     

    

 

The Bank hereby appoints The Securities
Management Trust Limited of 8 Lothbury, London EC2 7HH to be its agent for the purpose of accepting service of legal process.

 

		11.04	Place of performance

 

Unless otherwise specifically agreed
by the Bank in writing, the place of performance under this Contract, shall be the seat of the Bank.

 

		11.05	Evidence of sums due

 

In any legal action arising out of
this Contract the certificate of the Bank as to any amount or rate due to the Bank under this Contract shall, in the absence of
manifest error, be prima facie evidence of such amount or rate.

 

		11.06	Third party rights

 

A person who is not a party has no
right under the Contracts (Rights of Third Parties) Act 1999 to enforce or to enjoy the benefit of any term of this Contract.

 

		11.07	Entire Agreement

 

This Contract constitutes the entire
agreement between the Bank and the Borrower in relation to the provision of the Credit hereunder, and supersedes any previous agreement,
whether express or implied, on the same matter.

 

		11.08	Invalidity

 

If at any time any term of this Contract
is or becomes illegal, invalid or unenforceable in any respect, or this Contract is or becomes ineffective in any respect, under
the laws of any jurisdiction, such illegality, invalidity, unenforceability or ineffectiveness shall not affect:

 

		(a)	the legality, validity or enforceability in that jurisdiction of any other term of this Contract
or the effectiveness in any other respect of this Contract in that jurisdiction; or

 

		(b)	the legality, validity or enforceability in other jurisdictions of that or any other term of this
Contract or the effectiveness of this Contract under the laws of such other jurisdictions.

 

		11.09	Amendments

 

Any amendment to this Contract shall
be made in writing and shall be signed by the parties hereto.

 

    	57

     

    

 

		11.10	Counterparts

 

This Contract may be executed in
any number of counterparts, all of which taken together shall constitute one and the same instrument. Each counterpart is an original,
but all counterparts shall together constitute one and the same instrument.

 

ARTICLE
12

 

Final clauses

 

		12.01	Notices to either party

 

Notices and other communications
given under this Contract addressed to either party to this Contract shall be made to the address, email address or facsimile number
as set out below, or to such other address, email address or facsimile number as a party previously notifies to the other in writing:

 

	For the Bank	Attention Ops
	 	100 boulevard Konrad Adenauer
	 	L-2950 Luxembourg
	 	 
	 	Facsimile no: +352 43 79 67397
	 	 
	 	Email address:	ops-enpst3-shared©eib.org
	 	 	y.zhang@eib.org
	 	 	 
	For the Borrower	Attention:  Chief Financial Officer
	 	 
	 	Hemmelrather Weg 201, 51377 Leverkusen, Germany
	 	Facsimile no.:	+49 (214) 876 3290
	 	Email address: 	press@biofrontera.com

 

		12.02	Form of notice

 

Any notice or other communication
given under this Contract must be in writing.

 

Notices and other communications,
for which fixed periods are laid down in this Contract or which themselves fix periods binding on the addressee, may be made by
hand delivery, registered letter, facsimile or e-mail. Such notices and communications shall be deemed to have been received by
the other party on the date of delivery in relation to a hand-delivered or registered letter, on receipt of transmission in relation
to a facsimile, or on the date when the e-mail is sent in relation to an e-mail message from the Bank to the Borrower or when confirmed
by return e-mail by an authorised officer of the Bank to have been received in readable form, in the case of an e-mail sent by
the Borrower to the Bank.

 

Other notices and communications
may be made by hand delivery, registered letter, facsimile or e mail.

 

    	58

     

    

 

Without affecting the validity of
any notice delivered by e-mail or facsimile according to the paragraphs above, a copy of each notice delivered by e-mail or facsimile
shall also be sent by letter to the relevant party on the next following Business Day at the latest.

 

Notices issued by the Borrower pursuant
to any provision of this Contract shall, where required by the Bank, be delivered to the Bank together with satisfactory evidence
of the authority of the person or persons authorised to sign such notice on behalf of the Borrower and the authenticated specimen
signature of such person or persons.

 

		12.03	Recitals and Schedules

 

The Recitals and the following Schedules
form part of this Contract:

 

	Schedule A	Project Specification and Reporting
	 	 
	Schedule B	Definition of EURIBOR
	 	 
	Schedule C	Forms for Borrower
	 	 
	Schedule D	Form of Certificate from Borrower
	 	 
	Schedule E	Compliance Certificate
	 	 
	Schedule F	Performance Participation Interest Examples
	 	 
	Schedule G	Existing Indebtedness
	 	 

 

IN WITNESS WHEREOF the parties hereto
have caused this Contract to be executed on the date referred to below:

 

At Luxembourg, this _____ May 2017

 

	Signed for and on behalf of	Signed for and on behalf of
	 	 
	EUROPEAN INVESTMENT BANK	BIOFRONTERA AG
	 	 
	Name:	Adrian Kamenitzer	Name:	Stefan Becker	Name:	Prof. Dr. Hermann Lübbert	Name:	Thomas Schaffer
	Title:	Director	Title:	Senior Counsel	Title:	CEO (Vorstadsvorsitzender)	Title:	CFO (Vorstand)
	 	 	 	 	 	 	 	 
	Signature:	Signature:	Signature:	Signature:

 

    	59

     

    

 

Schedule A

 

Project Specification and Reporting

 

Part A1 Technical Description (Article
6.02)

 

Purpose, Location

 

The Project concerns the Borrowers research
and development activity on the expansion of indications for its lead product, Ameluz. These indications include the treatment
of non-melanoma skin cancers, such as Basal Cell Carcinoma. The Borrower, established in 1997, is headquartered in Leverkusen,
Germany and currently employs over 60 people.

 

Description

 

The Project comprises of running post-marketing
level clinical trials to produce data for obtaining regulatory clearances, both in the European Union and the US, for their lead
product in different indications and treatment modalities. In addition, such data is to be used for gaining reimbursement in all
main markets. More specifically, it includes four sub-projects:

 

		(i)	Producing supportive clinical and preclinical data to gain marketing authorization for Ameluz in
various new indications in the European Union;

 

		(ii)	Generating an Active Substance Masterfile (ASMF) for 5-aminolevulic acid to be used in regulatory
filings outside the US;

 

		(iii)	Activities related to filing in the US of a New Drug Application (NDA) for Ameluz to be used in
conjunction with Rhodoled; and

 

		(iv)	Collecting clinical data to support a label claim of using Ameluz in daylight phatodynamic therapy
(PDT).

 

Calendar

 

The Project will be implemented over the period
2016-2020.

 

    	60

     

    

 

Part A2 - Information Duties under Article
8.01(a)

 

		1.	Dispatch of information: designation of the person responsible

 

The information below has to be sent
to the Bank under the responsibility of:

 

	 	Contact
	Company	Biofrontera AG
	Contact person	Hermann Lübbert
	Title	CEO
	Address	Hemmelrather Weg 20, D-51377 Leverkusen
	Phone	+49 214 876 32 0
	Fax	+49 214 876 32 90
	Email	h.luebbert@biofrontera.com

 

The above-mentioned contact person(s)
is (are) the responsible contact(s) for the time being. The Borrower shall inform the Bank immediately in case of any change.

 

		2.	Information on specific subjects

 

The Borrower shall deliver to the
Bank the following information at the latest by the deadline indicated below.

 

	Document / information	 	Deadline
	N/A	 	 

 

		3.	Information on the project’s implementation

 

The Borrower shall deliver to the
Bank the following information on project progress during implementation at the latest by the deadline indicated below.

 

	Document / information	 	Deadline	 	Frequency

of

Reporting
	Project Progress Report	 	30 April 2016	 	Annually
	 	 	 	 	 
	-	A brief update on the Technical Description, explaining the reasons for significant changes vs. initial scope;	 	30 April 2019	 	 
	-	Update on the date of completion of each of the main	 	 	 	 
	-	Project’s components, explaining reasons for any possible delay;	 	 	 	 
	-	Update on the cost of the Project, explaining reasons for any possible cost variations vs. initial budgeted cost;	 	 	 	 

 

    	61

     

    

 

	Document / information	 	Deadline	 	Frequency

of

Reporting
	-	A description of any major issue with impact on the environment;	 	 	 	 
	-	Update on the Project’s demand or usage and comments;	 	 	 	 
	-	Any significant issue that has occurred and any significant risk that may affect the Project’s operation;	 	 	 	 
	-	Any legal action concerning the Project that may be on-going;	 	 	 	 
	-	Non-confidential project-related pictures, if available.	 	 	 	 

 

Table 1. Initial Project Cost Breakdown
(monitoring reference):

 

	EUR 000	 	2016	 	 	2017	 	 	2018	 	 	2019	 	 	2020	 	 	Total	 
	Personnel	 	 	1.5	 	 	 	1.9	 	 	 	2.1	 	 	 	2.2	 	 	 	2.3	 	 	 	10.0	 
	Consumables	 	 	0.8	 	 	 	0.3	 	 	 	0.4	 	 	 	0.5	 	 	 	0.6	 	 	 	2.6	 
	CROs	 	 	10	 	 	 	2.9	 	 	 	2.6	 	 	 	2.9	 	 	 	2.9	 	 	 	12.2	 
	Regulatory approval	 	 	1.6	 	 	 	1.0	 	 	 	1.0	 	 	 	1.1	 	 	 	1.1	 	 	 	5.9	 
	Services	 	 	0.6	 	 	 	0.6	 	 	 	1,8	 	 	 	1.4	 	 	 	1.4	 	 	 	5.8	 
	Other	 	 	0.8	 	 	 	0.8	 	 	 	0.8	 	 	 	0.8	 	 	 	0.9	 	 	 	4.1	 
	Total costs	 	 	6.2	 	 	 	7.4	 	 	 	8.7	 	 	 	9.0	 	 	 	9.2	 	 	 	40.5	 

 

		4.	Information on the end of works and first year of operation

 

The Borrower shall deliver to the
Bank the following information on project completion and initial operation at the latest by the deadline indicated below.

 

	Document / information	 	Date of delivery

to the Bank
	Project Completion Report, including	 	30 June 2020
	-	A final Technical Description of the Project as completed, explaining the reasons for any significant change compared to the Technical Description in A.1.;	 	 
	-	The date of completion of each of the main project’s components, explaining reasons for any possible delay;	 	 
	-	The date of completion of each of the main project’s components, explaining reasons for any possible delay;	 	 
	-	The final cost of the Project, explaining reasons for any possible cost variations vs. initial budgeted cost;	 	 
	-	Employment effects of the project: person-days required during implementation as well as permanent new jobs created;	 	 
	-	A description of any major issue with impact on the environment or social impacts;	 	 
	-	Update on procurement procedures and explanation of deviations from the procurement plan;	 	 
	-	Update on the Project’s demand or usage and comments;	 	 
	-	Any significant issue that has occurred and any significant risk that may affect the Project’s operation;	 	 
	-	Any legal action concerning the Project that may be on-going;	 	 
	-	An update on the following Monitoring Indicators:	 	 

 

	Language of reports	English

 

    	62

     

    

 

Schedule B

 

Definitions of EURIBOR

 

		A.	EURIBOR

 

“EURIBOR” means:

 

		(a)	in respect of a relevant period of less than one month, the Screen Rate (as defined below) for
a term of one month;

 

		(b)	in respect of a relevant period of one or more months for which a Screen Rate is available, the
applicable Screen Rate for a term for the corresponding number of months; and

 

		(c)	in respect of a relevant period of more than one month for which a Screen Rate is not available,
the rate resulting from a linear interpolation by reference to two Screen Rates, one of which is applicable for a period next shorter
and the other for a period next longer than the length of the relevant period,

 

(the period for which the rate is
taken or from which the rates are interpolated being the “Representative Period”).

 

For the purposes of paragraphs (b)
and (c) above, “available” means the rates, for given maturities, that are calculated and published by Global Rate
Set Systems Ltd (GRSS), or such other service provider selected by the European Money Markets Institute (EMMI), under the sponsorship
of EMMI and EURIBOR AC I, or any successor to that function of EMMI and EURIBOR ACI as determined by the Bank.

 

“Screen Rate”
means the rate of interest for deposits in EUR far the relevant period as published at 11h00, Brussels time, or at a later time
acceptable to the Sank on the day (the “Reset Date”) which falls 2 (two) Relevant Business Days prior to the first
day of the relevant period, on Reuters page EURIBOR 01 or its successor page or, failing which, by any other means of publication
chosen for this purpose by the Bank.

 

If such Screen Rate is not so published,
the Bank shall request the principal euro-zone offices of four major banks in the euro-zone, selected by the Bank. to quote the
rate at which EUR deposits in a comparable amount are offered by each of them as at approximately 111100, Brussels time, on the
Reset Date to prime banks in the euro-zone interbank market for a period equal to the Representative Period. If at least 2 (two)
quotations are provided, the rate for that Reset Date will be the arithmetic mean of the quotations.

 

If fewer than 2 (two) quotations
are provided as requested, the rate for that. Reset Date will be the arithmetic mean of the rates quoted by major banks in the
euro-zone, selected by the Bank, at approximately 11h00, Brussels time, on the day which falls 2 (two) Relevant Business Days after
the Reset Date, for loans in EUR in a comparable amount to leading European Banks for a period equal to the Representative Period.

 

    	63

     

    

 

If no rate is available as provided
above, EURIBOR shall be the rate (expressed as a percentage rate per annum) which is determined by the Bank to be the all-inclusive
cost to the Bank for the funding of the relevant Tranche based upon the then applicable internally generated Bank reference rate
or an alternative rate determination method reasonably determined by the Bank.

 

		B.	GENERAL

 

For the purposes of the foregoing
definitions

 

		(a)	All percentages resulting from any calculations referred to in this Schedule will be rounded, if
necessary, to the nearest one hundred-thousandth of a percentage point, with halves being rounded up.

 

		(b)	The Bank shall inform the Borrower without delay of the quotations received by the Bank.

 

		(c)	If any of the foregoing provisions becomes inconsistent with provisions adopted under the aegis
of EMMI and EURIBOR ACI (or any successor to that function of EMMI and EURIBOR ACI as determined by the Bank), the Bank may by
notice to the Borrower amend the provision to bring it into line with such other provisions.

 

    	64

     

    

 

Schedule C

 

Form of Disbursement Offer/Acceptance (Articles
1.02B and 1.02C)

 

		To:	Biofrontera AG

 

		From:	European Investment Bank

 

Date:

 

	Subject:	Disbursement Offer/Acceptance for the Finance Contract between European Investment Bank and Biofrontera AG dated [•] (the “Finance Contract”)
	 	 	 
	 	Fl number ________	Serapis number ________

 

 

Dear Sirs.

 

We refer to the Finance Contract. Terms defined
in the Finance Contract have the same meaning when used in this letter.

 

Following your request for a Disbursement Offer
from the Bank, in accordance with Article 1.02B of the Finance Contract, we hereby offer to make available to you the following
Tranche:

 

		(a)	the amount and currency to be disbursed:

 

		(b)	Scheduled Disbursement Date.

 

		(c)	the Cash Pay Margin applicable until the Maturity Date:

 

		(d)	the Disbursement Date Market Capitalisation:

 

		(e)	the Disbursement Date Notional Equity Proportion:

 

		(f)	the Deferred Interest Rate:

 

		(g)	the Interest payment periodicity;

 

		(h)	the Payment Dates:

 

		(i)	the Maturity Date:

 

To make the Tranche available subject to the
terms and conditions of the Finance Contract, the Bank must receive a Disbursement Acceptance in the form of a copy of this Disbursement
Offer duly signed on your behalf, to the following fax number [___] no later than the Disbursement Acceptance Deadline of Time),
Luxembourg time, on [date].

 

    	65

     

    

 

The Disbursement Acceptance must be accompanied
(if it has not been previously supplied) by:

 

		(a)	the indication of the bank account (with IBAN code in case of disbursements in FUR or the appropriate
format for the relevant currency) where disbursement of the Tranche should be made; and

 

		(b)	evidence of the authority of the person or persons authorised to sign it on behalf of the Borrower
and the specimen signature of such person or persons.

 

If not accepted by the above stated time, the
offer contained in this document shall be deemed to have been refused and shall automatically lapse,

 

If you do accept the Tranche as described in
this Disbursement Offer, all the related terms and conditions of the Finance Contract shall apply, in particular, the provisions
of Article 1.04.

 

	Yours faithfully,	 
	 	 
	EUROPEAN INVESTMENT BANK	 
	 	 
	We hereby accept the above Disbursement Offer:
	 	 
	 	 
	 	 
	For and behalf of Biofrontera AG	 
	 	 
	Date:	 

 

    	66

     

    

 

Schedule D

 

Form of Certificate from Borrower (Article
1.04(B))

 

		To:	European Investment Bank

 

		From:	Biofrontera AG

 

		Date:	 

 

	Subject:	Finance Contract between European Investment Bank and Biofrontera AG dated [•] (the “Finance Contract”)
	 	 	 
	 	Fl number ________	Serapis number ________

 

 

Dear Sirs,

 

Terms defined in the Finance Contract have
the same meaning when used in this letter. For the purposes of Article 1.04 of the Finance Contract we hereby certify to you as
follows:

 

		(a)	no Prepayment Event has occurred and is continuing unremedied;

 

		(b)	no security of the type prohibited under Article 7.02 has been created or is in existence;

 

		(c)	there has been no material change to any aspect of the Project or in respect of which we are obliged
to report under Article 8.01, save as previously communicated by us;

 

		(d)	no Default has occurred and is continuing unremedied or unwaived;

 

		(e)	no litigation, arbitration administrative proceedings or investigation is current or to our knowledge
is threatened or pending before any court, arbitral body or agency which has resulted or if adversely determined is reasonably
likely to result in a Material Adverse Change, nor is there subsisting against us or any of our subsidiaries any unsatisfied judgement
or award;

 

		(f)	the representations and warranties to be made or repeated by us under Article 6.21 are true
in all respects; and

 

		(g)	no Material Adverse Change has occurred, as compared with the situation at the date of the Finance
Contract.

 

	Yours faithfully,	 
	 	 
	 	 
	For and on behalf of Biofrontera AG	 
	Date:	 

 

    	67

     

    

 

Schedule E

 

Form of Compliance Certificate

 

		To	European Investment Bank

 

		From:	Biofrontera AG

 

		Date:	 

 

	Subject:	Finance Contract between European Investment Bank and Biofrontera AG dated [6] (the “Finance Contract”)
	 	 	 
	 	Fl number ________	Serapis number ________

 

 

Dear Sirs,

 

We refer to the Finance Contract. This is a
Compliance Certificate. Terms defined in the Finance Contract have the same meaning when used in this Compliance Certificate.

 

We hereby confirm:

 

(i)          no
security of the type prohibited under Article 7.02 has been created or is in existence;

 

(ii)         no
event or circumstance which constitutes or would with the passage of time or giving of notice under the Finance Contract constitute
an Event of Default has occurred and is continuing unremedied or unwaived. [If this statement cannot be made, this certificate
should identify any potential event of default that is continuing and the steps, if any, being taken to remedy it]; and

 

(iii)        it
has no other Material Subsidiaries other than the Material Subsidiaries identified in Recital 6 of the Finance Contract. [If this
statement cannot be made, this certificate should identify the relevant subsidiary and the steps under Article 7.01 will have to
occur].

 

	Yours faithfully,	 
	 	 
	For and on behalf of Biofrontera AG	 
	 	 
	[director]	[director]

 

    	68

     

    

 

Schedule F

 

Performance Participation Interest Examples

 

The following examples have been provided as
a worked example to illustrate the calculation of the Performance Participation Interest. These examples have been provided for
illustration purposes only

 

		1.	Disbursement Date in respect of the relevant Tranche (Year
1)

 

		•	Disbursement of Tranche = EUR 10,000,000

 

		•	Disbursement Date Market Capitalisation = EUR 160,000,000

 

		•	Disbursement Date Notional Equity Proportion = (EUR 10,000,000) x (2%) x (5 years) / (EUR 160,000,000)
= 0.00625 (or 0.625%)

 

		2.	Maturity Date in respect of the relevant Tranche (Year
5)

 

		(a)	Upside Scenario

 

		•	Maturity Date Market Capitalisation (in relation to the Maturity Date or on any date earlier than
the Maturity Date in the event of a prepayment or an acceleration of all or part of that Tranche) = EUR 200,000,000

 

		•	Performance Participation Interest = 0.00625 x EUR 200,000,000
= EUR 1,250,000

 

		(b)	Downside Scenario

 

		•	Maturity Date Market Capitalisation (in relation to the Maturity Date or on any date earlier than
the Maturity Date in the event of a prepayment or an acceleration of ail or part of that Tranche) = EUR 100,000,000.

 

		•	Performance Participation Interest = 0.00625 x EUR 100,000,000
= FUR 625,000

 

    	69

     

    

 

Schedule G

 

Existing Indebtedness

 

	Source	 	Outstanding amount	 	De-minimis repayment provision
	 	 	 	 	 
	8% option bond due 1 January 2018	 	EUR 4,930,000 (of which EUR 1,500,000 are held by Borrower)	 	N/A
	 	 	 	 	 
	6% subordinated convertible bond due 1 January 2021	 	EUR 83,000	 	Paragraph 4(4) of the terms of the bond states:
	 	 	 	 	 
	 	 	 	 	“Early Redemption for reasons of minimal outstanding Principal Amount. The Issuer may at any time redeem all, but not part of the Bonds at their Principal Amount, together with interest accrued thereon until (but excluding) the date of redemption if at any time the Principal Amount of the Bonds outstanding is below 15% of the initially issued amount of Bonds.  Notice of early redemption shall be given not less than 30 nor more than 60 days before the day fixed in the notice on which any Bonds become due for early redemption.  The Provisions of the preceding paragraph shall apply accordingly.”  
	 	 	 	 	 
	 	 	 	 	The provisions of the preceding paragraph state that such notice will be irrevocable and must state the date of the early redemption and the last day on which Conversion Rights may be exercised by Bondholders.
	 	 	 	 	 
	 	 	 	 	The initially issued amount of the Bonds was 49,990 bonds in a total nominal amount of EUR 4,999,000, so the de minimis threshold is reached when EUR 749,850 or less are outstanding (which is already the case as at the date of this Contract).
	 	 	 	 	 
	 	 	 	 	Defined terms used above have the meaning given to them under the terms and conditions of the 6% subordinated convertible bond due 1 January 2021.

 

    	70

     

    

 

	6% subordinated convertible bond due 1 January 20221	 	EUR 2,663,400	 	Paragraph 4(3) of the terms of the bond states:
	 	 	 	 	 
	 	 	 	 	“Early Redemption for reasons of minimal outstanding Principal Amount.  The Issuer may at any time redeem all, but not part of the Bonds at their Principal Amount, together with interest accrued thereon until (but excluding) the date of redemption if at any time the Principal Amount of the Bonds outstanding is below 15% of the initially issued amount of Bonds, Notice of early redemption shall be given not less than 30 nor more than 60 days before the day fixed in the notice on which any Bonds become due for early redemption. The provisions of the preceding paragraph shall apply accordingly.”
	 	 	 	 	 
	 	 	 	 	The provisions of the preceding paragraph state that such notice will be irrevocable and must state the date of the early redemption and the last day on which Conversion Rights may be exercised by Bondholders.
	 	 	 	 	 
	 	 	 	 	The initially issued amount of the Bonds is EUR 4,999,000. Therefore, the Borrower may repay the convertible bond under the above de-minimis clause once the outstanding amount reaches EUR 749,850 or falls below that amount.
	 	 	 	 	 
	 	 	 	 	Defined terms used above have the meaning given to them under the terms and conditions of the 6% subordinated convertible bond due 1 January 2022.

 

 

1 (1)
includes the following covenant :

 

“Each Bondholder is entitled to declare
due and payable by submitting a notice of termination (Termination Notice”) its entire claims arising from the Bonds and
demand payment of their Principal Amount, plus interest accrued on the Principal Amount until (but excluding) the day of actual
redemption, if

 

the Issuer, for any reason whatsoever, fails
within 30 days after the relevant payment date to pay any amounts due and payable on the Bonds; or

 

the Issuer Exceeds the Permissible Indebtedness
by debt borrowing.

 

    	71

     

    

 

The issuer ‘Exceeds the Permissible Indebtedness’
if by debt borrowing both (i) the Net Financial Indebtedness of the Issuer exceeds EUR 25 million, and (ii) the Net Indebtedness
Quota of the Issuer exceeds 4.0. Exempt are any debt borrowings for the purpose of financing the claims of Bondholders arising
out of these Bonds.

 

“Net Financial Indebtedness’ means
the sum of long-term financial liabilities and short-term financial debt, less cash and cash equivalents.

 

“Net Indebtedness Quota” means
the quotient of Net Financial Indebtedness divided by EBITDA.

 

“EBITDA” means the profit or loss
for the period, adjusted for depreciation and amortization, tax, interest expenses and interest income.

 

The calculation of Net Financial Indebtedness,
Net Indebtedness Quota and EBITDA shall be based on the respective most recent published annual group or interim quarterly financial
reports at the time of the debt borrowing. Insofar as the audited financial report shows Net Financial Indebtedness, Net Indebtedness
Quota and/or EBITDA, the respective calculation shall be binding both for the Issuer and the Bondholders.

 

The Issuer shall not be considered to Exceed
the Permissible Indebtedness if the Net Indebtedness Quota exceeds 4.0 due to a reduction of the EBITDA.”

 

    	72EX-10.1

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Exhibit 10.1 
 PPAR-d LICENSE AGREEMENT 
 THIS LICENSE
AGREEMENT (the “Agreement”) is made and entered into as of the Effective Date (as defined below), by and between METABOLEX, INC., a Delaware corporation having its principal
place of business at 3876 Bay Center Place, Hayward, CA 94545 (“Metabolex”), and JANSSEN PHARMACEUTICA NV, a corporation organized under the laws of Belgium having a place of business at 30
Turnhoutseweg, 2340 Beerse, Belgium (“Janssen”). Metabolex and Janssen are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Ortho-McNeil, Inc. (an Affiliate of Janssen) and Metabolex are party to a Strategic Alliance Agreement
setting forth the scope and terms of a strategic alliance between the Parties in the area of metabolic diseases; 

WHEREAS, as part of such alliance, Metabolex desires to obtain from Janssen an exclusive,
worldwide license under certain patents, know-how and other intellectual property relating to Janssen’s PPAR-d program; and 

WHEREAS, Janssen is willing to grant such license under the terms and conditions set forth in this
Agreement. 
 NOW, THEREFORE, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 As used herein, the following terms shall have the following meanings: 

1.1 “Affiliate” means, with respect to a particular Party, a corporation, partnership, or other entity that controls,
is controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1, the word “control” (including, with correlative meaning, the terms “controlled by” or “under
common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of at least fifty percent
(50%) of the voting stock of such entity, or by contract or otherwise. 
 1.2 “Confidential Information” has the
meaning set forth in Section 6.1. 

 1.3 “Controlled” means, with respect to an item of
Information or an intellectual property right, that a Party or one of its Affiliates owns or has a license to such item or right and has the ability to disclose to the other Party and/or grant a license or sublicense under such item or right as
provided for in this Agreement without violating the terms of any agreement with any Third Party, or other obligation to any Third Party. 

1.4 “CTA” means a clinical trial authorization, as described in Article 9 of Directive 2001/20/EC of the European
Parliament and of the Council. 
 1.5 “Diligent Efforts” means, with respect to a Party’s
obligation under this Agreement, the level of efforts required to carry out a task or obligation in a manner consistent with its normal business practices the Party would devote to a product at a similar stage of development or commercialization and
of similar market potential, profit potential or strategic value, based on conditions then prevailing. 
 1.6 “Effective
Date” means the Effective Date as defined in the PPAR-g License Agreement. 

1.7 “Execution Date” means June 20, 2006, the date upon which this Agreement has been executed and delivered by
both Parties. 
 1.8 “FDA” means the U.S. Food and Drug Administration, or a successor federal agency thereto. 

1.9 “First Commercial Sale” means, with respect to a PPAR-d Product in a
particular country, the first commercial sale of such product in such country after all needed Regulatory Approvals have been obtained in such country. 

1.10 “IND” means an investigational new drug application filed with the FDA for approval to commence
human clinical trials, or any equivalent application filed with any equivalent regulatory authority in a country other than the U.S. 

1.11 “Information” means all tangible and intangible (a) information, techniques, technology, practices, trade
secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and clinical test data and results), analytical and
quality control data, results or descriptions, software and algorithms and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material.  

1.12 “Major Market” means France, Germany, Italy, Japan, Spain, the United Kingdom, or the U.S. 

1.13 “Metabolex Know-How” means all Information that (a) is Controlled by
Metabolex or its Affiliates during the Term, (b) is developed or acquired by Metabolex or its Affiliates after the Effective Date and (c) relates to a PPAR-d Compound or a PPAR-d Product or its development, manufacture, promotion or use, but excluding the Metabolex Patents, PPAR-d Patents, and
PPAR-d Know-How. 

  
 2 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.14 “Metabolex Patents” means all Patents (other than PPAR-d Patents) that (a) are filed during the Term with a priority date after the Effective Date; (b) are Controlled during the Term by Metabolex or a Metabolex Affiliate; and (c) claim or cover the
composition of matter, manufacture or use of a PPAR-d Compound or a PPAR-d Product. 

1.15 “NDA” means a New Drug Application filed pursuant to the requirements of the FDA, as more fully defined in 21
C.F.R. § 314.5 et seq. or any equivalent application filed with any equivalent regulatory authority in a country other than the U.S. 

1.16 “Net Sales” means, with respect to a given period of time, [*], less the following deductions and offsets
that are actually incurred, allowed, accrued and/or taken and are specifically allocated with respect to such sale or distribution, but solely to the extent that such deductions or offsets are not otherwise recovered by or reimbursed to Metabolex or
its Affiliates, distributors or sublicensees: 
 [*] 

The methodology for calculating (a) – (f), on a country-by-country basis,
shall conform to generally accepted accounting principles consistently applied by Metabolex and its Affiliates across its product lines. 

Net Sales shall also include the fair market value of all consideration received by Metabolex and its Affiliates and their distributors and
sublicensees in respect of any sale of PPAR-d Products, whether such consideration is in cash, payment in kind, exchange for value or another form. 

In the case of discounts, reductions, payments or rebates offered for the PPAR-d Products where
the PPAR-d Products are sold to a customer as a grouped set of products and/or services, Metabolex may discount the bona fide list price of a PPAR-d Product by
no more than the average weighted percentage discount (off of the applicable list prices) of all the products of Metabolex and/or its Affiliates in such particular grouped set of products. The methodology for calculating the “average weighted
percentage discounts” for PPAR-d Products will be consistent with Metabolex’s and its Affiliates’ usual course of dealing with all its products other than the PPAR-d Products. An example of the calculation of “average weighted percentage discount” for a particular grouped set is set forth in the attached Exhibit A. 

If a PPAR-d Product is sold in the form of a combination product containing both a PPAR-d Product and one or more independently therapeutically active pharmaceutical molecules that are not PPAR-d Products (for the purpose of this Section 1.16, a
“Combination Product”), [*]. 
 [*] 

  
 3 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 If Metabolex (or its Affiliate) sublicenses the development and/or commercialization of a PPAR-d Product to a Third Party in consideration of the payment (inter alia) of royalties by such sublicensee on sales by such sublicensee of the PPAR-d Product, then
Metabolex (or its Affiliate) shall use commercially reasonable efforts to use a definition of net sales in the sublicense agreement between Metabolex and such sublicensee that exactly matches the definition of “Net Sales” as used in this
Agreement. However, in the event such definitions differ, for purposes of calculating the royalty owed by Metabolex to Janssen based on such sublicensee’s sales of such PPAR-d Product, the definition
of “Net Sales” as used in this Agreement, solely for purposes of calculating such royalty owed, shall be deemed to be the definition of net sales in the sublicense agreement between Metabolex (or such Affiliate) and such sublicensee,
provided, however, that (i) the two definitions are substantially similar and (ii) the methodology for calculating any deductions or offsets listed in such definition, on a country-by-country basis, conforms to generally accepted accounting principles consistently applied by such sublicensee across its product lines. 

1.17 “Other Product” means any pharmaceutical product (other than a
PPAR-d Product) containing a Selective PPAR-d Modulator, and including all formulations, line extensions and modes of administration thereof. 

1.18 “Patents” means (a) U.S. patents, re-examinations, reissues,
renewals, extensions and term restorations, and foreign counterparts thereof, and (b) pending applications for U.S. patents, including, without limitation, provisional applications, continuations, continuations-in-part, divisional and substitute applications, inventors’ certificates, and extensions, and foreign counterparts of any of the foregoing. 

1.19 “Phase III Trial” means that portion of the clinical development program that provides for trials
of a PPAR-d Product in an extended human patient population designed to obtain data determining efficacy and safety of the PPAR-d Product to support Regulatory
Approvals in the proposed therapeutic indication as more fully defined in 21 C.F.R. § 312.21(c), or its successor regulation, or the equivalent in any foreign country. 

1.20 “PPAR-d Compound” means: (a) any of the compounds
known as RWJ 800025, [*] (each as described in Exhibit B); (b) any other compound that is a Selective PPAR-d Modulator [*] as defined in: [*], or [*] or [*], and/or [*]; and (c) any [*]
of any of the foregoing compounds. 
 1.21 “PPAR-d Know-How” means all Information that is Controlled by Janssen or its Affiliates as of the Effective Date and relates to a PPAR-d Compound, or is otherwise
necessary for the development, manufacture, promotion, or use of a PPAR-d Compound, but excluding the PPAR-d Patents. For clarity, PPAR-d Know-How shall include the Product Data Package. 

1.22 “PPAR-d Patents” means all Patents that are Controlled
during the Term by Janssen or a Janssen Affiliate and that include one or more claims that claim or cover a PPAR-d Compound, or the manufacture or use of a
PPAR-d Compound, including without limitation those listed on Exhibit C. In addition, “PPAR-d Patents” shall include all Patents that
are Controlled as of the Effective Date by Janssen or a Janssen Affiliate to the extent that such Patents include one or more claims that claim or cover the formulation, manufacture or use of a PPAR-d
Product as it exists as of the Effective Date. 

  
 4 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 1.23 “PPAR-d
Product” means any pharmaceutical product that contains a PPAR-d Compound, and including all formulations, line extensions and modes of administration thereof. 

1.24 “PPAR-g License Agreement” means the Development and
License Agreement executed on June     , 2006, by and between Metabolex and Ortho-McNeil, Inc. 
 1.25
“Product Data Package” shall mean any and all files, data, records and other Information (including without limitation regulatory documents, pre-clinical and clinical protocols, data, and
reports, product complaint files, and adverse event files) relating to development of PPAR-d Compounds or PPAR-d Products anywhere in the world, to the extent
such files, data, records or Information are Controlled by Janssen or its Affiliates. 
 1.26 “Regulatory Approval”
means any and all approvals (including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g.,
the European Commission or the Council of the European Union), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, distribution, use or sale of a
PPAR-d Product in the particular regulatory jurisdiction. 
 1.27
“Selective PPAR-d Modulator” means any small molecule compound that (a) [*] interacts with the PPAR-d receptor to
[*] or [*], and (b) shows activity toward [*] the PPAR-d receptor in the [*] assay using [*] (or any [*] thereof). To constitute a Selective PPAR-d
Modulator, the compound must not [*] (i) [*] or (ii) [*]. For the purposes of clause (i) of this Section 1.27, “[*]” means [*] in either the [*] and/or [*], as applicable, that is [*] obtained in the [*] assay. For the
purposes of clause (ii) of this Section 1.27, “[*]” means [*] of the [*] of the compound for the [*] (measured at [*] determined in the [*] assay) in the generally accepted assay for the [*] (or if there is no such generally
accepted assay, a validated assay for the [*]). Notwithstanding the above, the term “Selective PPAR-d Modulator” shall include, without limitation, RWJ 800025, [*]. 

1.28 “Term” means the term of this Agreement as provided in Section 9.1. 

1.29 “Third Party” means any Person other than (a) Metabolex, (b) Janssen, or (c) an Affiliate of either
Metabolex or Janssen. 
 1.30 “U.S.” means the United States of America, including its territories, protectorates
and possessions. 
 1.31 “Valid Claim” means (i) a valid and enforceable claim of an issued, unexpired PPAR-d Patent, or (ii) a claim in any pending application for a PPAR-d Patent for which not more than [*] years have elapsed from the [*]. A claim of an issued,
unexpired patent shall be deemed to be valid and enforceable unless and until it has been held to be invalid and/or 

  
 5 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
unenforceable by a final judgment of a court of competent jurisdiction from which no further appeal can be taken. If a claim of a patent application that ceased to be a Valid Claim under clause
(ii) of this Section 1.31 later issues or grants as a patent within the scope of clause (i) of this Section 1.31, then such claim shall again be considered to be a Valid Claim, effective as of the earlier of the grant or issuance
of such patent. 
 ARTICLE 2 

LICENSES 
 2.1
License Grant. Subject to the terms and conditions of this Agreement, Janssen hereby grants to Metabolex an exclusive (even as to Janssen and its Affiliates), worldwide, royalty-bearing license, with the right to grant sublicenses to
Affiliates and/or Third Parties through multiple tiers, under the PPAR-d Patents and PPAR-d Know-How solely to
research, develop, use, market, offer for sale, sell, import, manufacture, have manufactured, and distribute the PPAR-d Products. 

2.2 Third Party Licenses. Janssen shall be solely responsible for all costs and expenses of any licenses in effect as of the
Effective Date between a Third Party and Janssen or its Affiliates related to the PPAR-d Products. Subject to Section 4.2(a), Metabolex shall be solely responsible for all costs and expenses of any
other license required in order to lawfully develop and commercialize the PPAR-d Products. 

2.3 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property,
whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement. 
 2.4
No Non-Permitted Use. Metabolex hereby covenants that it shall not, nor shall it cause or permit any Affiliate or sublicensee to use or practice, any PPAR-d
Patents or PPAR-d Know-How, for any purposes other than those expressly permitted in Section 2.1, or Section 9.5(f) or (h). Janssen hereby covenants that
it shall not, nor shall it cause or permit any Affiliate or sublicensee to use or practice any PPAR-d Patents or PPAR-d
Know-How, for any purposes other than those expressly set forth in Section 9.5(a). 

2.5 Third Party Contracts. Metabolex shall use reasonable commercial efforts to ensure that each Third Party contract that
Metabolex (or any Affiliate) enters into solely related to PPAR-d Products contains provision(s) permitting such Third Party contract to be assigned in accordance with Section 9.5(e). As to other
contracts entered into by Metabolex (or its Affiliates) that relate to PPAR-d Products, Metabolex shall reasonably cooperate (if requested by Janssen after termination of the Agreement under Article 9) to
assist Janssen in obtaining the benefits of such contracts. To the extent any such Third-Party contract relates to products or services generally available upon commercially reasonable terms, Metabolex shall not be required to assign such
agreement(s), or provide such assistance (as applicable), to Janssen. 
 2.6 Sublicensee Agreements. Metabolex shall, in each
sublicense that it grants hereunder, require the sublicensee to transfer any regulatory filings with respect to any PPAR-d Product or PPAR-d Compound in the
event of a termination of this Agreement or such sublicense, to Janssen if this Agreement terminates, and to Metabolex if only such sublicense terminates. 

  
 6 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 2.7 Exclusivity. 

(a) Metabolex. Metabolex hereby covenants that Metabolex and its Affiliates shall not [*] for the period of [*], or until [*],
any compound (other than a PPAR-d Compound), or product that contains a compound (other than a PPAR-d Product), that has [*] that such compound or product [*]
unless that compound, or compound in the product, also has [*] that is either (i) [*] or (ii) [*], as well as [*] that is not [*] (such compound or product that [*] hereinafter referred to as an “Excluded Product”). If the product
is a combination product (i.e., it contains multiple independently therapeutically active pharmaceutical molecules), the product shall be analyzed on a therapeutically active pharmaceutical molecule by therapeutically active pharmaceutical molecule
basis to determine if it is an Excluded Product. Notwithstanding the above, RWJ 800025, [*] shall be deemed to be Excluded Products. 

(b) Metabolex Sublicensees. Metabolex hereby covenants that any sublicense related to the [*] of a PPAR-d Product that Metabolex or its Affiliates grant under this Agreement shall include a covenant by the sublicensee that such sublicensee shall not [*] for the period of [*], or until [*]. Metabolex hereby agrees
to use reasonable efforts to enforce such covenant [*] if it, or its Affiliates, become aware of a breach or anticipated breach of such covenant by any sublicensee. 

(c) Janssen. Janssen hereby covenants that Janssen and its Affiliates shall not [*] for the period of [*], or until [*]. 

(d) [*]. For the purposes of this Section 2.7, [*] means [*] that is responsible for the achievement of a [*] in one of the
[*] used to [*] in the [*], which [*] as indicated in the [*] and [*] may be used to [*]. 
 (e) Exception for Acquired Excluded
Products. Notwithstanding the foregoing, if either Party or any of its respective Affiliates, enters into a definitive agreement with respect to a merger or acquisition by operation of which such Party or its Affiliate would (i) acquire an
Excluded Product that at the time of the closing of the acquisition [*] or (ii) be acquired by, or merge with, a Third Party that has an Excluded Product that at the time of the closing of the acquisition [*], then such Party or its Affiliate
(or the entity that acquired such Party or its Affiliate or the entity into which such Party or its Affiliate has merged) shall have [*] from the execution date of such definitive agreement to divest itself of such Excluded Product and, during such
[*] period, the [*] of such Excluded Product shall be deemed to be not in violation of Section 2.7(a) or Section 2.7(c), as applicable. Such divestiture can occur by either (1) an outright sale to a Third Party of all rights to
such Excluded Product, or (2) an out-license (exclusive as to the divesting Party and its Affiliates) to a Third Party of all rights to [*] such Excluded Product; provided, however, that the
divesting Party or its Affiliate must not exercise or have the ability to exercise any role, or influence in any manner, the [*] of such Excluded Product. If a Party or its Affiliate fails to divest itself of such Excluded Product during such [*]
period, then if such Party is (A) Metabolex, then [*]; or (B) Janssen, then Metabolex shall have the right [*], at its discretion, upon written notice to Janssen, to [*] and/or [*] under this Agreement. 

  
 7 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 ARTICLE 3 

DEVELOPMENT & COMMERCIALIZATION 

3.1 Development and Commercialization of PPAR-d Compounds. Subject to
Section 3.6, Metabolex shall have full control and responsibility over the research, development and registration (including but not limited to, clinical activities and submissions to regulatory agencies, and all expenses related thereto)
of any PPAR-d Products, subject to the terms of this Agreement. Metabolex shall use Diligent Efforts to conduct all such research, development, and regulatory activities. 

3.2 Development Information and Reporting. Metabolex shall use Diligent Efforts to prepare and maintain complete and accurate
records regarding the worldwide clinical development of PPAR-d Products. Metabolex shall provide to Janssen on a semi-annual basis a summary of the development efforts being conducted on PPAR-d Product and the results of such development. Metabolex shall also provide to Janssen copies of all FDA and other Regulatory Authority communications associated with Major Market filings and shall inform
Janssen promptly following the occurrence of any significant development event that occurs relating to such PPAR-d Products (e.g. initiation or completion of a clinical trial, submission of a U.S. or
international regulatory filing, receipt of a response to such U.S. or international regulatory filing, or serious adverse clinical safety event associated with a PPAR-d Product). 

3.3 Diligence in Development of PPAR-d Products. Metabolex shall use
Diligent Efforts to clinically develop at least one PPAR-d Product under this Agreement, provided that in Metabolex’s reasonable judgment it is commercially feasible to file for Regulatory Approval
for such PPAR-d Product in at least the U.S. and the other Major Markets. 
 3.4
Technology Transfer. Janssen and its Affiliates shall cooperate with Metabolex and provide access and transfer to Metabolex of its PPAR-d Know-How by such
dates after the Effective Date as are reasonably requested by Metabolex. For the avoidance of doubt, neither providing access to nor transfer of any PPAR-d Know-How
pursuant to this Section 3.4 shall alter the ownership or other rights of any Party or its Affiliates with respect to such PPAR-d Know-How. Each Party shall be
responsible for its own costs and expenses related to any such cooperation, provided however, that the costs of the transfer of any Materials by Janssen and its Affiliates shall be borne by Janssen. 

3.5 Materials Transfer. In order to facilitate the technology transfer provided in Section 3.4 and facilitate
Metabolex’s research and development of PPAR-d Products, Janssen shall provide to Metabolex upon the prior written request of Metabolex, at no charge, the biological material, chemical compounds and
Information Controlled by Janssen and its Affiliates listed on Exhibit D that Janssen and/or its Affiliates have on hand at the relevant time, and other material reasonably requested by Metabolex prior to [*] that Janssen and/or its

  
 8 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
Affiliates have on hand at the relevant time (collectively, the “Materials”) for use by Metabolex solely to research and develop
PPAR-d Products. To the extent that such Materials consist of reports that are in the process of being written/completed as of the relevant time, Janssen agrees to write/complete such reports prior to
providing them to Metabolex. It is agreed that Janssen and/or its Affiliates shall transfer to Metabolex upon prior written request of Metabolex, all of its stock of the compounds known as RWJ 800025, [*] (including any clinical materials containing
such compounds), other than such amounts that Janssen needs to retain for regulatory purposes. The Materials shall be transferred within a reasonably practicable time after the written request of Metabolex. It is the expectation of the Parties that
prior to [*], Metabolex shall only request the transfer of Materials that it needs in order to [*]. All Materials provided by Janssen and/or its Affiliates under this Agreement will be used by Metabolex only for the specific research and development
purposes as disclosed and as permitted under the applicable license rights granted under Section 2.1 and subject to all the other restrictions and obligations under this Agreement. Such Materials will not be used or delivered to or for the
benefit of any Third Party except as otherwise permitted under this Agreement without the prior written consent of Janssen, and will be used in compliance with all applicable laws, rules and regulations. The Materials supplied under this Agreement
must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as expressly set forth herein, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR
WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
 3.6 Regulatory Matters. At all times
after the Effective Date, Metabolex shall own and maintain, at its own cost, all regulatory filings and Regulatory Approvals for PPAR-d Products that Metabolex is developing or commercializing pursuant to
this Agreement, including all INDs, CTAs, NDAs, and statistical analyses. As such, Metabolex shall be responsible for reporting all adverse drug reactions related to PPAR-d Products to the appropriate
regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of such countries. As soon as practicable, but not more than thirty (30) days after the Effective Date, Janssen shall transfer ownership
of, and all files relating to, its regulatory filings and associated with PPAR-d Products to Metabolex (including, but not limited to, any INDs Controlled by Janssen or its Affiliates). Metabolex shall
provide Janssen with copies of the draft registration submissions in connection with obtaining Regulatory Approval for a PPAR-d Product in the Major Markets, prior to their submission, and Janssen shall
have the right to review such draft submission and provide comments thereon to Metabolex, which Metabolex agrees to reasonably consider. Janssen also agrees to discuss and answer any questions relating to
PPAR-d Know-How that Metabolex may have regarding regulatory matters for PPAR-d Products. Metabolex shall also be
responsible for all meetings with regulatory authorities and all post-approval commitments. Notwithstanding the above, Janssen shall prepare and file a FDA regulatory submission covering the [*]. Janssen shall provide Metabolex with a copy of the
draft submission prior to its submission, and Metabolex shall review such draft submission and provide comments thereon to Janssen, which Janssen agrees to consider and incorporate into the submission if in Janssen’s reasonable judgment such
suggestions are justified and proper. 

  
 9 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 3.7 Commercialization of
PPAR-d Products. Metabolex will plan, control, carry out and fund all activities related to the promotion, marketing and sale of any PPAR-d
Products. Metabolex shall use Diligent Efforts to market, promote and commercialize any and all PPAR-d Products as to which Regulatory Approval has been achieved in a Major Market provided that such
commercial launch is commercially reasonable given label and pricing issue. Prior to launch of any PPAR-d Product and from time to time thereafter (but no less frequently than annually), Metabolex will
provide Janssen with updates on marketing activities relating to PPAR-d Products. 
 3.8
Commercialization Costs. Metabolex shall be responsible for all costs and expenses associated with its commercialization activities, including manufacturing of PPAR-d Products. 

3.9 Right of First Negotiation. 

(a) Right of First Negotiation. Metabolex hereby grants to Janssen a right of first negotiation under the terms of this
Section 3.9 (the “Right of First Negotiation”) to license a particular PPAR-d Product or Other Product from Metabolex in the event that Metabolex elects to seek a Third Party
corporate partner for the research, development, promotion, and/or commercialization of such PPAR-d Product or Other Product. 

(b) Notice; Exercise. In the event that Metabolex decides to seek a partner for the research, development, promotion, and/or
commercialization of a PPAR-d Product or Other Product, Metabolex shall provide notice in writing (the “Notice to Partner”) to Janssen of such intention. Within thirty (30) days of
receipt of such Notice to Partner, Janssen shall submit a reasonable due diligence request to Metabolex (“Diligence Request”) in order for Janssen to evaluate Janssen’s interest in such
PPAR-d Product or Other Product (as the case may be). Janssen shall then have thirty (30) days from the date of receipt of either (i) Metabolex’s detailed answer to the Diligence Request
(which answer may be provided by Metabolex allowing appropriate Janssen employees access to a facility having the Metabolex Information that is responsive to such Diligence Request and reasonable time to review such Information), or (ii) the
Notice to Partner, if no such Diligence Request was timely submitted by Janssen (as applicable), to notify Metabolex in writing of its desire to exercise the PPAR-d Right of First Negotiation (the
“Exercise”). After receipt of Janssen’s timely Exercise, the Parties shall then negotiate in good faith, for up to [*] after the date of such Exercise, the terms of an agreement (the “PPAR-d License Agreement”) under which Janssen would receive an exclusive license to the PPAR-d Product or Other Product (as the case may be) on
commercially reasonable terms, taking into account the stage of development of the PPAR-d Product or Other Product at the time of such negotiations and Metabolex’s prior efforts and resources
expended in developing the PPAR-d Product or Other Product. 
 (c) Failure to Reach
Agreement. If the Parties do not enter into the License Agreement within [*] after the date of the Notice to Partner, then Metabolex shall have no 

  
 10 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
further restrictions or obligations vis-à-vis Janssen with respect to the applicable PPAR-d Product or Other Product under this Section 3.9, and Metabolex shall be free to enter into a license, collaboration, joint venture or other agreement with a Third Party covering such PPAR-d Product or Other Product (a “Third Party Agreement”) at its discretion. 

(d) Failure to Consummate Partnering Transaction. If Metabolex does not execute, within [*] after the expiration of the [*]
period contemplated in Section 3.9(b), a definitive Third Party Agreement with a Third Party, then the Right of First Negotiation would then again apply if Metabolex subsequently seeks to partner such
PPAR-d Product or Other Product. 
 (e) Independent Development. Subject to
Section 2.7(a), Metabolex and its Affiliates shall at all times retain the right, at its discretion, to develop and commercialize any PPAR-d Product or Other Product independently. 

3.10 Replacement Product. 

(a) Metabolex shall have the option (the “Replacement Product Option”) to discontinue its development of the PPAR-d Compounds and PPAR-d Products and select [*] as a Replacement Compound (as defined below), which option shall become exercisable on the Effective Date and shall
terminate on [*]. 
 (b) In the event Metabolex exercises the Replacement Product Option, such Replacement Compound (and any
applicable product) shall be subject to the terms and conditions set forth in this Agreement in the same manner as a PPAR-d Compound (and associated PPAR-d
Product) and all other terms and obligations accordingly modified, including without limitation, the representations and warranties in Section 7.2. Without limiting the generality of the foregoing, the terms
PPAR-d Compound, PPAR-d Know-How, PPAR-d Patent, and PPAR-d Product shall be replaced with appropriate acronyms and definitions relating to such replacement product, as follows: 

(i) “Replacement Compound” means the composition known as [*] as described in Exhibit E.

 (ii) “Replacement Know-How” means all Information that is Controlled by
Janssen or its Affiliates as of the Effective Date and relates to the Replacement Compound, or is otherwise necessary for the development, manufacture, promotion, or use of the Replacement Compound, but excluding the Replacement Patents. For
clarity, Replacement Know-How shall include the Product Data Package. 
 (iii)
“Replacement Patents” means all Patents that are Controlled during the Term by Janssen or a Janssen Affiliate and that include one or more claims that claim or cover the Replacement Compound, or the manufacture or use of the
Replacement Compound, including without limitation those listed on Exhibit F. In addition, “Replacement Patents” shall include all Patents that are Controlled, as of the date the option is exercised, by Janssen or a Janssen
Affiliate to the extent that such Patents include one or more claims that claim or cover the formulation, manufacture or use of the Replacement Compound as it exists as of the date the option is exercised. 

  
 11 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (iv) “Replacement Product” means any pharmaceutical product that
contains the Replacement Compound, and including all formulations, line extensions and modes of administration thereof. 
 (c) In
addition, in the event Metabolex exercises the Replacement Product Option, Section 2.7 shall be deleted in its entirety and replaced with the following; 

(i) Metabolex. Metabolex hereby covenants that Metabolex and its Affiliates shall not [*] any [*] product (other than a
Replacement Product) for the period of [*]. 
 (ii) Metabolex Sublicensees. Metabolex hereby covenants that any sublicense
related to the [*] of a Replacement Product that Metabolex or its Affiliates grant under this Agreement shall include a covenant by the sublicensee that such sublicensee shall not [*] any [*] product (other than a Replacement Product) for the period
of [*]. Metabolex hereby agrees to use reasonable efforts to enforce such covenant [*] if it, or its Affiliates, become aware of a breach or anticipated breach of such covenant by any sublicensee. 

(iii) Janssen. Janssen hereby covenants that Janssen and its Affiliates shall not [*] any [*] product for the period of [*].

 (d) In the event Metabolex exercises the Replacement Product Option, all rights with respect to the PPAR-d Patents and PPAR-d Know-How shall revert back to Janssen and the terms of Section 9.5 (without giving effect to the
replacement of terms contemplated by Section 3.10(b)) shall apply to the PPAR-d Products and PPAR-d Compounds. 

ARTICLE 4 
 PAYMENTS

 4.1 Royalties. 

(a) Royalty Percentage. For the term specified in Section 4.1(b), Metabolex shall pay to Janssen a running royalty equal to
eight percent (8%) of Net Sales; provided, however, that the royalties owed to Janssen on Net Sales attributable to [*] shall [*] eight percent (8%) of such Net Sales and [*]; provided, further, that the royalties owed to
Janssen on Net Sales attributable to [*] shall not [*]. For the purpose of this Section 4.1(a), the [*] on Net Sales shall be equal to [*] plus [*] as a result of such Net Sales [*]. 

(b) Royalty Term. Metabolex’s royalty obligations under this Section 4.1 as to a particular PPAR-d Product in a particular country shall be in effect from the First Commercial Sale in the country and shall expire, on a
country-by-country basis, on the later of (i) [*] years following the First Commercial Sale of such PPAR-d Product in such
country and (ii) the expiration of the last to expire Valid Claim of a PPAR-d Patent covering such
PPAR-d

  
 12 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
Compound or PPAR-d Product, or its manufacture or use in such country. Notwithstanding the foregoing, Metabolex shall be obligated to pay the
royalties set forth in Section 4.1(a) on sales of a PPAR-d Product in any country where such PPAR-d Product [*] at the time [*].  

4.2 Royalty Reductions. 

(a) Janssen shall be solely responsible for all costs and expenses of any licenses between a Third Party and Janssen or its Affiliates
in effect as of the Effective Date related to the PPAR-d Products. If a Patent or Patents of a Third Party should exist in any country during the Term covering the development, manufacture, use or sale of
any PPAR-d Product, and which Metabolex believes in Metabolex’s reasonable judgment impractical or impossible for Metabolex or any Affiliate or sublicensee to engage in the activity or activities
licensed under this Agreement without obtaining a royalty bearing license from such Third Party under such Patent or Patents in a particular country, then Metabolex shall be entitled to a credit, against the royalty payments due to Janssen upon
sales of such PPAR-d Product in the applicable country, of an amount equal to [*] the royalty paid to such Third Party based upon the sales of the PPAR-d
Product in such country, but provided that such credit shall not exceed [*] the royalty otherwise payable to Janssen in the absence of such royalty offset. 

(b) If (i) [*] generic products or [*] equivalent (in either case, “Generic Products”) are sold by Third Parties in a
country where Metabolex is selling a PPAR-d Product, (ii) the Generic Products each contain the PPAR-d Compound in the
PPAR-d Product, or any [*] of such PPAR-d Compound; and (iii) sales of the Generic Products [*] in such country [*], the royalty owed under
Section 4.1 for such PPAR-d Product shall be determined under the following formula: The contribution of sales of such PPAR-d Product in such country
shall be reduced by [*] when calculating aggregate Metabolex Net Sales, but only for so long as the conditions set forth in subclauses (i), (ii), and (iii) continue to be satisfied. 

4.3 Timing of Payment. Royalties obligations under Section 4.1 shall accrue at the time the sale of the royalty-bearing
product is made, or invoice is delivered, whichever is earliest, and royalty or other payment obligations that have accrued during a particular calendar quarter shall be paid, on a quarterly basis, within forty-five (45) days after the end of
the calendar quarter during which the obligation accrued. For clarity, Metabolex’s obligation to pay royalties under this Agreement is imposed only once with respect to the same unit of PPAR-d
Product regardless of the number of Patents pertaining thereto. 
 4.4 Sublicenses. In the event Metabolex grants licenses or
sublicenses to others to sell PPAR-d Products that are subject to royalties under Section 4.1, such licenses or sublicenses shall include an obligation for the sublicensee to account for and report
its sales of PPAR-d Products on the same basis as if such sales were sales by Metabolex, and Metabolex shall pay to Janssen, with respect to such sales, such royalties and payments as if such sales of the
sublicensee were sales of Metabolex. 
 4.5 Mode of Payment. All payments to a Party hereunder shall be made by deposit of
U.S. Dollars by wire transfer in immediately available funds in the requisite amount to such bank account as such Party may from time to time designate by notice to the other Party. With 

  
 13 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
respect to sales outside the U.S., royalty and other sales-based amounts owed shall first be calculated in the currency of sale, and then such amounts shall be converted into U.S. Dollars using
the average exchange rates as calculated and utilized by Metabolex’s reporting systems and published accounts as used throughout Metabolex’ business. 

4.6 Royalty Reports and Records Retention. Within forty-five (45) days after the end of each calendar quarter during which
PPAR-d Products have been sold, Metabolex shall deliver to Janssen a written report of the amount of gross sales of each PPAR-d Product in each country during
the applicable calendar quarter, an itemized calculation of Net Sales, consistent with Metabolex’s normal and customary reporting procedure, and a calculation of the amount of royalty payment due on such sales during such calendar quarter. For
three (3) years after each sale of each PPAR-d Product, Metabolex shall keep (and shall ensure that its Affiliates and sublicensees shall keep) complete and accurate records of such sale in
sufficient detail to confirm the accuracy of the royalty and other payment calculations hereunder. 
 4.7 Audits. 

(a) Upon the written request of Janssen, and not more than once in each calendar year, Metabolex shall permit an independent certified
public accounting firm of internationally recognized standing selected by Janssen, and reasonably acceptable to Metabolex, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written
notice, the applicable records of Metabolex and its Affiliates to verify the accuracy and timeliness of the reports and payments made by Metabolex under this Agreement. Such review may cover the records for sales made in any calendar year ending not
more than thirty-six (36) months prior to the date of such request. The accounting firm shall disclose to Janssen only whether the royalty reports are correct or incorrect and the specific details
concerning any discrepancies. 
 (b) If such accounting firm concludes that any payments were late or additional amounts were owed
during such period, Metabolex shall pay the late payments and/or additional amounts, with interest from the date originally due as set forth in Section 4.8, within thirty (30) days after the date Janssen delivers to Metabolex a notice
referencing the accounting firm’s written report and requesting such payment. If the amount of the underpayment is greater than [*] of the total amount actually owed for the period audited, then Metabolex shall in addition reimburse Janssen for
all reasonable costs related to such audit; otherwise, Janssen shall pay all costs of the audit. In the event of overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar
quarter(s); provided, however, that if the overpayment exceeds [*], then such credit cannot be applied to reduce the amounts payable by Metabolex to Janssen for any particular calendar quarter by more than [*] of the amount
otherwise due to Janssen. 
 (c) Metabolex shall include in each distribution agreement or sublicense granted by it pursuant to this
Agreement a provision requiring the distributor or sublicensee to make reports to Metabolex, to keep and maintain records of sales made pursuant to such distribution agreement or sublicense and to grant access to such records by Janssen’s
independent accountant to the same extent required by Metabolex under this Agreement. 

  
 14 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) Janssen shall (i) treat all information that it receives under this
Section 4.7 or under any sublicense agreement of Metabolex in accordance with the confidentiality provisions of Article 6 of this Agreement and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with
Metabolex obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each case except to the extent necessary for Janssen to enforce its rights under the Agreement. 

4.8 Interest. If either Party fails to make any payment due to the other Party under this Agreement, then interest shall accrue
on a daily basis at an annual rate of [*] above the then-applicable prime commercial lending rate of Citibank, N.A. San Francisco, California, or at the maximum rate permitted by applicable law, whichever is the lower. Notwithstanding the foregoing,
the interest shall only accrue on payments actually owed, from the original due date until payment made. If the Parties have a dispute regarding the results of the audit, they shall resolve the dispute through the mechanisms set forth in
Section 10.9 below. 
 4.9 Taxes. 

(a) Metabolex will make all payments to Janssen under this Agreement without deduction or withholding for taxes except to the extent
that any such deduction or withholding is required by applicable law to be made on account of Taxes (as defined in Section 4.9(e)). 

(b) Any tax required to be withheld under applicable law on amounts payable under this Agreement will promptly be paid by Metabolex on
behalf of Janssen to the appropriate governmental authority, and Metabolex will furnish Janssen with proof of payment of such tax. Any such tax required to be withheld will be an expense of and borne by Janssen. 

(c) Metabolex and Janssen will cooperate with respect to all documentation required by any taxing authority or reasonably requested by
Metabolex to secure a reduction in the rate of applicable withholding taxes. 
 (d) If Metabolex had a duty to withhold taxes in
connection with any payment it made to Janssen under this Agreement but Metabolex failed to withhold, and such taxes were assessed against and paid by Metabolex, then Janssen will reimburse Metabolex for such taxes (including interest but excluding
penalties), upon delivery by Metabolex of the documents evidencing Metabolex payment of the taxes and the basis for such payment. If Metabolex makes a claim under this Section 4.9(d) it will comply with the obligations imposed by
Section 4.9(b) as if Metabolex had withheld taxes from a payment to Janssen. 
 (e) Solely for purposes of this Section 4.9,
“Tax” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including interest, penalties and additions thereto) that are imposed by the applicable federal government or other taxing
authority. 

  
 15 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 ARTICLE 5 

PATENTS 
 5.1 Patent
Prosecution. 
 (a) Janssen will have the sole (except as otherwise provided below), responsibility, [*] for the preparation,
filing, prosecution and maintenance of, and conducting or defending any interferences or similar proceedings and in obtaining and maintaining any patent extensions, supplementary protection certificates and the like with respect to, the PPAR-d Patents. [*] Janssen will keep Metabolex informed of the progress with regard to all activities relating to the Janssen patent prosecution, including providing to Metabolex copies of all proposed filings and
patent office responses and of all office actions and other material communications from patent offices relating to such prosecution efforts a reasonable time in advance of any proposed filing or required response, and Metabolex will have the right
to comment on any such filings and responses. Janssen will consider in good faith the timely received requests and suggestions of Metabolex with respect to such filings or responses and Metabolex’ strategies for Janssen patent prosecution.
During [*], Janssen shall not discontinue the filing, prosecution or maintenance of any PPAR-d Patent in a Major Market without Metabolex’s prior written consent. 

(b) Subject to the last sentence of Section 5.1(a), if Janssen intends to abandon or not maintain any PPAR-d Patent and Janssen is not abandoning such PPAR-d Patent in favor of another PPAR-d Patent, Janssen will provide
reasonable prior written notice to Metabolex of such intention to abandon (which notice will, in any event, [*] prior to the next deadline for any action that may be taken with respect to such Patent with the U.S. Patent & Trademark Office
or any applicable foreign patent office) and, unless Janssen reasonably believes prosecution by Metabolex could have a material adverse impact on other patent applications or patents owned or Controlled by Janssen, then Janssen shall provide
Metabolex the opportunity to assume responsibility for prosecuting and maintaining such PPAR-d Patent. The foregoing sentence shall not apply to any patent application or patent for which Janssen does not
have the right to grant to Metabolex such rights. In the event that Metabolex, in its sole discretion, elects to assume responsibility for prosecuting and maintaining such PPAR-d Patent, then [*] such
PPAR-d Patent will then be deemed [*] for all purposes of this Agreement. 
 5.2
Common Interest Disclosures. With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, Metabolex or Janssen (or its
Affiliates), Metabolex and Janssen agree that they have a common legal interest in determining whether, and to what extent, third party intellectual property rights may affect the conduct of the development, manufacturing, marketing and/or sale of
PPAR-d Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights
relating to the development, manufacturing, marketing and/or sale of PPAR-d Products. Accordingly, Metabolex and Janssen agree that all such information and materials obtained by Metabolex and Janssen
from each other 

  
 16 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
will be used solely for purposes of the Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the
attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may
apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or
immunity resulting from the conduct of one Party be deemed to apply against any other Party. 
 5.3 Enforcement of PPAR-d Patents.
 (a) Notice. The Parties shall promptly inform each other of
any information that comes to their attention involving actual or apparent infringements or misappropriations by any Third Party of any PPAR-d Patent or PPAR-d
Know-How used in connection with this Agreement. 
 (b) PPAR-d Patents. If any PPAR-d Patent is infringed by a Third Party in any country, in connection with the manufacture, use, importation, offer for sale, or
sale in such country of a compound that is a PPAR-d Compound, which manufacture, use or sale is likely to have a material adverse effect on current or future sales of any PPAR-d Product being researched, developed or commercialized by Metabolex or its Affiliates or sublicensees (a “Field Infringement”), Metabolex shall have the first right, but not the obligation, to
bring an action or suit with respect to such Field Infringement at its own expense using counsel chosen by Metabolex, and approved by Janssen, which approval shall not be unreasonably withheld. In any such action or suit involving a PPAR-d Patent, Janssen shall have the opportunity to review any pleadings and provide comments with respect to such pleadings, which comments shall be reasonably considered by Metabolex. If requested by Janssen in
writing, Metabolex will allow Janssen to join as a party in such action or suit, to the extent permitted by law, and in such regard Janssen may have counsel of its choosing and at its expense to represent its interest in such action or suit, but
Metabolex will control the conduct of the action or suit, and Janssen shall not bring any claim against Metabolex based on the conduct of such action or suit. If Metabolex does not choose to commence such action within [*] after Metabolex becomes
aware of such Field Infringement ([*] in the event of receiving a Paragraph IV Certification as described in 21 C.F.R. §314.50(i)(1)(i)(A)(4)), then Janssen may, at its discretion, choose to bring an action or suit at Janssen’s own
expense. In any such action or suit brought by Janssen, Metabolex will have the right, at its own expense, to be represented in any such action by counsel of its own choice, but shall not have any right to control or interfere with Janssen’s
conduct of the suit or action. In no event shall Janssen notify any Third Party of any alleged Field Infringement or bring any suit or other action against any Third Party seeking to enforce any PPAR-d
Patents against any alleged Field Infringement (or otherwise), without first obtaining Metabolex’s prior written consent. Janssen will have the sole and exclusive right and discretion (i) to defend or otherwise respond to any alleged
invalidity or unenforceability of a PPAR-d Patent, unless Janssen provides Metabolex such right or (ii) to bring an action or suit against or otherwise respond to Third Party activity that allegedly
infringes a PPAR-d Patent, that is not a Field Infringement. Notwithstanding the foregoing, in any such action or suit involving a PPAR-d Patent, Metabolex
shall have the opportunity to review any pleadings and provide comments with respect to such pleadings, which comments shall be reasonably considered by Janssen. 

  
 17 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (c) Settlement. The Party bringing suit under this Section 5.3 shall keep the
other Party reasonably informed as to the progress of the suit and all settlement discussions. A settlement or consent judgment or other voluntary final disposition of a suit brought by a Party under this Section may not be entered into without the
prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed); provided, however, that such settlement, consent judgment or other disposition does not admit the invalidity or unenforceability of any
Patent; and provided further, that any rights to continue the infringing activity in such settlement, consent judgment or other disposition shall be limited to the product or activity that was the subject of the suit. 

(d) Recovery. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any recovery realized by a
Party as a result of a litigation or other action with respect to a Field Infringement will first be applied to reimburse Metabolex for any actual litigation costs and expenses borne by Metabolex and not yet reimbursed by Janssen, and Janssen for
any actual litigation costs and expenses borne by Janssen (including amounts paid to Metabolex to reimburse Metabolex for its litigation costs), and any amounts remaining after such reimbursement (a “Net Recovery”) will be shared by
the Parties as follows: (i) if recovered by Metabolex, Metabolex will retain [*] of such Net Recovery and pay Janssen [*] of such Net Recovery [*] of receipt of payment, or (ii) if recovered by Janssen, Janssen will retain [*] of such Net
Recovery and pay Metabolex [*] of such Net Recovery [*] of receipt of payment. Janssen will have the sole right to bring and control, and to retain all recovery from, any action or proceeding with respect to infringement of any PPAR-d Patent at its own expense and by counsel of its own choice with respect to any activities by a Third Party that are not Field Infringements. 

(e) Assistance. In the event of any patent infringement litigation involving a
PPAR-d Product and any Patent, the non-prosecuting or non-defending Party shall render such reasonable assistance as may be
requested by the prosecuting or defending Party in connection with such infringement actions. If one Party requests the other Party’s reasonable assistance in connection with such infringement claims or actions, the requesting Party shall
reimburse the other Party for such direct, documented out-of-pocket expenses as are reasonably incurred during the course of its providing such requested assistance.
Before incurring such expenses, the Parties shall in good faith agree on the nature and extent of assistance to be rendered. The non-prosecuting or non-defending Party
agrees to be joined as a party plaintiff, at the other Party’s expense, in any such action if necessary for such other Party to have standing to bring or continue an infringement action hereunder. If a
PPAR-d Patent is licensed-in to Janssen, Janssen agrees to use reasonable commercial efforts to obtain the licensor’s consent to sue under such licensed-in Patent. 
 5.4 Cooperation by Metabolex and Janssen in Patent and Regulatory
Filings. The Parties shall cooperate in order to avoid loss of any rights that may otherwise be available to the Parties under the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection
of the Member States of the European Union and other 

  
 18 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
similar measures in any other country. Without limiting the foregoing, Metabolex shall notify Janssen upon receipt of Regulatory Approval to market a
PPAR-d Compound or PPAR-d Product in the U.S., and timely supply Janssen with all information necessary to file an application for patent term extension for a
relevant PPAR-d Patent within the required period following Regulatory Approval. The Parties shall, if necessary and appropriate use reasonable efforts to agree upon a joint strategy relating to patent
term extension, but in the absence of mutual agreement with respect to such extension issue, Metabolex shall make the final decision on which Patent and/or the claims of the Patent will be selected for patent term extension. The obligations set
forth in this Section 5.4 shall apply with respect to patent term extensions, or the equivalent, in any other country. Any application for patent term extension in the U.S. shall be made by the Party who Controls the relevant patent. 

ARTICLE 6 

CONFIDENTIALITY 

6.1 Confidentiality Obligations. All Information disclosed by one Party to the other Party pursuant to this Agreement and all
Information relating to a PPAR-d Compound disclosed pursuant to the Confidentiality Agreements entered into by and between Affiliates of Janssen and Metabolex dated [*] (as amended) and [*], shall be
“Confidential Information” of the disclosing Party for all purposes hereunder. Each Party agrees that, for the Term and for [*] years thereafter, such Party shall, and shall ensure that its officers, directors, employees and agents
shall, keep completely confidential (using at least the same standard of care as it uses to protect proprietary or confidential information of its own, but in no event less than reasonable care) and not publish or otherwise disclose and not use for
any purpose except as expressly permitted hereunder any Confidential Information furnished to it by the other Party (including, without limitation, know-how of the disclosing Party). The foregoing obligations
shall not apply to any Information disclosed by a Party hereunder to the extent that the receiving Party can demonstrate with competent evidence that such Information: 

(a) was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of
disclosure; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the
receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and other
than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was subsequently lawfully disclosed to the
receiving Party or its Affiliate by a Third Party other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or 

(e) was developed or discovered by employees of the receiving Party or its Affiliates who had no access to the Confidential Information
of the disclosing Party. 

  
 19 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 6.2 Authorized Disclosure. A Party may disclose the Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) Filing or
prosecuting Patents relating to PPAR-d Products as permitted under this Agreement; 
 (b)
Regulatory filings relating to PPAR-d Products; 
 (c) Prosecuting or defending
litigation as permitted under this Agreement; 
 (d) Disclosure, in connection with the performance of this Agreement, to Affiliates,
sublicensees, research collaborators, employees, consultants, subcontractors or agents, each of whom prior to disclosure must be bound by similar obligations of confidentiality and non-use at least equivalent
in scope to those set forth in this Article 6. 
 Further, a Party may disclose the other Party’s Confidential Information to the
extent such disclosure is required by valid court order or legal process, provided that such Party gives the other Party advance notice of such required disclosure, limits the disclosure to that actually required, and cooperates in the other
Party’s attempts to obtain a protective order or confidential treatment of the information required to be disclosed. 
 6.3
Confidentiality of Agreement Terms. The Parties acknowledge that the terms of this Agreement shall be treated confidentially as Confidential Information of both Parties. Notwithstanding the foregoing, such terms may be disclosed by a Party to
investment bankers, investors, and potential investors or acquirers, in the context of a potential transaction, each of whom prior to disclosure must be bound by similar obligations of confidentiality and
non-use at least equivalent in scope to those set forth in this Article 6. A copy of this Agreement may be filed with the Federal Trade Commission or the Justice Department for HSR review. In addition, a copy
of this Agreement may be filed by a Party with the Securities and Exchange Commission, The New York Stock Exchange and/or the Nasdaq National Market as required by applicable law or regulation. In connection with any such filing, such Party shall
endeavor to obtain confidential treatment of economic and trade secret information. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information except as permitted hereunder. 

6.4 Publicity. Upon the execution of this Agreement, Metabolex may issue a press release announcing the execution of this
Agreement, the text of which is set forth in an Exhibit to the PPAR-g License Agreement. After such initial press release, Metabolex may make periodic press releases or other public disclosures relating
to the Agreement or developments under the Agreement at its discretion. Metabolex shall not disclose the Confidential Information of Janssen in any press release and shall not use the name of Janssen or any Janssen Affiliate in any press release, in
each case without the prior written approval of Janssen. Janssen and its Affiliates shall not issue a press release or public announcement relating to the PPAR-d Product or this Agreement without the
prior written approval of Metabolex, which approval shall not be unreasonably withheld or delayed. 

  
 20 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 6.5 Publications. Metabolex and its Affiliates and sublicensees shall be free to
publish or present the results of any research or development carried out under this Agreement, provided that Metabolex shall provide Janssen the opportunity for prior review and comment on any such publication to the extent it would disclose
specific, proprietary Confidential Information of Janssen. In such latter case, Metabolex would provide Janssen the opportunity to review any proposed abstracts, manuscripts or presentations (including verbal presentations) that contain specific,
proprietary Confidential Information of Janssen at least thirty (30) days prior to its intended submission for publication, and to reasonably consider deleting such Confidential Information at Janssen’s reasonable request. 

ARTICLE 7 

REPRESENTATIONS AND WARRANTIES 

7.1 Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Execution Date: 

(a) such Party is duly organized and validly existing under the laws of the state or jurisdiction of its incorporation and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof; 
 (b) such Party has taken all
corporate action necessary to authorize the execution and delivery of this Agreement and the performance its obligations under this Agreement; 

(c) this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in
accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy or other debtor’s rights laws and regulations. The execution, delivery and performance of this Agreement by such Party does not violate
any agreement or instrument to which such Party is a party or by which such Party is bound, and does not violate any law or regulation of any court, governmental body or administrative or other agency having authority over such Party. All consents,
approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained, or will be obtained on or prior to the Effective Date; 

(d) it has the full right, power and authority to enter into this Agreement, and to perform its obligations hereunder; and 

(e) has independently in good faith determined whether or not notification is required under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, and will file such notification if deemed necessary. 

  
 21 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 7.2 Janssen Warranties. Janssen represents and warrants that: 

(a) Exhibit C accurately identifies all Patent rights Controlled by Janssen as of the Execution Date that claim a PPAR-d Compound, PPAR-d Product or its manufacture or use; 

(b) as of the Execution Date it has not granted any right, license or interest in or to the
PPAR-d Patents or PPAR-d Know-How that is in conflict with the rights and licenses granted to Metabolex under this
Agreement; and 
 (c) as of the Execution Date, other than Third Party allegations disclosed to Metabolex with respect to the
Replacement Patents, it owns or has a license to the PPAR-d Patents and PPAR-d Know-How and has the ability to grant to
Metabolex the licenses thereunder as granted in this Agreement. 
 7.3 Neither Party makes any representation or warranty that
development and marketing of PPAR-d Product shall be the exclusive means by which such Party will participate in development, manufacture, use and/or sale of pharmaceutical products for treatment or
prevention of metabolic syndrome, insulin resistance, diabetes, obesity, or dyslipidemia. 
 7.4 Disclaimer of Warranties.
EXCEPT AS SET FORTH IN SECTIONS 7.1 AND 7.2, EACH PARTY EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR
NON-INFRINGEMENT OF THIRD PARTY RIGHTS. IN PARTICULAR, THE PPAR-d COMPOUNDS AND PPAR-d PRODUCTS ARE PROVIDED “AS
IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF PPAR-d PRODUCTS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY, OTHER THAN AS EXPRESSLY SET FORTH IN SECTION 7.2. 

ARTICLE 8 

INDEMNIFICATION 

8.1 Indemnification by Metabolex. Metabolex shall indemnify, defend and hold Janssen and its Affiliates and each
of their respective employees, officers, directors and agents (the “Janssen Indemnitees”) harmless from and against any and all liability, damages, loss, cost or expense (including reasonable attorneys’ fees) arising out
of Third Party claims, actions, proceedings, or suits against an Janssen Indemnitee resulting from (a) Metabolex’s performance or non-performance of its obligations under this Agreement; (b) the
development, manufacture, use, importation, promotion or sale of PPAR-d Products and/or PPAR-d Compounds by Metabolex and/or its Affiliates, sublicensees,
distributors, agents and customers; or (c) breach by Metabolex of its representations and warranties set forth in Article 7; provided, however, Metabolex’s obligations pursuant to this Section 8.1 shall not apply to the extent
such claims or suits result from the negligence or willful misconduct of any of the Janssen Indemnitees or breach by Janssen of its representations and warranties set forth in Article 7. 

  
 22 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 8.2 Indemnification by Janssen. Janssen shall indemnify, defend and hold Metabolex
and its Affiliates and each of their respective agents, employees, officers and directors (the “Metabolex Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including
reasonable attorney’s fees) arising out of Third Party claims or suits against a Metabolex Indemnitee resulting from (a) Janssen’s performance or non-performance of its obligations under this
Agreement; or (b) breach by Janssen of its representations and warranties set forth in Article 7; provided, however, that Janssen’s obligations pursuant to this Section 8.2 shall not apply to the extent that such claims or
suits result from the negligence or willful misconduct of any of the Metabolex Indemnitees or breach by Metabolex of its representations and warranties set forth in Article 7. 

8.3 Notification of Claims; Conditions to Indemnification Obligations. As a condition to a Party’s right to receive
indemnification under this Article 8, it shall (a) promptly notify the other Party as soon as it becomes aware of a claim or action for which indemnification may be sought pursuant hereto, (b) cooperate with the indemnifying Party in the
defense of such claim or suit, and (c) permit the indemnifying Party to control the defense of such claim or suit, including without limitation the right to select defense counsel, which counsel shall be reasonably satisfactory to the
indemnified Party. In no event, however, may the indemnifying Party compromise or settle any claim or suit in a manner that admits fault or negligence on the part of the indemnified Party without the prior written consent of the indemnified Party.
The indemnifying Party shall have no liability under this Article 8 with respect to claims or suits settled or compromised without its prior written consent. 

8.4 Insurance. Metabolex at its own expense, will maintain during the term of the Agreement clinical trial insurance in
compliance with local regulations but in no event shall such coverage be in amounts less than [*] per occurrence. In addition, prior to any First Commercial Sale, Metabolex at its own expense, will maintain through termination of the Agreement and
for a period of at least [*] years thereafter, product liability insurance in amounts not less than [*] per occurrence and [*] annual aggregate. Such insurance shall include worldwide coverage. Janssen agrees during the term of the Agreement and for
a period of at least [*] years thereafter to maintain (a) workers’ compensation insurance for all of its employees, the limits of which shall be as required under statute; (b) commercial general liability insurance having limits of
not less than [*] in the aggregate and [*] per occurrence. Each Party shall provide evidence of insurance in accordance with this Section 8.4 to the other Party upon the request of the other Party. 

ARTICLE 9 
 TERM;
TERMINATION 
 9.1 Term and Expiration. The term of this Agreement shall commence upon the Effective Date and, unless
earlier terminated pursuant to Section 9.2 or 9.3, shall expire on a 

  
 23 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
country-by-country and PPAR-d Product-by-PPAR-d Product basis, upon the expiration of the royalty term as set forth in Section 4.1(b) as to such country with regard to such PPAR-d Product. Thereafter, the licenses granted to Metabolex in Section 2.1 as to such PPAR-d Product in such country shall survive but shall be non-exclusive, fully-paid and royalty-free. 
 9.2 Termination for Material Breach. 

(a) If a Party breaches any of its material obligations under the Agreement, the Party not in default may give to the breaching Party a
written notice specifying the nature of the default, requiring it to make good or otherwise cure such breach, and stating its intention to terminate this Agreement if such breach is not cured. Subject to Section 10.12 of this Agreement, if such
breach is not cured within [*] (or [*] with respect to breach of a payment obligation) after the receipt of such notice, the Party not in default shall be entitled, without prejudice to any of its other rights conferred under this Agreement, and in
addition to any other remedies available to it by law or in equity, to terminate this Agreement by written notice to the other Party. 

(b) The right of a Party to terminate this Agreement, as herein above provided, shall not be affected in any way by its waiver or
failure to take action with respect to any prior default or breach. 
 9.3 Termination by Metabolex. Metabolex may terminate
this Agreement in its entirety for any reason or no reason upon at least [*] prior written notice to Janssen. 
 9.4
“Anti-Shelving” Provision. 
 (a) If Metabolex does not expend more than a de minimus amount of effort and resources on
the research and/or development of at least one (1) PPAR-d Product for any period of [*] or more, then (regardless of whether such failure constitutes a failure to expend Diligent Efforts) Janssen
shall have the right to terminate this Agreement on written notice with respect to all PPAR-d Products, provided that Metabolex does not commence and thereafter continue to expend a material amount of
effort and resources on the research and/or development of at least one (1) PPAR-d Product within [*] of such written notice by Janssen. This Section 9.4(a) shall automatically terminate at such
time as Metabolex (or its Affiliate or sublicensee) has [*] on a PPAR-d Product. 
 (b)
Notwithstanding Section 9.4(a), Janssen shall not have the right to terminate this Agreement pursuant to Section 9.4(a) if Metabolex has delayed development of its PPAR-d Products due to either:

 (i) financial constraints that have caused Metabolex to delay its PPAR-d programs as
well as a majority of its other programs; provided, however, that: 
 (1) Metabolex has provided written to notice to Janssen
that it wishes to rely on this Section 9.4(b)(i); 

  
 24 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (2) [*] the written notice described in Section 9.4(b)(i)(1); and 

(3) Metabolex restarts development of its PPAR-d Products within [*] after the conclusion
of the [*] period of inactivity described in Section 9.4(a); or 
 (ii) safety or material technical or regulatory cause;
provided, however, that Metabolex in good faith intends to continue development of its PPAR-d Products as soon as practicable if and after the safety, technical and/or regulatory issues are resolved.

 9.5 Consequences of Termination. If a Party terminates this Agreement pursuant to Section 9.2(a); Janssen terminates
this Agreement pursuant to Section 9.4; or Metabolex terminates this Agreement pursuant to Section 9.3, then: 
 (a)
Licenses to Janssen. Metabolex shall grant to Janssen a worldwide, exclusive (even as to Metabolex and its Affiliates), irrevocable, license (with full rights to sublicense) under the Metabolex Know-How
and Metabolex Patents, to make, have made, import, use, offer for sale and sell PPAR-d Products and PPAR-d Compounds. Metabolex shall also grant to
Janssen a worldwide, exclusive (even as to Metabolex and its Affiliates), irrevocable, license (with full rights to sublicense) under Patents that are Controlled as of the Effective Date by Metabolex or a Metabolex Affiliate to the extent that such
Patents include one or more claims that claim or cover the composition of matter, formulation, manufacture or use of a PPAR-d Compound or PPAR-d Product as
such exists on the date of termination, to make, have made, import, use, offer for sale and sell such PPAR-d Compound and PPAR-d Product (as such may be
further developed and commercialized). Notwithstanding the foregoing, Janssen shall reimburse Metabolex for Third Party royalties and other out-of-pocket payments
incurred by Metabolex as a result of any Third-Party obligations of Metabolex triggered by supplying such licenses to Janssen. Further, the licenses granted in this Section 9.5(a) shall be [*] to the extent such licenses [*] PPAR-d Products and PPAR-d Compounds. To the extent that such licenses [*] PPAR-d Products and PPAR-d Compounds, the licenses shall be [*] and shall be [*]. 
 (b) Regulatory Filings.
Metabolex shall assign to Janssen, and will provide full copies of, all Regulatory Approvals and INDs, NDAs and other similar regulatory applications that relate to PPAR-d Products and/or PPAR-d Compounds and are owned or Controlled by Metabolex or its Affiliates. Metabolex shall also take such actions and execute such other instruments, assignments and documents as may be necessary to effect the
transfer of rights thereunder to Janssen. 
 (c) Data Disclosure. Metabolex will provide to Janssen copies of the relevant
portions of all material reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of Metabolex or its Affiliates pursuant to this Agreement to the extent
that they relate to PPAR-d Products and PPAR-d Compounds, within sixty (60) days of such termination unless otherwise agreed, and Janssen shall have the
right to use any such Information in developing and commercializing PPAR-d Products and PPAR-d Compounds, and to license any Third Parties to do so. 

 

  
 25 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) Trademarks. If Metabolex used with regard to any PPAR-d Product or PPAR-d Compound in a country any trademark, tradename or logo related solely to a PPAR-d Product and/or
PPAR-d Compound (“Metabolex PPAR-d Product Mark(s)”) Metabolex shall assign to Janssen, at Janssen’s cost for the
transactional documents and any governmental fees for effecting such assignment (upon written request from Janssen within one (1) year of such termination under this Section 9.5), the Metabolex
PPAR-d Product Mark(s). For clarity, Janssen shall under no circumstance receive any rights under the housemarks of Metabolex or its Affiliates, except with respect to selling off existing inventory. 

(e) Third-Party Contracts. At Janssen’s request, Metabolex shall promptly provide to Janssen copies of all Third-Party
agreements with Metabolex or its Affiliates containing a license under Patents or patent applications claiming inventions or know-how specific to or used or incorporated into the development, manufacture
and/or commercialization of the PPAR-d Products and PPAR-d Compounds. At Janssen’s reasonable request, Metabolex shall reasonably cooperate with Janssen
to make available to Janssen the benefits of such Third-Party agreements, at Janssen’s expense. 
 (f) Further Sales. In
the event of any such termination, Metabolex may continue to sell its remaining inventory of the PPAR-d Product or PPAR-d Compound for a period of [*] from the
effective date of such termination, subject to the payment of royalties pursuant to Section 4.1. Metabolex covenants that promptly after such [*] period it and its Affiliates and former sublicensees hereunder shall cease to sell, and thereafter
shall not sell, any PPAR-d Products or PPAR-d Compounds. 

(g) Remaining Materials. At the end of the period described in Section 9.5(f) or if this Agreement is terminated prior to
the First Commercial Sale, at the request of Janssen, Metabolex shall transfer to Janssen, at a price to be agreed in good faith, which shall not be lower than [*] of Metabolex’s manufacturing cost for the
PPAR-d Products and/or PPAR-d Compounds or higher than [*] of Metabolex’s manufacturing cost for the PPAR-d
Products and/or PPAR-d Compounds, all quantities of PPAR-d Products and/or PPAR-d Compounds in the possession of
Metabolex or its Affiliates (including, without limitation, clinical trial supplies and PPAR-d Products and/or PPAR-d Compounds intended for commercial sale).

 (h) PPAR-d Product/Compound Manufactured by Metabolex. If any
PPAR-d Product and/or PPAR-d Compound was manufactured by Metabolex (including, without limitation, any testing and/or release) at the time of such
termination, at Janssen’s request, Metabolex shall continue to manufacture such PPAR-d Product and/or PPAR-d Compound for Janssen, unless such would be an
undue burden on Metabolex, at a cost equal to [*] of Metabolex’s manufacturing cost for the PPAR-d Product and/or PPAR-d Compound from the time of the
effective date of termination, until such time (not to exceed [*]) as Janssen is able to secure an equivalent alternative commercial manufacturing source from which quantities of PPAR-d Product and/or
PPAR-d Compound are registered for commercial sale in each country of the Territory; provided, however, that this Section 9.6(h) shall not be construed to require Metabolex to manufacture the
PPAR-d Product and/or PPAR-d Compound beyond the capacity of Metabolex as of the date of termination and provided that this Section 9.5(h) shall not be
construed to require Metabolex in its reasonable judgment to infringe any Patent of a Third Party for which it does not have an appropriate license. 

  
 26 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (i) Technical Assistance. Promptly after the effective date of such termination,
Metabolex shall provide, at Janssen’s request and expense (at Metabolex’s actual cost) technical assistance of the equivalent of up to a total of [*] full-time equivalent persons (i.e., a total not to exceed [*] of person-time), in the
period from the effective date of such termination until [*] months after such date, to provide technology transfer necessary for Janssen to commence or continue to commercially manufacture PPAR-d
Products and/or PPAR-d Compounds, and a non-exclusive, royalty-free, perpetual license under any Know-How disclosed by
Metabolex to Janssen in the course of such activities to manufacture PPAR-d Products and/or PPAR-d Compounds. 

(j) No Further Representations. Subject to Sections 9.5(f) and (h), Metabolex and its Affiliates shall (1) discontinue
making any representation regarding its status as a licensee of or distributor for Janssen, for all PPAR-d Products and/or PPAR-d Compounds and (2) cease
conducting any activities with respect to the marketing, promotion, sale or distribution of the PPAR-d Products and/or PPAR-d Compounds. 

(k) Commercialization. Janssen shall have the sole right under the PPAR-d Patents
and PPAR-d Know-How to develop and commercialize the PPAR-d Products and/or
PPAR-d Compounds itself or with one or more Third Parties, and shall have the right, without obligation to Metabolex, to take any such actions in connection with such activities as Janssen (or its
designee), at its discretion, deems appropriate. 
 (l) Other Consequences. Subject to Section 9.6 and this
Section 9.5, each Party shall promptly return to the other Party all relevant records and materials in its possession or control containing or comprising the other Party’s Confidential Information and to which the Party does not retain
rights hereunder; provided, however, that each Party shall be entitled to retain copies of the other Party’s Confidential Information to the extent necessary to comply with applicable regulatory obligations and shall be entitled to
retain one copy of the other Party’s Confidential Information for archival purposes; (ii) all licenses granted by each Party to the other under this Agreement shall terminate (except as set forth in this Section 9.5); (iii) all rights
in any and all PPAR-d Patents and PPAR-d Know-How shall revert to Janssen, and (iv) any and all claims and payment
obligations that accrued prior to the date of such termination shall survive such termination. 
 9.6 Accrued Rights; Surviving
Obligations. 
 (a) Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any
rights that shall have accrued to the benefit of a Party prior to such termination, or expiration. Such termination, relinquishment or expiration shall not relieve a Party from obligations that are expressly indicated to survive termination or
expiration of this Agreement. 
 (b) Without limiting the foregoing, 

 

  
 27 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (i) Sections [*] of this Agreement shall survive the expiration or termination of this
Agreement for any reason; and 
 (ii) Section [*] of this Agreement shall survive the expiration or termination of this Agreement for
any reason but only to the extent relating to matters commenced, or facts occurring, prior to the date of termination or relating to obligations or rights set forth in this Article 9. 

9.7 Rights in Bankruptcy. All licenses granted under this Agreement by Janssen are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(34A) of the U.S. Bankruptcy Code. The Parties agree that Metabolex, as a licensee of such rights
under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Janssen under the
U.S. Bankruptcy Code, Metabolex shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property (including all Information related to such
intellectual property and rights of reference with respect to Regulatory Approvals), and same, if not already in its possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its written
request therefore, unless Janssen continues to perform all of its obligations under this Agreement, or (b) if not delivered or granted under (a) above, following the rejection of this Agreement by or on behalf of Janssen upon written
request therefore by Metabolex. 
 9.8 Consequences of Material Breach by Janssen. If Janssen breaches a material obligation
under Section [*], Metabolex shall give Janssen a written notice specifying the nature of the default, requiring Janssen to make good or otherwise cure such breach, and stating its intention to terminate the rights specified below if such breach is
not cured. Subject to Section 10.12 of this Agreement, if such breach is not cured within [*] (or [*] with respect to breach of a payment obligation) after the receipt of such notice, and Metabolex does not wish to terminate the Agreement in
its entirety pursuant to Section 9.2(a), then Metabolex shall be entitled, without prejudice to any of its other rights conferred under this Agreement, and in addition to any other remedies available to it by law or in equity, to [*] and/or [*]
under this Agreement, upon written notice to Janssen. 
 ARTICLE 10 

MISCELLANEOUS PROVISIONS 

10.1 Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency
or employer-employee relationship between the Parties. Neither Party shall incur any debts or make any commitments for the other. 

10.2 Assignments. Except as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable,
nor any other obligation delegable, by a Party without the prior written consent of the other; provided, however, that a Party may assign this Agreement 

  
 28 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
to any Affiliate or to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets provided that such successor agrees in writing to be bound by the
terms of this Agreement as if it were the assigning Party. This Agreement shall be binding upon the successors and permitted assigns of the Parties. Any assignment not in accordance with this Section 10.2 shall be void. Notwithstanding the
foregoing, in the event that a Party assigns this Agreement to its successor in interest by way of merger, acquisition, or sale of all or substantially all of its assets, the intellectual property rights of such successor in interest, and of any of
its Affiliates as of just prior to such assignment, as existing immediately prior to the closing of such transaction, shall be automatically excluded from the rights licensed to the other Party under this Agreement. 

10.3 Responsibility for Affiliates. Either Party may use one or more of its Affiliates to perform its obligations and duties
hereunder; provided however, that each Party shall remain liable hereunder for the prompt payment and performance of all its obligations hereunder. To the extent that the rights granted to a Party hereunder are exercised by an Affiliate of such
Party (or by any sublicensee of an Affiliate), such Affiliate or sublicensee shall be bound by the corresponding obligations of such Party. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Affiliates shall perform
such obligations and such Party shall be responsible for any failure of such Affiliate to perform such obligations. 
 10.4
Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other reasonable acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 10.5 Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its
obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, strike, flood, act of terrorism, governmental acts or restrictions or any other reason that is beyond the
control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the
interference with its activities), and will use Diligent Efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. 

10.6 Entire Agreement of the Parties; Amendments. This Agreement and the attachments hereto constitute and contain the entire
understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such
subject matter (including the Confidentiality Agreement entered into by and between Affiliates of Janssen and Metabolex [*] and the addendums thereto); provided, however, the Four-Party Nondisclosure Agreement, by and among an Affiliate of
Janssen, Metabolex and two Third Parties, dated [*], and a second Four-Party Nondisclosure Agreement, by and among an Affiliate of Janssen, Metabolex and two other Third Parties, dated [*] shall remain in force and effect in accordance with their
terms. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

  
 29 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 10.7 Captions. The captions to this Agreement are for convenience only, and are to
be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
 10.8 Applicable Law. This
Agreement shall be governed by and interpreted in accordance with the laws of California, USA, excluding application of any conflict of laws principles that would require application of different law. Notwithstanding the above, any dispute regarding
and limited to validity or enforceability of any patent shall be governed by the patent laws of the jurisdiction in which such patent was granted. 

10.9 Disputes. In the event of any controversy or claim arising out of, relating to or in connection with any provision of this
Agreement, or the rights or obligations of the Parties hereunder, the Parties shall try to settle their differences amicably between themselves. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to
the other Party, and within ten (10) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter,
it shall be referred to the Chief Executive Officer of Metabolex and to the President of Janssen, for discussion and resolution. If such personnel are unable to resolve such dispute within thirty (30) days of initiating such negotiations,
unless otherwise agreed by the Parties, such dispute shall be finally settled under Sections 10.10 and 10.11. 
 10.10 Mediation 

(a) Any dispute, controversy or claim arising out of or related to this agreement, or the interpretation, application, breach,
termination or validity thereof, including any claim of inducement by fraud or otherwise, which claim would, but for this provision, be submitted to arbitration shall, before submission to arbitration, first be mediated through non-binding mediation
in accordance with the CPR Mediation Procedure then in effect of the CPR Institute for Dispute Resolution (“CPR”) available at www.cpradr.org/m_proced.htm, except where that procedure conflicts with these provisions, in which
case these provisions control. The mediation shall be conducted in San Francisco, CA and shall be attended by a senior executive with authority to resolve the dispute from each of the operating companies that are Parties. 

(b) The mediator shall be neutral, independent, disinterested and shall be selected from a professional mediation firm such as ADR
Associates or JAMS/ENDISPUTE or CPR. 
 (c) The Parties shall promptly confer in an effort to select a mediator by agreement. In the
absence of such an agreement within ten (10) days of initiation of the mediation, the mediator shall be selected by CPR as follows: CPR shall provide the Parties with a list of at least fifteen (15) names from the CPR Panels of Distinguished
Neutrals. Each Party shall exercise challenges for cause, two (2) peremptory challenges, and rank the remaining candidates within five (5) working days of receiving the CPR list. The Parties may together interview the three top-ranked candidates for no more than one hour each and, after the interviews, may each exercise one peremptory challenge. The mediator shall be the remaining candidate with the highest aggregate ranking. 

  
 30 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) The mediator shall confer with the Parties to design procedures to conclude the
mediation within no more than forty-five (45) days after initiation. Under no circumstances may the commencement of arbitration under Section 10.11 be delayed more than forty-five (45) days by the mediation process specified herein
absent contrary agreement of the Parties. 
 (e) Each Party agrees not to use the period or pendency of the mediation to disadvantage
the other Party procedurally or otherwise. No statements made by either side during the mediation may be used by the other or referred to during any subsequent proceedings. 

(f) Each Party has the right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc. to
avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration, even though mediation has not been commenced or completed. 

10.11 Dispute Resolution 

(a) Any dispute, claim or controversy arising from or related in any way to this Agreement or the interpretation, application, breach,
termination or validity thereof, including any claim of inducement of this Agreement by fraud or otherwise, will be submitted for resolution to arbitration pursuant to the rules then pertaining of the CPR Institute for Dispute Resolution for Non-Administered Arbitration (available at www.cpradr.org/arb-rules.htm), or successor (“CPR”), except where those rules conflict with these
provisions, in which case these provisions control. The arbitration will be held in San Francisco, CA. 
 (b) The panel shall consist
of three (3) arbitrators chosen from the CPR Panels of Distinguished Neutrals (or, by agreement, from another provider of arbitrators) each of whom is a lawyer with at least fifteen (15) years experience with a law firm or corporate law
department of over twenty-five (25) lawyers or who was a judge of a court of general jurisdiction. In the event the aggregate damages sought by the claimant are stated to be less than $5 million, and the aggregate damages sought by the
counterclaimant are stated to be less than $5 million, and neither side seeks equitable relief, then a single arbitrator shall be chosen, having the same qualifications and experience specified above. Each arbitrator shall be neutral,
independent, disinterested, impartial and shall abide by the CPR-Georgetown Commission Proposed Model Rule for the Lawyer as Neutral available at
www.cpradr.org/cpr-george.html. 
 (c) The Parties agree to cooperate (1) to
attempt to select the arbitrator(s) by agreement within forty-five (45) days of initiation of the arbitration, including jointly interviewing the final candidates, (2) to meet with the arbitrator(s) within forty-five (45) days of
selection and (3) to agree at that meeting or before upon procedures for discovery and as to the conduct of the hearing which will result in the hearing being concluded within no more than nine (9) months after selection of the
arbitrator(s) and in the award being rendered within sixty (60) days of the conclusion of the hearings, or of any post-hearing briefing, which briefing will be completed by both sides within forty-five (45) days after the conclusion of the
hearings. 

  
 31 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (d) In the event the Parties cannot agree upon selection of the arbitrator(s), the CPR
will select arbitrator(s) as follows: CPR shall provide the Parties with a list of no less than twenty-five (25) proposed arbitrators (fifteen (15) if a single arbitrator is to be selected) having the credentials referenced above. Within
twenty-five (25) days of receiving such list, the Parties shall rank at least sixty-five percent (65%) of the proposed arbitrators on the initial CPR list, after exercising cause challenges. The Parties may then interview the five
(5) candidates (three (3) if a single arbitrator is to be selected) with the highest combined rankings for no more than one (1) hour each and, following the interviews, may exercise one (1) peremptory challenge each. The panel
will consist of the remaining three (3) candidates (or one, if one arbitrator is to be selected) with the highest combined rankings. In the event these procedures fail to result in selection of the required number of arbitrators, CPR shall
select the appropriate number of arbitrators from among the members of the various CPR Panels of Distinguished Neutrals, allowing each side challenges for cause and three (3) peremptory challenges each. 

(e) In the event the Parties cannot agree upon procedures for discovery and conduct of the hearing meeting the schedule set forth in
paragraph (c) above, then the arbitrator(s) shall set dates for the hearing, any post-hearing briefing, and the issuance of the award in accord with the paragraph (c) schedule. The arbitrator(s)
shall provide for discovery according to those time limits, giving recognition to the understanding of the Parties that they contemplate reasonable discovery, including document demands and depositions, but that such discovery be limited so that the
paragraph (c) schedule may be met without difficulty. In no event will the arbitrator(s), absent agreement of the Parties, allow more than a total of ten (10) days for the hearing or permit either side to obtain more than a total of forty
(40) hours of deposition testimony from all witnesses, including both fact and expert witnesses, or serve more than twenty (20) individual requests for documents, including subparts, or twenty (20) individual requests for admission or
interrogatories, including subparts. Multiple hearing days will be scheduled consecutively to the greatest extent possible. 
 (f) The
arbitrator(s) must render their award by application of the substantive law of California and are not free to apply “amiable compositeur” or “natural justice and equity.” The arbitrator(s) shall render a written opinion setting
forth findings of fact and conclusions of law with the reasons therefore stated. A transcript of the evidence adduced at the hearing shall be made and shall, upon request, be made available to either Party. The arbitrator(s) shall have power to
exclude evidence on grounds of hearsay, prejudice beyond its probative value, redundancy, or irrelevance and no award shall be overturned by reason of such ruling on evidence. To the extent possible, the arbitration hearings and award will be
maintained in confidence. 
 (g) In the event the panel’s award exceeds $5 million in monetary damages or includes or
consists of equitable relief, or rejects a claim in excess of that amount or for that relief, then the losing Party may obtain review of the arbitrators’ award or decision by a single appellate arbitrator (the “Appeal
Arbitrator”) selected from the CPR Panels of Distinguished 

  
 32 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
Neutrals by agreement or, failing agreement within seven (7) working days, pursuant to the selection procedures specified in paragraph (d) above. If CPR cannot provide such services,
the Parties will together select another provider of arbitration services that can. No Appeal Arbitrator shall be selected unless he or she can commit to rendering a decision within forty-five (45) days
following oral argument as provided in paragraph (h). Any such review must be initiated within thirty (30) days following the rendering of the award referenced in (f) above. 

(h) The Appeal Arbitrator will make the same review of the arbitration panel’s ruling and its bases that the U.S. Court of Appeals
of the Circuit where the arbitration hearings are held would make of findings of fact and conclusions of law rendered by a district court after a bench trial and then modify, vacate or affirm the arbitration panel’s award or decision
accordingly, or remand to the panel for further proceedings. The Appeal Arbitrator will consider only the arbitration panel’s findings of fact and conclusions of law, pertinent portions of the hearing transcript and evidentiary record as
submitted by the Parties, opening and reply briefs of the Party pursuing the review, and the answering brief of the opposing Party, plus a total of no more than four (4) hours of oral argument evenly divided between the Parties. The Party
seeking review must submit its opening brief and any reply brief within seventy-five (75) and one hundred thirty (130) days, respectively, following the date of the award under review, whereas the
opposing Party must submit its responsive brief within one hundred ten (110) days of that date. Oral argument shall take place within five (5) months after the date of the award under review, and the Appeal Arbitrator shall render a
decision within forty-five (45) days following oral argument. That decision will be final and not subject to further review, except pursuant to the Federal Arbitration Act. 

(i) The Parties consent to the jurisdiction of the Federal District Court for the district in which the arbitration is held for the
enforcement of these provisions and the entry of judgment on any award rendered hereunder (including after review by the Appeal Arbitrator where such an appeal is pursued). Should such court for any reason lack jurisdiction, any court with
jurisdiction shall act in the same fashion. 
 (j) Each Party has the right before or, if the arbitrator(s) cannot hear the matter
within an acceptable period, during the arbitration to seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve
the subject matter of the arbitration. 
 (k) EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL BY JURY OF ANY ISSUE RELATED TO THIS AGREEMENT.

 (l) EACH PARTY HERETO WAIVES ANY CLAIM TO PUNITIVE, EXEMPLARY OR MULTIPLIED DAMAGES FROM THE OTHER RESULTING FROM THIS AGREEMENT.

 (m) EACH PARTY HERETO WAIVES ANY CLAIM OF CONSEQUENTIAL DAMAGES FROM THE OTHER RELATED TO THIS AGREEMENT. 

  
 33 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 (n) NOTWITHSTANDING THE FOREGOING, NOTHING HEREIN IS INTENDED TO OR SHALL LIMIT THE
INDEMNIFICATION OBLIGATION OF A PARTY PROVIDED FOR UNDER ARTICLE 8. 
 10.12 Tolling of Time Periods. In the event that a
controversy or claim has been raised and is in the process of dispute resolution in accordance with Sections 10.9, 10.10 or 10.11, any applicable time period governing the underlying controversy or claim shall be tolled pending the outcome of the
resolution process after which the time period shall again begin to run. 
 10.13 Notices and Deliveries. Any notice, request,
delivery, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by telecopier (receipt verified) or by express courier
service (signature required) or five (5) days after it was sent by registered letter, return receipt requested (or its equivalent), to the Party to which it is directed at its address or facsimile number shown below or such other address or
facsimile number as such Party shall have last given by notice to the other Parties. 
 If to Janssen, addressed to: 

Janssen Pharmaceutica NV 
 30
Turnhoutseweg 
 2340 Beerse, Belgium 

Attention of: Managing Director 

Fax: +32 14 60 8296 
 With copy to: 

Johnson & Johnson Law Department Europe 

6 Lenneke Marelaan 
 1932 St.
Stevens Woluwe, Belgium 
 Attention of: Head of the Law Department Europe 

Fax: +32 2 749 2558 
 If to Metabolex, addressed
to: 
 Metabolex, Inc. 
 3876
Bay Center Place 
 Hayward, CA 94545 

Attention of: General Counsel 

Fax: (510) 293-6853 

10.14 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed
or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 

  
 34 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 10.15 Translation. This Agreement is in English language only, which language shall
be controlling in all respects, and all versions hereof in any other language shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement, and any dispute
proceeding related to or arising hereunder, shall be in the English language. If there is a discrepancy between any translation of this Agreement and this Agreement, this Agreement shall prevail. 

10.16 Export Laws. Notwithstanding anything to the contrary contained herein, all obligations of Metabolex and Janssen are
subject to prior compliance with U.S. export regulations and such other U.S. laws and regulations as may be applicable, and to obtaining all necessary approvals required by the applicable agencies of the government of the U.S. or the European Union.
Metabolex and Janssen, respectively, shall each use its reasonable efforts to obtain such approvals for its own activities. Each Party shall cooperate with the other Party and shall provide assistance to the other Party as reasonably necessary to
obtain any required approvals. 
 10.17 Severability. When possible, each provision of this Agreement will be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or
invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one that conforms as nearly as possible with the original intent of the
Parties. 
 10.18 No Implied Licenses. Except as expressly and specifically provided under this Agreement, the Parties
agree that neither Party is granted any implied rights to or under any of the other Party’s current or future patents, trade secrets, copyrights, moral rights, trade or service marks, trade dress, or any other intellectual property rights. 

10.19 Third Party Beneficiaries. Except for the rights of the Metabolex Indemnitees and Janssen Indemnitees set forth in Article
8, all rights, benefits and remedies under this Agreement are solely intended for the benefit of Metabolex and Janssen, and no Third Party shall have any rights whatsoever to (i) enforce any obligation contained in this Agreement;
(ii) seek a benefit or remedy for any breach of this Agreement; or (iii) take any other action relating to this Agreement under any legal theory, including but not limited to, actions in contract, tort (including but not limited to
negligence, gross negligence and strict liability), or as a defense, setoff or counterclaim to any action or claim brought or made by the Parties. 

10.20 Advice of Counsel. Metabolex and Janssen have each consulted counsel of their choice regarding this Agreement, and each
acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 

  
 35 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 10.21 Other Obligations. Except as expressly provided in this Agreement or as
separately agreed upon in writing between Metabolex and Janssen, each Party shall bear its own costs incurred in connection with the implementation of the obligations under this Agreement. 

10.22 Governmental Matters. 

(a) To the extent, if any, that a Party concludes in good faith that it is required to file or register this Agreement or a notification
thereof with any governmental authority, including without limitation the U.S. Securities and Exchange Commission, the U.S. Department of Justice, the U.S. Federal Trade Commission and the Competition Directorate of the Commission of the European
Communities, in accordance with applicable laws and regulations, such Party may do so, and the other Party shall cooperate in such filing or notification and shall execute all documents reasonably required in connection therewith, at the expense of
the requesting Party. The Parties shall promptly notify each other as to the activities or inquires of any such governmental authority relating to this Agreement, and shall cooperate, to respond to any request for further information therefrom at
the expense of the requesting Party. 
 (b) Metabolex may, at its expense, register the exclusive license granted under this Agreement
in any country or community or association of countries. Janssen shall reasonably cooperate in such registration at Metabolex’s expense. Upon request by Metabolex, Janssen agrees promptly to execute any “short form” licenses developed
in a form reasonably acceptable to both Metabolex and Janssen and reasonably submitted to it by Metabolex from time to time in order to effect the foregoing registration in such country. No such “short form” license shall be deemed to
amend or be used to interpret this Agreement. If there is any conflict between such a license or other recordation document and this Agreement, this Agreement shall control. 

10.23 Counterparts. This Agreement may be executed simultaneously in any number of counterparts, any one of which need not
contain the signature of more than one Party but all such counterparts taken together shall constitute one and the same agreement. 
 [The
remainder of this page has been intentionally left blank] 

  
 36 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties have caused
this Agreement to be executed by their respective duly authorized officers as of the day and year first above written. 
  

			
	JANSSEN PHARMACEUTICA NV
		
	By:	 	 /s/ Didier De Chaffoy De Courcelles

	Name:	 	 Didier De Chaffoy De Courcelles

	Title:	 	 Board member

		
	By:	 	 /s/ René Hex

	Name:	 	 René Hex

	Title:	 	 Board member

	
	METABOLEX, INC.
		
	By:	 	 /s/ Harold Van Wart

	Name:	 	 Harold Van Wart

	Title:	 	 Chief Executive Officer

 Exhibit A: Weighted Average Percentage Discount 

Exhibit B: Description of Numbered PPAR-d Compounds 

Exhibit C: PPAR-d Patents 

Exhibit D: Materials to be Transferred 
 Exhibit E: Description of
[*] 
 Exhibit F: Replacement Compound Patents 

  
 37 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT A 

WEIGHTED AVERAGE PERCENTAGE DISCOUNT 

(see attached) 
 [*] 

  
 38 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT B 

DESCRIPTION OF NUMBERED PPAR-d
COMPOUNDS 
 DESCRIPTION OF RWJ 800025 (JNJ-25873367) 

Chemical Name 
 (R)-{4-[2-Ethoxy-3-(4-trifluoromethyl-phenoxy)propylsulfanyl]-2-methyl-phenoxy}-acetic
 acid 
 Chemical Structure 

 
 

 
 [*] 

  
 39 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT C 

PPAR-d PATENTS 

[*] 

  
 40 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT D 

MATERIALS TO BE TRANSFERRED 

[*] 

  
 41 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT E 

DESCRIPTION OF [*] 

[*] 

  
 42 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT F 

REPLACEMENT COMPOUND PATENTS 

[*] 

  
 43 

 

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]